ORIGINAL RESEARCH

Expert Consensus Statement on Proficiency Standards for Dermoscopy Education in Primary Care

Tiffaney Tran, BS, Peggy R. Cyr, MD, MS, Alex Verdieck, MD, Miranda D. Lu, MD, Hadjh T. Ahrns, MD, Elizabeth G. Berry, MD, William Bowen, MD, Ralph P. Braun, MD, Joshua M. Cusick-Lewis, MD, Hung O. Doan, MD, PhD, Valerie L. Donohue, MD, Deborah R. Erlich, MD, MMedEd, Laura K. Ferris, MD, PhD, Evelyne Harkemanne, MD, Rebecca I. Hartman, MD, MPH, James Holt, MD, Natalia Jaimes, MD, Timothy A. Joslin, MD, Zhyldyz Kabaeva, MD, Tracey N. Liebman, MD, Joanna Ludzik, MD, PhD, Ashfaq A. Marghoob, MD, Isac Simpson, DO, Jennifer A. Stein, MD, PhD, Daniel L. Stulberg, MD, Isabelle Tromme, MD, PhD, Matthew J. Turnquist, MD, Richard P. Usatine, MD, Alison M. Walker, MD, Bryan L. Walker, MD, Robert F. West, MD, MMed, Megan L. Wilson, MD, Alexander Witkowski, MD, PhD, Dominic J. Wu, MD, Elizabeth V. Seiverling, MD, and Kelly C. Nelson, MD

Background: Primary care providers (PCPs) frequently address dermatologic concerns and perform skin examinations during clinical encounters. For PCPs who evaluate concerning skin lesions, dermoscopy (a noninvasive skin visualization technique) has been shown to increase the sensitivity for skin cancer diagnosis compared with unassisted clinical examinations. Because no formal consensus existed on the fundamental knowledge and skills that PCPs should have with respect to dermoscopy for skin cancer detection, the objective of this study was to develop an expert consensus statement on proficiency standards for PCPs learning or using dermoscopy.

Methods: A 2-phase modified Delphi method was used to develop 2 proficiency standards. In the study's first phase, a focus group of PCPs and dermatologists generated a list of dermoscopic diagnoses and associated features. In the second phase, a larger panel evaluated the proposed list and determined whether each diagnosis was reflective of a foundational or intermediate proficiency or neither.

Results: Of the 35 initial panelists, 5 PCPs were lost to follow-up or withdrew; 30 completed the fifth and last round. The final consensus-based list contained 39 dermoscopic diagnoses and associated features.

Conclusions: This consensus statement will inform the development of PCP-targeted dermoscopy training initiatives designed to support early cancer detection. (J Am Board Fam Med 2023;36:25–38.)

Keywords: Continuing Medical Education, Delphi Method, Dermoscopy, Expert Opinion, Focus Groups, General Practitioners, Melanoma, Primary Care Physicians, Primary Health Care, Skin Cancer

Background

Skin cancer is the most common cancer in the United States, and the 3 major types are basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. While most BCCs and SCCs are treatable and curable, melanoma is fatal when

(PRC, DRE); Department of Family Medicine, Oregon Health & Science University School of Medicine, Portland (AV, TAJ); Swedish First Hill Family Medicine Residency, Seattle, WA (MDL); Department of Dermatology, Oregon Health & Science University School of Medicine, Portland (EGB, JL, AW); Christus St. Vincent Family Medicine Center, Sante Fe, NM (WB); Department of Dermatology, University Hospital of Zürich, University of Zürich, Zürich,

This article was externally peer reviewed.

Submitted 8 April 2022; revised 16 August 2022; accepted 17 August 2022.

From the Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston (TT, HQD, KCN); Department of Family Medicine, Maine Medical Center, Portland (PRC, HTA); Department of Family Medicine, Tufts University School of Medicine, Boston, MA

detected at advanced stages.^{1,2} Delays in diagnosis and treatment can be caused by lack of timely recognition exacerbated by poor access to dermatology specialists for evaluation of skin lesions. In the United States, these access disparities occur along the lines of patient socioeconomic status, race/ethnicity, and rural residence.^{3,4} In regions with barriers to dermatology access, trained primary care providers (PCPs) including advanced practice practitioners, such as physician assistants and nurse practitioners, play an important role in the detection, diagnosis, and management of skin cancer.⁵

For the early detection of skin cancer, clinical skin examinations are 1 of the safest and most costeffective screening interventions available to patients.⁶ Skin examinations may be performed unassisted (with the naked eve) or with dermoscopy, a visualization technique involving use of a dermatoscope. A dermatoscope is a handheld instrument consisting of a magnifier and a polarized light source that enables detailed examination of surface and subsurface features not discernible by the naked eye.⁷ Dermoscopy use results in a higher diagnostic accuracy for melanoma detection compared with unassisted examinations.8 In a large meta-analysis of 104 published studies, dermoscopy was shown to significantly improve both the sensitivity and specificity for melanoma diagnosis when compared with visual inspection alone. This significantly reduces the number of melanomas overlooked and the number of benign lesions unnecessarily biopsied in the course of identifying melanoma, reducing patient morbidity and mortality.

On the frontline of health care delivery, PCPs frequently address dermatologic problems and perform skin examinations, 10 and an estimated 12% to 25% of primary care encounters address a patient's dermatologic problem. 11,12 In a population-based study, 65.1% of patients presenting to their PCPs with skin-related issues did not seek further dermatologic care from a dermatologist or other health care provider that year. 11 For patients at risk for skin cancer, each of these encounters in the primary

Switzerland (RPB); Cabin Creek Health Systems, Dawes, WV (JMC-L); Lincoln Medical Partners, Damariscotta, ME (VLD); Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA (LKF); Dermatology Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium (EH); Institute of Experimental & Clinical Research, Université Catholique de Louvain, Brussels, Belgium (EH); Department of Dermatology,

care setting represents an opportunity to detect skin cancer at an early stage.

Among PCPs who treat skin conditions, appropriate training in the dermoscopic evaluation of skin lesions has been shown to improve their diagnostic sensitivity for skin cancer, including melanoma.13-17 To gain proficiency in dermoscopy, clinicians must become familiar with the dermoscopic features (eg, colors, structures, patterns) of common dermatologic diagnoses. 18 The recognition of these features supports a clinician's decision of whether to biopsy, refer, or offer reassurance.

Before this study, no formal consensus existed on the fundamental competencies that PCPs should have with respect to dermoscopy for skin cancer detection. 19,20 While a foundational dermoscopy proficiency standard has been developed for dermatology residents,²¹ the practice needs of PCPs differ from those of dermatologists, warranting a focused effort tailored to the primary care context. Therefore, the objective of this study was to develop an expert consensus statement on proficiency standards for PCPs learning or using dermoscopy.

To achieve this, the research team coordinated a modified Delphi exercise, an iterative method commonly used to obtain consensus opinion from a group of subject matter experts. 22,23 For each proficiency standard, the expert panel determined which diagnoses and features are important for PCPs to identify, informing learner expectations for dermoscopy educators. In seeking agreement on specific competencies, this study will also establish content validity²⁴ for PCP-targeted dermoscopy training programs and proficiency assessments.


Methods

Study Design

This study received approval from the MD Anderson Cancer Center Institutional Review Board (Protocol #2020-0667). The consensus process, as shown in Figure 1, used a 2-phase modified Delphi method for both the diagnoses and features stages. In the first phase, a smaller focus group

Brigham and Women's Hospital, Boston, MA (RIH); Melanoma Program, Dana-Farber Cancer Institute, Boston, MA (RIH); Veterans Integrated Services Network, Jamaica Plain, MA (RIH); Department of Family Medicine, East Tennessee State University James H. Quillen College of Medicine, Johnson City, TN (JH); Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL

Figure 1. Consensus process using a 2-phase modified Delphi method.



generated a preliminary statement, and in the second phase, a larger panel refined the proposed statement through a controlled feedback process.²¹ This structured method guarantees that outcomes most closely represent the collective viewpoints of the group. 22,23 To ensure anonymity of panelists, the research team administered electronic surveys using the web-based platform REDCap (Version 12.2.6, Vanderbilt University, Nashville, TN).

This consensus process was organized as 2 successive stages: (1) a diagnoses survey series, and (2) a features survey series. To steer the consensus process, a focus group of 5 experts was assembled: 3 PCPs (PRC, AV & MDL) who routinely use dermoscopy in clinical practice and 2 pigmented lesion experts (EVS & KCN) who are highly engaged in PCP dermoscopy training initiatives. The focus group convened virtually before each survey series to propose, discuss, and approve survey items.

For the diagnoses survey series, the objective was to create an expert-approved list of common dermatologic diagnoses with characteristic

(NJ); Sylvester Comprehensive Cancer Center, Miami, FL (NJ); Department of Internal Medicine, Maine Medical Center, Cape Elizabeth, ME (ZK); The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York (TNL, JAS); Department of Telemedicine and Bioinformatics, Jagiellonian University Medical College, Krakow, Poland (JL); Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY (AAM); Simpson DermCare & Family Medicine, Ammon, ID (IS); Department of Family & Community Medicine, University of New Mexico School of Medicine, Albuquerque (DLS); Dermatology Department, King Albert II Cancer and Hematology Institute, Cliniques Universitaires Saint-Luc, Brussels, Belgium (IT); Department of Family Medicine, Millinocket Regional Hospital, Millinocket, ME (MJT); Western Maine

dermoscopic features that should be included in dermoscopy training for PCPs. In the initial round, the panel reviewed a proposed list of diagnoses developed by the focus group. Most items on the list were drawn from a prior modified Delphi study that generated a foundational dermoscopy proficiency standard for dermatology residents.²¹ Contributors to this prior effort included members of the Melanoma Prevention Working Group-Pigmented Lesion Subcommittee (MPWG-PLS, affiliated with the Southwest Oncology Group and the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network) and other pigmented lesion experts.²¹

The proposed list was divided into 5 categories: nonmelanocytic lesions, benign melanocytic lesions, melanoma, special sites, and other diagnoses such as skin infections and infestations.²¹ This last category encompassed additional diagnoses (eg, verruca, molluscum contagiosum) that PCPs frequently encounter in clinical practice. Given the range of interest in and engagement with dermoscopy among PCPs, panelists were asked to assign each diagnosis to 1 of the following 3 options:

- Level 1 (foundational): Clinicians who desire a basic yet practical understanding of dermoscopy and its application for skin cancer detection should be able to recognize these diagnoses with basic training.
- Level 2 (intermediate): More experienced clinicians who are highly interested in learning dermoscopy beyond level 1 should be able to recognize these diagnoses. With adequate training, recognition of these "above and beyond" diagnoses would demonstrate an additional level of mastery beyond level 1. Diagnoses that do not reach consensus for inclusion in level 1 may be considered for inclusion in level 2.
- Neither level 1 nor level 2: Recognition of these diagnoses using dermoscopy would not reflect either foundational or intermediate dermoscopy proficiency for PCPs. This may include diagnoses that are extremely rare in the population or

that are especially challenging to diagnose, even by advanced dermoscopy users.

For each diagnosis, panelists rated how strongly they agreed or disagreed (via a 5-point Likert scale) with its inclusion in level 1, level 2, or neither. Panelists were also able to provide written feedback or suggest additional diagnoses to be presented in the next round. In subsequent rounds, panelists rerated diagnoses that nearly reached consensus for inclusion at a particular level (positive responses from >50% to 60% but <70% of participating panelists). Panelists also assigned additional diagnoses to level 1, level 2, or neither. Three formal rounds of surveys were performed between October and December 2021 until all diagnoses received a consensus-based assignment.

For the features survey series, the objective was to develop an expert-approved list of dermoscopic features for each included diagnosis. The aim was to capture features that are highly characteristic and important to recognize and that should be included in PCP dermoscopy education. Commonly seen structures may be included even if not specific to that diagnosis.

Based on a literature review, a proposed list of features was developed by the steering committee and presented to the panel. References for this list included the MPWG-PLS consensus on dermoscopy proficiency expectations for dermatology residents,²¹ the Dermoscopedia website,²⁵ the 2016 International Dermoscopy Society consensus on dermoscopy terminology,²⁶ the International Skin Imaging Collaboration dictionary of standardized terms, and other medical literature on PubMed, as documented in the online appendices.

For each feature, panelists rated on a 5-point Likert scale how strongly they would agree or disagree with its inclusion in dermoscopy training for primary care. Panelists were also able to propose wording modifications or suggest additional features. In the subsequent round, panelists rerated features that nearly reached consensus (positive responses from >60% but <70% of participating

Primary Care, Norway (MJT); Department of Dermatology & Cutaneous Surgery, Department of Family & Community Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, TX (RPU); Brigham and Women's Health Care Center, Pembroke, MA (AMW); South Shore Medical Center, Norwell, MA (BLW); Redirect Health, Glendale, AZ (RFW); Department of Family Medicine, University of Washington School of

Medicine, Seattle (MLW); Department of Dermatology, University of Kansas Medical Center, Kansas City (DJW); Division of Dermatology, Maine Medical Center, Portland (EVS); Department of Dermatology, Tufts University School of Medicine, Boston, MA (EVS)

Funding: This project was supported in part by the generous philanthropic contributions of the Lyda Hill Foundation to the University of Texas MD Anderson panelists) and rated additional features. Two formal rounds of features surveys were performed between December 2021 and February 2022.

On the conclusion of each round, all responses were deidentified, and data analyses were performed using REDCap and Microsoft Excel. Panelists received a summary of the preliminary results that reported the percentage of positive responses for each diagnosis. These results summaries were intended to inform panelists' decisions in subsequent rounds.

Each specific item that reached final consensus for inclusion received positive responses (defined as selection of "strongly agree" or "agree" on the Likert scale) from >70% of participating panelists. This threshold criterion was derived from the MPWG-PLS's consensus process that used a similar 2-phase modified Delphi method.²¹ Features that received >50% but <70% positive responses were not formally included in the final consensus statement but were labeled as "optional to include" for PCP-targeted dermoscopy training.

Panel Recruitment

Through known professional networks, 40 subject matter experts were invited to join the panel: 25 PCPs (23 family medicine physicians and 2 internal medicine physicians) who routinely use dermoscopy in clinical practice and 15 dermatologists. Of the 15 invited dermatologists, most are directly involved in dermoscopy education and skin cancer detection training for PCPs, and 2 previously worked in primary care.

At the beginning of each survey, panelists reviewed and acknowledged a consent statement. No monetary compensation for panel participation was offered. For both survey series, copies of the consent statement, survey instruments, and results summaries can be found in the online appendices.

Results

Panelist Demographics

Of the 40 active physicians invited to join the panel, 35 (87.5%) participated in the initial round (Table 1). Of these 35, 21 (60.0%, 19 family medicine

physicians and 2 internal medicine physicians) were PCPs (76.2% response rate), and the remaining 14 (40.0%) were dermatologists (93.3% response rate). Sixteen of the initial panelists (45.7%) reported specializing in pigmented lesions, dermoscopy, or melanoma as an attending physician. Of these 16, 3 were PCPs (2 family medicine physicians and 1 internal medicine physician), while the remainder were dermatologists. A majority (62.9%) reported being directly involved in dermoscopy training for primary care, offering training in the clinic and/or through lectures.

Over the course of the study, 5 PCPs were lost to follow-up or withdrew from the study. Of the 30 who completed the fifth and last round, 16 (53.3%, 14 family medicine physicians and 2 internal medicine physicians) were PCPs (76.2% retention rate), and 14 (46.7%) were dermatologists (100% retention rate).

Survey Results

The consensus process involved 2 successive survey series: (1) diagnoses, and (2) features. In the diagnoses survey series, panelists voted on a total of 51 diagnoses (Table 2). Of this total, 15 represented additional diagnoses written in by panelists, and 39 received >70% positive responses and reached final consensus for inclusion (13 in level 1 and 26 in level 2).

In the features survey series, panelists voted on the inclusion of different dermoscopic features for each included diagnosis. A summary of the features survey results-organized into the categories of nonmelanocytic lesions, benign melanocytic lesions, melanoma, special sites, and other diagnoses—is included in Tables 3-7. Of the 156 total features surveyed, 6 represented additional features written in by panelists, and 120 features received >70% positive responses and reached final consensus for inclusion (62 in level 1 and 58 in level 2). Certain features may have been excluded if they are rarely seen, challenging to discern, and/or of poor diagnostic value. Of note, 19 features (4 in level 1

Prior presentation: A summary of this original work was presented as a medical student poster by Ms. Tiffaney Tran

Cancer Center Moon Shots Program. The funding source was not involved in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

Conflict of interest: None.

at the annual American Dermoscopy Meeting in St. George, Utah, on July 1, 2022. This work has otherwise not been previously posted or published elsewhere, nor is it under consideration for publication elsewhere.

Corresponding author: Kelly C. Nelson, MD, Department of Dermatology, 1400 Pressler St., Unit 1452, University of Texas MD Anderson Cancer Center, Houston, TX 77030 (E-mail: kcnelson1@mdanderson.org).

Table 1. Demographic Characteristics of Larger **Expert Panel (n = 35 Participants in First Round)**

| Specialty (n = 35) | Count | | % |
|---|--|----------------------------------|--|
| Family medicine | 19 | | 54.3% |
| Internal medicine | 2 | | 5.7% |
| Medicine—pediatrics | 0 | | 0.0% |
| Dermatology | 14 | | 40.0% |
| Other | 0 | | 0.0% |
| Dermoscopy use in clinical p | ractice (n = 35) | Count | % |
| Yes | | 35 | 100% |
| No | | 0 | 0.0% |
| No. years of dermoscopy use tice (n = 35) | in clinical prac- | Count | % |
| 0 to 1 year | | 0 | 0.0% |
| 1 to 5 years | | 16 | 45.7% |
| 6 to 10 years | | 10 | 28.6% |
| 11 to 15 years | | 4 | 11.4% |
| 15 + years | | 5 | 14.3% |
| Specialization in pigmented l scopy, or melanoma as an att (n = 35) | | Count | % |
| Yes | | 16 | 45.7% |
| No | | 19 | 54.3% |
| No. years of specialization in lesions, dermoscopy, or mela attending physician (n = 16) | | Count | % |
| 0 to 1 year | | 0 | 0.0% |
| | | | |
| 1 to 5 years | | 7 | 43.8% |
| 1 to 5 years 6 to 10 years | | 7 2 | |
| | | • | 43.8% 12.5% 25.0% |
| 6 to 10 years | | 2 | 12.5% |
| 6 to 10 years 11 to 15 years | scopy training for | 2 4 | 12.5% 25.0% |
| 6 to 10 years 11 to 15 years 15 + years Direct involvement in dermo primary care (n = 35) | scopy training for | 2 4 3 Count | 12.5% 25.0% 18.8% |
| 6 to 10 years 11 to 15 years 15 + years Direct involvement in dermo | scopy training for | 2 4 3 | 12.5% 25.0% 18.8% |
| 6 to 10 years 11 to 15 years 15 + years Direct involvement in dermo primary care (n = 35) Yes | scopy training for | 2 4 3 Count | 12.5% 25.0% 18.8% % |
| 6 to 10 years 11 to 15 years 15 + years Direct involvement in dermo primary care (n = 35) Yes No If directly involved in dermos | scopy training for coffered* (n = 22) | 2 4 3 Count | 12.5% 25.0% 18.8% % 62.9% 37.1% |
| 6 to 10 years 11 to 15 years 15 + years Direct involvement in dermo primary care (n = 35) Yes No If directly involved in dermo primary care, type of training | scopy training for coffered* (n = 22) | 2 4 3 Count 22 13 | 12.5% 25.0% 18.8% % 62.9% 37.1% |

^{*}Multiple selections allowed, sum of percentages >100%.

and 15 in level 2) received >50% but <70% positive responses and thus did not reach final consensus. However, depending on the degree of interest and skill level of the educational cohort, these features may be added as a learning objective at the discretion of the curricular development team.

The online appendices contain the final list of diagnoses and their associated features, organized into levels 1 and 2 based on Delphi agreement. For each associated feature, dermoscopy users may customarily refer to different nomenclatures to describe the same pattern. In this study, the exact wording for each feature was considered less important than the described feature itself.

Discussion

Through a modified Delphi exercise, an expert panel that comprised family medicine physicians, internal medicine physicians, and dermatology specialists achieved consensus on proficiency standards for PCPs learning or using dermoscopy. This collaboration between primary care and dermatology reflects a growing national partnership that has been emerging as an important strategy for skin cancer prevention and detection, especially in rural areas.

Given the range of interest in dermoscopy among PCPs, the consensus process generated 2 levels of proficiency standards. The focus of level 1 (foundational proficiency) is training in the basic skills required to differentiate between benign and malignant lesions under dermoscopy. As expected, level 1 teaches an overview of nevi patterns and melanoma patterns as well as classic features for keratinocyte carcinomas, namely BCC and SCC.

Level 1 also contains common benign diagnoses that closely align with the triage amalgamated dermoscopy algorithm (TADA). 27,28 This diagnostic aid trains learners to first search for specific features of common benign diagnoses (ie, angioma/hemangioma, seborrheic keratosis, dermatofibroma).^{29,30} In suspicious lesions, learners next evaluate for characteristic features of malignant diagnoses that would warrant biopsy, excision, or referral to a specialist.31 Training programs based on TADA have been shown to improve the sensitivity for skin cancer detection compared with baseline.²⁹⁻³² Given the proven effectiveness of TADA in training PCPs and novices, 33 PCP-targeted dermoscopy education based on level 1 may begin with TADA and then continue to the other level 1 diagnoses.

Extending beyond level 1, level 2 is intended for more experienced PCPs who desire more advanced dermoscopy skills. Compared with those in level 1,

[†]Other delivery methods for dermoscopy training, as reported by panelists, included virtual training, e-learning, distance learning.

Table 2. Dermoscopic Diagnoses by Lesion Category and Proficiency Standard

| Category | Level 1 (Foundational) | Level 2 (Intermediate) | Neither |
|----------------------------|------------------------------------|--|---|
| Nonmelanocytic lesions | Hemangioma | Sebaceous hyperplasia | Clear cell acanthoma |
| | Seborrheic keratosis | Pigmented actinic keratosis | Merkel cell carcinoma[†] |
| | • Dermatofibroma | Squamous cell carcinoma in situ | • Porokeratosois [†] |
| | Solar lentigo | Keratoacanthoma | • Poroma [‡] |
| | Basal cell carcinoma | Angiokeratoma | Xanthogranuloma[‡] |
| | Squamous cell carcinoma | • Lichen planus-like keratosis | |
| | Actinic keratosis | • Ink spot lentigo [†] | |
| Benign melanocytic lesions | • Overview of benign nevi patterns | Blue nevi | Combined nevi[†] |
| | Intradermal nevi | Spitz nevi | |
| | | Congenital melanocytic nevi Recurrent/persistent nevi | |
| | | Halo nevi[†] | |
| Melanoma | Overview of melanoma patterns | Acral melanoma | Desmoplastic melanoma[†] |
| | | Lentigo maligna melanoma | Nevoid melanoma[†] |
| | | Melanoma of the nail | Verrucous melanoma[†] |
| | | Amelanotic/hypomelanotic melanoma | |
| Special sites | Subungual hemorrhage | Dermoscopic features of the face | Nevi of the mucosa[†] |
| | | Benign patterns of acral nevi Nevus of the nail | • Nevi of the mucocutaneous junction [†] |
| | | Lentigo of the nail | |
| | | • Talon noir [†] | |
| Other | • Verruca* | Molluscum contagiosum* | Atopic dermatitis[†] |
| | • Scabies | • Radiation tattoo* | - |
| | | • Scars* | |
| | | Venous lake* | |
| | | • Psoriasis [†] | |

^{*}Suggested by the expert focus group to add onto the Melanoma Prevention Working Group-Pigmented Lesions Subcommittee consensus-based list for dermatology residents.

diagnoses in level 2 are mostly considered less common in the general population and/or more challenging to discern (eg, pigmented actinic keratosis, lichen planus-like keratosis). Level 2 also incorporates different types of melanoma (eg, lentigo maligna melanoma, amelanotic/hypomelanotic melanoma) and benign nevi (eg, blue nevi, acral nevi) and demonstrates a broader utility of dermoscopy in the identification of other diagnoses frequently encountered by PCPs (eg, molluscum contagiosum, psoriasis).

With the exception of 1 diagnosis that required 2 rounds of feedback (ie, scabies), all level 1 diagnoses were deemed "foundational" by the panel during the very first round of voting, demonstrating strong consensus on the diagnoses reflective of a basic yet practical skillset for PCPs. Subsequent rounds focused on sorting between level 1 and 2 diagnoses and identifying diagnoses that should be excluded from either level. For instance, the decision-making process for lichen planus-like keratosis required 3 rounds of voting before assigning the diagnosis to level 2.

The outcome of this PCP-focused consensus effort differs in some ways from the proficiency standard developed by the MPWG-PLS for dermatology residents. ²¹ In addition to assigning diagnoses to level 1 or 2, this panel approved the inclusion of additional diagnoses and excluded clear cell acanthoma from either level. Of the 15 total additional diagnoses suggested by panelists, 1 (ie, verruca) reached consensus for inclusion in level 1, and 4 (ie,

[†]Suggested by a panelist during round 1 of the diagnoses survey series.

[‡]Suggested by a panelist during round 2 of the diagnoses survey series.

Table 3. Dermoscopic Characteristics of Nonmelanocytic Lesions

| Diagnosis (Level 1 or 2) Feature included as a learning objective (>70% positive responses) | Round 1: % Positive Responses* (n = 33) | Round 2: % Positive Responses* (n = 30) |
|---|---|---|
| Hemangioma (level 1) | | |
| Red, blue-red, red-purple, or maroon lacunae/lagoons with white septae | 72.7% | _ |
| Blue-black coloring in lacunae (when thrombosed) in absence of other structures | 72.7% | _ |
| Seborrheic keratosis (level 1) | 721,70 | |
| Milia-like cysts (cloudy or starry) and comedo-like openings | 93.9% | _ |
| "Fissures and ridges"/"gyri and sulci"/cerebriform pattern | 93.9% | _ |
| Moth-eaten (sharply demarcated) borders | 87.9% | _ |
| Fat fingers | 78.8% | _ |
| Fingerprint-like structures (parallel lines) | 78.8% | _ |
| Hairpin (looped) vessels | 78.8% | _ |
| Dermatofibroma (level 1) | | |
| Central scar-like white patch/depigmentation | 100.0% | _ |
| Fine/delicate surrounding/peripheral network-like structures | 100.0% | _ |
| Central shiny white lines/streaks under polarized dermoscopy | 84.8% | _ |
| Ring-like globules | 66.7% | ↓ 60.0% |
| Solar lentigo (level 1) | 331, 73 | \$ 00.070 |
| Moth-eaten (sharply demarcated) borders | 90.9% | _ |
| Fingerprint-like structures (parallel lines) | 90.9% | _ |
| Homogenous light brown pigmentation | 87.9% | _ |
| Uniform brown perifollicular pigmentation | 75.8% | _ |
| Network-like structures | 63.6% | ↓ 63.3% |
| Basal cell carcinoma (level 1) | 03.070 | Ų 03.370 |
| Arborizing vessels | 97.0% | _ |
| Ulceration/erosion | 93.9% | _ |
| Leaf-like structures/areas | 90.9% | _ |
| Blue-gray ovoid nests | 87.9% | _ |
| Spoke-wheel-like structures/areas/concentric structures | 87.9% | _ |
| Multiple blue-gray dots and globules (buckshot scatter) | 84.8% | _ |
| Shiny white blotches and strands/structures under polarized dermoscopy | 69.7% | ↑ 76.7% |
| Short fine telangiectasias (superficial BCC) | 69.7% | ↑ 70.0% |
| Squamous cell carcinoma (level 1) | 07.770 | 7 0.0 70 |
| Yellow keratin mass/scale-crust | 100.0% | _ |
| Ulceration/blood spots/hemorrhage | 93.9% | _ |
| White circles ("keratin pearls") | 90.9% | _ |
| Glomerular (coiled) vessels | 90.9% | _ |
| Hairpin vessels | 78.8% | _ |
| Rosettes | 75.8% | _ |
| Actinic keratosis (level 1) | 73.070 | _ |
| Surface scale | 97.0% | |
| Rosettes | 81.8% | _ |
| Strawberry pattern (pink-red pseudonetwork \pm fine wavy vessels [straight or coiled] surrounding | 78.8% | _ |
| hair follicles \pm white circles with central yellow clod [targetoid hair follicles]) | 7 0.0 70 | _ |
| Sebaceous hyperplasia (level 2) | 100.007 | |
| Pale yellow lobules (popcorn-like structures) around a central follicular opening | 100.0% | _ |
| Crown vessels, out of focus | 90.9% | _ |

Continued

Table 3. Continued

| Diagnosis (Level 1 or 2) Feature included as a learning objective (>70% positive responses) | Round 1: % Positive Responses* (n = 33) | Round 2: % Positive Responses* (n = 30) |
|---|---|--|
| Pigmented actinic keratosis (level 2) | | |
| Surface scale | 90.9% | _ |
| Rosettes | 75.8% | _ |
| Annular-granular pattern (gray dots around follicular openings) | 66.7% | ↓ 53.3% |
| Red pseudonetwork [†] | 57.6% | _ |
| Patent/evident follicles [†] | 57.6% | _ |
| Squamous cell carcinoma in situ (level 2) | | |
| Irregularly arranged glomerular (coiled)/dotted vessels | 93.9% | _ |
| Surface scale | 87.9% | _ |
| Keratoacanthoma (level 2) | | |
| Central keratin mass | 93.9% | _ |
| Hairpin (looped) or serpentine (linear-irregular) vessels, usually at the periphery, with white-yellow halo | 87.9% | _ |
| Angiokeratoma (level 2) | | |
| Red/purple/black ("dark") lacunae | 93.9% | _ |
| Hemorrhagic crust | 75.8% | _ |
| Lichen planus-like keratosis (level 2) | | |
| Features of a lentigo or seborrheic keratosis in an area | 72.7% | _ |
| Peppering (evenly spaced gray dots) | 69.7% | ↓ 63.3% |
| Sharp cut-off borders (scalloped/moth-eaten) | 69.7% | ↓ 63.3% |
| Coarse gray granularity | 63.6% | ↓ 53.3% |
| Ink spot lentigo (level 2) | | |
| Prominent dark homogenous (uniform) reticular network | 93.9% | _ |
| Chicken-wire fence | 63.6% | ↓ 50.0% |

^{*%} of panelists who indicated on a 5-point Likert scale that they "strongly agree" (5) or "agree" (4) with the feature being included in dermoscopy training for primary care providers.

ink spot lentigo, halo nevi, talon noir, psoriasis) in level 2. The expert focus group also removed simple lentigo from the list due to its overlap with solar lentigo. With the exception of psoriasis (level 2), all other diagnoses excluded from the foundational proficiency standard for dermatology residents (eg, poroma, Merkel cell carcinoma, nevoid melanoma, desmoplastic melanoma) were likewise excluded from the foundational and intermediate proficiency standards for PCPs. The mutual exclusion of these extremely rare and/or challenging diagnoses by this panel serves to validate the results of this consensus process.

This consensus statement will contribute to the development of effective educational interventions that teach expert-approved learning objectives and have content validity.²⁴ It may also serve as the basis of formal proficiency certification or continuing medical education credit for PCPs. Yet, the application of this consensus statement comes with an important caveat: educators and learners alike are strongly discouraged from approaching dermoscopy training as a process akin to the rote memorization of a list of diagnoses and features. Efficient interpretation of dermoscopic images relies heavily on pattern recognition skills³⁴ and "fast thinking."³⁵ Though the educational science for dermoscopy education remains to be further developed, active learning strategies, such as visual perceptual training³⁶ or deliberate practice,³⁷ are generally more effective than passive instructional approaches. Future studies will explore the application of this consensus statement to dermoscopy educational interventions for PCPs. Further

[†]Suggested by a panelist during round 1 of the features survey series.

Abbreviations: BCC, basal cell carcinoma; SCCIS, squamous cell carcinoma in situ (Bowen's disease).

Table 4. Dermoscopic Characteristics of Benign Melanocytic Lesions

| Diagnosis (Level 1 or 2) Feature included as a learning objective (>70% positive responses) | Round 1: % Positive Responses* (n = 33) | Round 2: % Positive Responses* (n = 30) |
|--|---|--|
| Overview of benign nevi patterns (level 1) | | |
| Diffuse reticular network | 100.0% | _ |
| Peripheral reticular network with central hypopigmentation | 100.0% | |
| Peripheral reticular network with central hyperpigmentation | 100.0% | |
| Globular pattern | 100.0% | _ |
| Patchy reticular network | 97.0% | _ |
| Homogenous (tan, brown, blue, or pink) | 93.9% | _ |
| Peripheral reticular network with central globules | 90.9% | _ |
| | 90.9 % 87.9% | _ |
| Central network with evenly distributed peripheral globules | 87.9% 75.8% | _ |
| Symmetric multicomponent pattern | | |
| Symmetric two-component pattern | 69.7% | ↓ 60.0% |
| Intradermal nevi (level 1) | 03.00/ | |
| Comma-shaped (curved) vessels | 93.9% | _ |
| Homogenous (structureless) brown/tan/pink pigmentation | 93.9% | _ |
| Peripheral network | 72.7% | _ |
| Globules | 87.9% | _ |
| Blue nevi (level 2) | | |
| Homogenous blue/blue-gray pigmentation | 100.0% | _ |
| Well-circumscribed lesion | 93.9% | _ |
| Spitz nevi (level 2) | | |
| Starburst pattern with tiered globules/streaks and regularly spaced pseudopods at the periphery (radial streaming) | 87.9% | _ |
| Vascular pattern (pink homogenous with dotted vessels) | 75.8% | _ |
| Congenital melanocytic nevi (level 2) | | |
| Cobblestone pattern/globular pattern | 93.9% | _ |
| Reticular network | 90.9% | _ |
| Homogenous background pigmentation | 87.9% | _ |
| Hypertrichosis | 78.8% | _ |
| Perifollicular hyper-/hypopigmentation | 69.7% | ↓ 60.0% |
| Recurrent/persistent nevi (level 2) | | |
| Pigment within the scar, not extending beyond | 81.8% | _ |
| Halo nevi (level 2) | | |
| Encircling/surrounding depigmentation/pallor | 93.9% | _ |
| Central reticulation with peripheral white depigmentation | 78.8% | _ |
| Benign nevi patterns, globular, homogenous | 78.8% | _ |

^{*%} of panelists who indicated on a 5-point Likert scale that they "strongly agree" (5) or "agree" (4) with the feature being included in dermoscopy training for primary care providers.

research is also needed to determine best practices for dermoscopy proficiency assessments.

Conclusions

Dermoscopy is a valuable tool that assists clinicians in discriminating malignant from benign skin lesions. For PCPs who treat skin conditions and evaluate skin lesions, dermoscopy training improves sensitivity for skin cancer diagnosis. However, 1 of the obstacles to developing a standardized dermoscopy curriculum for PCPs has been the lack of consensus on appropriate learning objectives. To PCPs using dermoscopy in clinical practice, this study provides meaningful insight into the diagnoses and features that an expert panel considers important to recognize, especially in the course of identifying skin cancer.

The consensus statement generated by this modified Delphi study will inform future dermoscopy

Table 5. Dermoscopic Characteristics of Melanomas

| Diagnosis (Level 1 or 2) Feature included as a learning objective (>70% positive responses) | Round 1: % Positive Responses* (n = 33) | Round 2: % Positive Responses* (n = 30) |
|---|---|---|
| | (= | () |
| Overview of melanoma patterns (level 1) | 400.007 | |
| Blue structures (blue-white veil, blue-gray structures) | 100.0% | _ |
| Shiny white lines/structures (crystalline structures) | 100.0% | _ |
| Atypical pigment network | 97.0% | _ |
| Atypical/irregular streaks (radial streaming, pseudopods) | 97.0% | _ |
| Atypical/irregular dots/globules | 93.9% | _ |
| Regression structures (white scar-like area and/or peppering) | 93.9% | _ |
| Negative pigment network | 87.9% | _ |
| Atypical vascular pattern/structures, polymorphous vessels $(2 + types of blood vessels)$ | 87.9% | _ |
| Peripheral brown/tan structureless area | 78.8% | _ |
| Angulated lines (extrafacial)/polygons/zig-zag pattern | 75.8% | _ |
| Atypical/off-center blotch(es) | 69.7% | ↑ 90.0% |
| Acral melanoma (level 2) | | |
| Parallel ridge pattern | 93.9% | _ |
| Ulceration | 90.9% | _ |
| Irregular diffuse pigmentation or blotch | 84.8% | _ |
| Multicomponent pattern, asymmetry of structures/colors | 84.8% | _ |
| Atypical fibrillar pattern | 72.7% | _ |
| Neovascularization, milky red | 72.7% | _ |
| Lentigo maligna melanoma (level 2) | | |
| Annular-granular pattern (gray dots around follicular openings) | 90.9% | _ |
| Asymmetric pigmentation around follicular openings/asymmetric follicular openings | 87.9% | _ |
| Rhomboidal structures (angulated lines)/zig-zag pattern | 81.8% | _ |
| Dark blotches \pm obliterated hair follicles | 75.8% | _ |
| Circle within a circle (isobar) | 60.6% | ↓ 56.7% |
| Melanoma of the nail (level 2) | 00.070 | ¥ 30.7 70 |
| Pigmentation of periungual skin (micro-Hutchinson's sign) | 90.9% | _ |
| Triangular shape of pigment band (band diameter wider at proximal end) | 87.9% | _ |
| Longitudinal brown/black broken lines with irregular spacing, width, coloration, or parallelism | 81.8% | _ |
| Band width >3 mm or two thirds of nail plate width | 78.8% | _ |
| Brown to black dots/globules associated with longitudinal lines | 60.6% | ↓ 50.0% |
| Amelanotic/hypomelanotic melanoma (level 2) | 00.070 | ţ 50.078 |
| | 81.8% | |
| Milky red areas Shinn white lines (empetalling charactures) | 81.8% | _ |
| Shiny white lines (crystalline structures) | | _ |
| Atypical vascular pattern, polymorphous vessels (2 + types of blood vessels) | 81.8% | _ |
| Scar-like depigmentation | 75.8% | |

^{*%} of panelists who indicated on a 5-point Likert scale that they "strongly agree" (5) or "agree" (4) with the feature being included in dermoscopy training for primary care providers.

training programs designed to support early skin cancer detection by PCPs. Through the dissemination of a standardized dermoscopy curriculum, the dermatoscope may become increasingly recognized as a valuable component of the PCP's toolbox alongside other commonly used medical instruments such as the ophthalmoscope, otoscope,

and stethoscope.³⁸ The ultimate goal of these dermoscopy training initiatives would be to decrease patient morbidity and mortality from skin cancer, especially in regions without convenient access to dermatology specialists.

The research team wishes to acknowledge Dr. Lauren Fried for her guidance on the study design.

Table 6. Dermoscopic Characteristics of Benign Diagnoses at Special Sites

| Diagnosis (Level 1 or 2) Feature included as a learning objective (>70% positive responses) | Round 1: % Positive Responses* (n = 33) | Round 2: % Positive Responses* (n = 30) |
|--|---|--|
| Subungual hemorrhage (level 1) | | |
| Well-circumscribed red-black dots or blotches/blood spots | 90.9% | _ |
| Discontiguous with the cuticle (not connected to the proximal nailfold or edge of nail) | 87.9% | _ |
| Distal streaks of red-brown coloration ("filamentous" distal end) | 81.8% | _ |
| Homogenous red/purple/black coloration without melanin granules Dermoscopic features of the face (level 2) | 69.7% | ↓ 60.0% |
| Pseudonetwork | 78.8% | _ |
| Benign patterns of acral nevi (level 2) | | |
| Parallel furrow pattern (with pattern variations including single line, double line, single dotted line, double dotted line) | 93.9% | _ |
| Lattice-like pattern | 87.9% | _ |
| Fibrillar pattern (soles only) | 84.8% | _ |
| Homogenous pattern | 75.8% | _ |
| Peas-in-a-pod pattern (parallel furrow + globules on ridges) (acral congenital melanocytic nevi) | 69.7% | ↓ 56.7% |
| Nevus of the nail (level 2) | | |
| Uniform band thickness, color, and spacing with parallel band configuration and unbroken lines | 87.9% | _ |
| Homogenous brown background coloration | 84.8% | _ |
| Lentigo of the nail (level 2) | | |
| Homogenous gray band or lines ± gray background | 78.8% | _ |
| Regular light-brown lines [†] | _ | 60.0% |
| Talon noir (level 2) | | |
| Homogenous red-brown coloration | 78.8% | _ |
| Cracks (lightning bolt sign)‡ | 51.5% | _ |

^{*%} of panelists who indicated on a 5-point Likert scale that they "strongly agree" (5) or "agree" (4) with the feature being included in dermoscopy training for primary care providers.

To see this article online, please go to: http://jabfm.org/content/ 36/1/25.full.

References

- 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clinicians 2022;72: 7 - 33.
- 2. Howlader NN, Krapcho M, Miller D, et al. editors. SEER cancer statistics review, 1975-2016 [Internet].2019 [cited 2021 July 1]. Available from: https://seer.cancer.gov/csr/1975_2016/.
- 3. Glazer AM, Farberg AS, Winkelmann RR, Rigel DS. Analysis of trends in geographic distribution and density of US dermatologists. JAMA Dermatol 2017:153:322-5.
- 4. Vaidya T, Zubritsky L, Alikhan A, Housholder A. Socioeconomic and geographic barriers to dermatology care in urban and rural US populations. J Am Acad Dermatol 2018;78:406-8.

- 5. Wu X, Marchetti MA, Marghoob AA. Dermoscopy: not just for dermatologists. Melanoma Manag 2015; 2:63-73.
- 6. Losina E, Walensky RP, Geller A, et al. Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol 2007;143:21-8.
- 7. Marghoob NG, Liopyris K, Jaimes N. Dermoscopy: a review of the structures that facilitate melanoma detection. J Am Osteopath Assoc 2019;119:380-90.
- 8. Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol 2008;159:669-76.
- 9. Dinnes J, Deeks JJ, Grainge MJ, et al. Visual inspection for diagnosing cutaneous melanoma in adults. Cochrane Database Syst Rev 2018;12:CD013194.
- 10. Prasad S, Black S, Chen HW, et al. Beliefs and barriers to care of primary care practitioners toward

[†]Suggested by a panelist during round 1 of the dermoscopic features survey series.

[‡]Feature did not undergo a revote in round 2 due to original threshold criteria for a revote being <70% but >60% positive responses.

Table 7. Dermoscopic Characteristics of Other Diagnoses, Including Skin Infections and Infestations

| Diagnosis (Level 1 or 2) Feature included as a learning objective (>70% positive responses) | Round 1: % Positive Responses* (n = 33) | Round 2: % Positive Responses* (n = 30) |
|---|---|---|
| Verruca (level 1) | | |
| Papilliform structures | 93.9% | _ |
| Tiny red-black dots (papillary capillaries) | 90.9% | _ |
| Scabies (level 1) | | |
| Delta-wing jet with contrail sign (small dark brown triangular structure located at the end of whitish structureless curved/wavy lines) | 90.9% | _ |
| Molluscum contagiosum (level 2) | | |
| Central pore or umbilication | 93.9% | _ |
| Polylobular white-yellow amorphous structures | 81.8% | _ |
| Linear or branched vessels (red corona)/crown vessels | 63.6% | ↓ 63.3% |
| Radiation tattoo (level 2) | | |
| Homogenous blue or black coloration | 84.8% | _ |
| Scars (level 2) | | |
| White depigmentation | 72.7% | _ |
| Venous lake (level 2) | | |
| Homogenous purple/blue/red coloration ± globules/clods | 93.9% | _ |
| Psoriasis (level 2) | | |
| Red or pink color with white scales/light-red background | 75.8% | _ |
| Dotted vessels in a regular distribution | 72.7% | _ |

^{*%} of panelists who indicated on a 5-point Likert scale that they "strongly agree" (5) or "agree" (4) with the feature being included in dermoscopy training for primary care providers.

- melanoma screening and education in rural Texas. J Am Acad Dermatol. Forthcoming 2022.
- 11. Verhoeven EW, Kraaimaat FW, van Weel C, et al. Skin diseases in family medicine: prevalence and health care use. Ann Fam Med 2008;6:349–54.
- Perera E, Xu C, Manoharan S. Real-life teledermatology cases. In: Soyer HP, Binder M, Smith AC, Wurm EMT, editors. Telemedicine in dermatology. Springer Science & Business Media; 2012. p. 123–9.
- 13. Westerhoff K, McCarthy WH, Menzies SW. Increase in the sensitivity for melanoma diagnosis by primary care physicians using skin surface microscopy. Br J Dermatol 2000;143:1016–20.
- Argenziano G, Puig S, Zalaudek I, et al. Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. J Clin Oncol 2006;24:1877–82.
- 15. Menzies SW, Emery J, Staples M, et al. Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial. Br J Dermatol 2009;161:1270–7.
- Koelink CJ, Vermeulen KM, Kollen BJ, et al. Diagnostic accuracy and cost-effectiveness of dermoscopy in primary care: a cluster randomized

- clinical trial. J Eur Acad Dermatol Venereol 2014;28:1442–9.
- 17. De Bedout V, Williams NM, Muñoz AM, et al. Skin cancer and dermoscopy training for primary care physicians: a pilot study. Dermatol Pract Concept 2021;11:e2021145.
- Pokhrel PK, Helm MF, Greene A, Helm LA, Partin M. Dermoscopy in primary care. Prim Care 2022;49:99–118.
- 19. Posada EL, Lauck KC, Tran T, Krause KJ, Nelson KC. Educational interventions to support primary care provider performance of diagnostic skin cancer examinations: a systematic literature review. J Cancer Educ 2022;1–10.
- Najmi M, Brown AE, Harrington SR, Farris D, Sepulveda S, Nelson KC. A systematic review and synthesis of qualitative and quantitative studies evaluating provider, patient, and health care system-related barriers to diagnostic skin cancer examinations. Arch Dermatol Res 2022; 314:329–40.
- 21. Fried LJ, Tan A, Berry EG, et al. Dermoscopy proficiency expectations for US dermatology resident physicians: results of a modified Delphi survey of pigmented lesion experts. JAMA Dermatol 2021; 157:189–97.

- 22. Dalkey NC, Helmer O. An experimental application of the DELPHI method to the use of experts. Manag Sci 1963;9:458–67.
- Dalkey NC. The Delphi method: an experimental study of group opinion. RAND Corporation; 1969.
- 24. Rusticus S. Content validity. In: Michalos AC, ed. Encyclopedia of quality of life and well-being research. Springer Netherlands; 2014. p. 1261–2.
- Dermoscopedia [Internet]. International Dermoscopy Society; 2021 [accessed 1 Nov 2021]. Available from: https://dermoscopedia.org/Main_Page.
- Kittler H, Marghoob AA, Argenziano G, et al. Standardization of terminology in dermoscopy/dermatoscopy: results of the third consensus conference of the International Society of Dermoscopy. J Am Acad Dermatol 2016;74:1093–106.
- 27. Rogers T, Marino ML, Dusza SW, et al. A clinical aid for detecting skin cancer: the triage amalgamated dermoscopic algorithm (TADA). J Am Board Fam Med 2016;29:694–701.
- Jaimes N, Marghoob AA. Triage amalgamated dermoscopic algorithm. J Am Acad Dermatol 2020; 82:1551–2.
- Seiverling EV, Ahrns HT, Greene A, et al. Teaching benign skin lesions as a strategy to improve the triage amalgamated dermoscopic algorithm (TADA). J Am Board Fam Med 2019;32:96–102.
- Sawyers EA, Wigle DT, Marghoob AA, Blum A. Dermoscopy training effect on diagnostic accuracy of skin lesions in Canadian family medicine physicians using the triage amalgamated dermoscopic algorithm. Dermatol Pract Concept 2020;10:e2020035.

- 31. Susong JR, Ahrns HT, Daugherty A, Marghoob AA, Seiverling EV. Evaluation of a virtual basic dermatology curriculum for dermoscopy by using the triage amalgamated dermoscopic algorithm for novice dermoscopists. J Am Acad Dermatol 2020;83:590–2.
- 32. Seiverling E, Ahrns H, Stevens K, et al. Dermoscopic lotus of learning: implementation and dissemination of a multimodal dermoscopy curriculum for primary care. J Med Educ Curric Dev 2021;8:2382120521989983–4.
- 33. Cyr PR, Craig W, Ahrns H, Stevens K, Wight C, Seiverling E. Teaching skin cancer detection to medical students using a dermoscopic algorithm. STFM PRIMER 2021;5:6.
- 34. Kellman PJ, Garrigan P. Perceptual learning and human expertise. Phys Life Rev 2009;6:53–84.
- 35. Gronchi G, Giovannelli F. Dual process theory of thought and default mode network: a possible neural foundation of fast thinking. Front Psychol 2018;9:1237.
- Rimoin L, Altieri L, Craft N, Krasne S, Kellman PJ. Training pattern recognition of skin lesion morphology, configuration, and distribution. J Am Acad Dermatol 2015;72:489–95.
- 37. Ericsson KA. Acquisition and maintenance of medical expertise: a perspective from the expert-performance approach with deliberate practice. Acad Med 2015;90:1471–86.
- 38. Lallas A, Argenziano G. Dermatoscope—the dermatologist's stethoscope. Indian J Dermatol Venereol Leprol 2014;80:493–4.

Appendices.

Appendix A. Modified Delphi method survey instruments

Dermatologic Diagnoses Survey Series

- Consent Statement
- Round 1: Survey Objective
- Section 1: Nonmelanocytic Lesions Section 2: Benign Melanocytic Lesions
- Section 3: Melanoma
- Section 4: Special Sites
- Section 5: Other
- Demographics Survey

Round 2

- Consent Statement
- Round 2: Survey Objective Section 1: Nonmelanocytic Lesions
- Section 2: Benign Melanocytic Lesions
- Section 3: Melanoma
- Section 4: Special Sites
- Section 5: Other

Round 3

- Consent Statement
- Round 3: Survey Objective
- Diagnoses: All Categories

Dermoscopic Features Survey Series

Round 1

- Consent Statement
- Round 1: Survey Objective
- Section 1: Nonmelanocytic Lesions
- Section 2: Benign Melanocytic Lesions
- Section 3: Melanoma
- Section 4: Special Sites
- Section 5: Other
- Miscellaneous

Round 2

- Consent Statement
- Round 2: Survey Objective
- Section 1: Nonmelanocytic Lesions
- Section 2: Benign Melanocytic Lesions
- Section 3: Melanoma
- Section 4: Special Sites Section 5: Other





| section | on 1: Nonmelanocytic L | esions | | | | AAA |
|---------------------------|--|---|--|--|---|--|
| | d like to identify the dermatologic diagr towards PCPs. | noses that sho | ould be included | in dermoscop | y education | programs |
| diagnosis | te how strongly you would agree or dis s. Given the diversity of interest, bandw o sort each diagnosis into three choice: | ridth, and enga | ch of the follow agement with d | ling statements dermoscopy acr | regarding a oss the PCP | specific spectrum, we |
| Les des traits bey No | vel 1 (Foundational) — PCPs who desi plications for the detection of skin can ining. vel 2 (Intermediate) — PCPs who are I moscopy beyond the Foundational Le- ining, recognition of these "above and I yond Level 1 (Foundational). t appropriate— Dermoscopic identifi- | ter should be a highly interest wel should be a beyond" diagn cation of these | able to recognized in dermosco able to recognize noses would der diagnoses wo | ze these diagno opy and desire f ze these diagno monstrate an a | ses with app further traini ses. With ap dditional lev | oropriate ing in opropriate el of mastery |
| | indational- or intermediate-level profici ste that a "Neutral" vote will not contrib i. | | | the inclusion o | r exclusion o | of that specific |
| Basal Cel | Il Carcinoma | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 1) | Basal Cell Carcinoma should be included in Level 1 (Foundational) | O | O | O | O | O |
| 2) | Basal Cell Carcinoma should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 3) | Basal Cell Carcinoma should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Actinic K | eratosis | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 4) | Actinic Keratosis should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| | Actinic Keratosis should be included in Level 2 (Intermediate) | 0 | 0 | 0 | | 0 |
| 6) | Actinic Keratosis should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Pigmente | ed Actinic Keratosis | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 7) | Pigmented Actinic Keratosis should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 8) | Pigmented Actinic Keratosis should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 9) | Pigmented Actinic Keratosis should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Squamou | us Cell Carcinoma in situ (Bowen's di | sease) | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 10) | Squamous Cell Carcinoma in situ should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 11) | Squamous Cell Carcinoma in situ should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| | | | | | | |

| | anthoma | | | | | |
|-----------|--|----------------------|----------|---------|-------|----------------|
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 13) | Keratoacanthoma should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 14) | Keratoacanthoma should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 15) | Keratoacanthoma should be NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Squamo | us Cell Carcinoma | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 16) | Squamous Cell Carcinoma should be included in Level 1 (Foundational) | | 0 | 0 | 0 | 0 |
| 17) | Squamous Cell Carcinoma should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 18) | Squamous Cell Carcinoma should NOT be included at either level | 0 | 0 | 00/ | 0 | 0 |
| Simple L | entigo | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 19) | Simple Lentigo should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 20) | Simple Lentigo should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 21) | Simple Lentigo should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Solar Ler | ntigo | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 22) | Solar Lentigo should be included in Level 1 (Foundational) | 0 | 0 | 0 | | - 0 |
| 23) | Solar Lentigo should be included in Level 2 (Intermediate) | 0 | | 0 | | 0 |
| 24) | Solar Lentigo should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Seborrhe | eic Keratosis | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 25) | Seborrheic Keratosis should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 26) | Seborrheic Keratosis should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 27) | Seborrheic Keratosis should NOT be | 0 | 0 | 0 | 0 | 0 |

| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
|----------|--|----------------------|-----------|---------|-------|---------------|
| 28) | Lichen Planus-Like Keratosis should be included in Level 1 (Foundational) | (0) | Ø | 0 | 0 | 0 |
| 29) | Lichen Planus-Like Keratosis should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 30) | Lichen Planus-Like Keratosis should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Angioma | | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 31) | Angioma should be included in Level 1 (Foundational) | O | O | 0 | 0 | O |
| 32) | Angioma should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 33) | Angioma should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Angioke | ratoma | | | | | |
| | | Strongly | Disagree | Neutral | Agree | Strongly agre |
| 34) | Angiokeratoma should be included in Level 1 (Foundational) | | Disagree | Neutral | Agree | Strongly agre |
| 35) | | 0 | 0 | 0 | 0 | 0 |
| 36) | | 0 | 0 | 0 | 0 | 0 |
| Dermate | ofibroma | | | | | |
| | and the second | Strongly | | | | |
| 37) | | disagree | Disagree | Neutral | Agree | Strongly agre |
| 38) | in Level 1 (Foundational) Dermatofibroma should be included | 0 | 0 | | 0 | |
| 39) | in Level 2 (Intermediate) | .0 | 0 | .0. | 0 | 0 |
| - " | included at either level | 132/1 | | 11001 | | 1300 |
| Clear Ce | ll Acanthoma | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 40) | Clear Cell Acanthoma should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 41) | Clear Cell Acanthoma should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 42) | Clear Cell Acanthoma should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Sebaceo | us Hyperplasia | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 43) | Sebaceous Hyperplasia should be included in Level 1 (Foundational) | O | O | O | O | O O |
| 44) | Sebaceous Hyperplasia should be included in Level 2 (Intermediate) | 0 | 0 | i o | 0 | 0 |
| 45) | Sebaceous Hyperplasia should NOT be included at either level | 0 | 0 | 0 | | 0 |
| 46) | Please include your suggestions for | | | | | |
| | diagnoses and any comments here | | Optio | nal | | |
| | , | Subm | nit | | | |
| | | Save & Retu | ırn Later | | | |

| 5000 | on 2: Benign Melanocyti | r resion | 15 | | | AAA |
|---------------------------|--|--------------------------------------|-----------------|-------------------|----------------|-----------------|
| | | | | | | ⊕ 😑 |
| | d like to identify the dermatologic diagratowards PCPs. | oses that sho | ould be include | d in dermoscop | y education | programs |
| diagnosi | ate how strongly you would agree or dis s. Given the diversity of interest, bandw to sort each diagnosis into three choice: | idth, and eng | | | | |
| Le ap tra | vel 1 (Foundational) — PCPs who desir plications for the detection of skin canc lining. | re a basic yet er should be | able to recogni | ze these diagno | ses with app | ropriate |
| de | vel 2 (Intermediate) — PCPs who are I rmoscopy beyond the Foundational Lev Ining, recognition of these "above and I yond Level 1 (Foundational). | el should be | able to recogni | ze these diagno | ses. With ap | propriate |
| • No | ot appropriate — Dermoscopic identific undational- or intermediate-level profici | | | ould not be refle | ective of eith | er |
| | | | | | | |
| | ote that a "Neutral" vote will not contrib | ute towards | consensus on | the inclusion o | r exclusion o | f that specific |
| diagnosi | S. | | | | | |
| | | | | | | |
| | | | | | | |
| Overvie | w of Benign Nevi Patterns (e.g., globu | lar pattern, | reticular netw | ork) | | |
| Overvie | v of Benign Nevi Patterns (e.g., globu | lar pattern, | reticular netw | ork) | | |
| Overvie | w of Benign Nevi Patterns (e.g., globu | Strongly | 20000000 | | Agree | Strongly agra |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| | w of Benign Nevi Patterns (e.g., globu An overview of benign nevi patterns should be included in Level 1 (Foundational) | Strongly | 20000000 | | Agree | Strongly agree |
| 1) | An overview of benign nevi patterns should be included in Level 1 | Strongly disagree | 20000000 | | | Strongly agree |
| 1) | An overview of benign nevi patterns should be included in Level 1 (Foundational) An overview of benign nevi patterns should be included in Level 2 | Strongly disagree | Disagree | Neutral | 0 | 0 |
| 2) | An overview of benign nevi patterns should be included in Level 1 (Foundational) An overview of benign nevi patterns should be included in Level 2 (Intermediate) An overview of benign nevi patterns should NOT be included at either | Strongly disagree | Disagree | Neutral • | 0 | 0 |
| 2) | An overview of benign nevi patterns should be included in Level 1 (Foundational) An overview of benign nevi patterns should be included in Level 2 (Intermediate) An overview of benign nevi patterns should NOT be included at either level | Strongly disagree Strongly | Disagree | Neutral O | 0 | 0 |
| 1) 2) 3) Congeni | An overview of benign nevi patterns should be included in Level 1 (Foundational) An overview of benign nevi patterns should be included in Level 2 (Intermediate) An overview of benign nevi patterns should NOT be included at either level | Strongly disagree Strongly disagree | Disagree | Neutral Neutral | Agree | 0 |
| 1) 2) 3) Congeni | An overview of benign nevi patterns should be included in Level 1 (Foundational) An overview of benign nevi patterns should be included in Level 2 (Intermediate) An overview of benign nevi patterns should NOT be included at either level | Strongly disagree Strongly | Disagree | Neutral O | 0 | 0 |
| 1) 2) 3) Congeni | An overview of benign nevi patterns should be included in Level 1 (Foundational) An overview of benign nevi patterns should be included in Level 2 (Intermediate) An overview of benign nevi patterns should NOT be included at either level tal Melanocytic Nevi Congenital Melanocytic Nevi should | Strongly disagree Strongly disagree | Disagree | Neutral Neutral | Agree | 0 |




| | d like to identify the dermatologic diagn towards PCPs. | oses that sho | ould be included | d in dermoscop | y education | programs |
|-------------------------|---|---|---|--|---|---|
| diagnosi | ate how strongly you would agree or disa s. Given the diversity of interest, bandwi to sort each diagnosis into three choices | dth, and eng | | | | |
| • Le de tra be | vel 1 (Foundational) — PCPs who desir plications for the detection of skin cancu- ining. vel 2 (Intermediate) — PCPs who are h rmoscopy beyond the Foundational Lev- ining, recognition of these "above and b yond Level 1 (Foundational). x appropriate — Dermoscopic identific undational- or intermediate-level proficie | er should be ighly interest el should be eyond" diagn ation of thes | able to recogni- ted in dermosci able to recogni- toses would de e diagnoses wo | ze these diagno opy and desire I ze these diagno monstrate an a | ses with app further traini ses. With ap dditional lev | ropriate ng in propriate el of mastery |
| Please n diagnosi | ote that a "Neutral" vote will not contrib s. | ute towards a | consensus on | the inclusion o | r exclusion o | f that specific |
| Overvier | w of Melanoma Patterns (e.g., blue-wh | nite veil, reg | ression struct | ures) | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1) | An overview of melanoma patterns should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 2) | An overview of melanoma patterns should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 3) | An overview of melanoma patterns should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Acral Le | ntiginous Melanoma | | | | | |
| | | Strongly | mi | Neutral | | |
| 4) | Acral Lentiginous Melanoma should be included in Level 1 (Foundational) | disagree | Disagree | Neutral | Agree | Strongly agree |
| 5) | Acral Lentiginous Melanoma should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 6) | Acral Lentiginous Melanoma should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Lentigo | Maligna Melanoma (melanoma on chi | onically sur | -damaged ski | n of the head/ | neck) | |
| 7) | Lentigo Maligna Melanoma should be | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| | included in Level 1 (Foundational) Lentigo Maligna Melanoma should be | 0 | 0 | 0 | | 0 |
| 9) | included in Level 2 (Intermediate) Lentigo Maligna Melanoma should NOT be included at either level | .0. | 0 | .0. | 0 | .0. |
| Amelano | otic/Hypomelanotic Melanoma | | | | | |
| | | Strongly | Ties . | | | 8 8 |
| 10) | Amelanotic/Hypomelanotic Melanoma should be included in Level 1 (Foundational) | disagree | Disagree | Neutral | Agree | Strongly agree |
| 11) | Amelanotic/Hypomelanotic Melanoma should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 12) | Amelanotic/Hypomelanotic Melanoma should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| 13) | Please include your suggestions for diagnoses and any comments here: | additional | Optio | mal | | |
| | | Subm | nit | | | |
| | | Save & Retu | en Later | | | |

| | d like to identify the dermatologic diag towards PCPs. | noses that sho | ould be included | d in dermoscop | y education | programs |
|------------------------------------|---|---|--|------------------------------------|-------------------------------|----------------------------|
| Please ra diagnosis | te how strongly you would agree or dis Given the diversity of interest, bandy o sort each diagnosis into three choice | vidth, and eng | | | | |
| • Lev | vel 1 (Foundational) — PCPs who des plications for the detection of skin can | ire a basic yet | practical under able to recogniz | standing of der ze these diagno | moscopy an | d its propriate |
| Lev dei tra be; No | ining. ele 2 (Intermediate) — PCPs who are moscopy beyond the Foundational Le ining, recognition of these "above and yond Level 1 (Foundational), t appropriate — Dermoscopic identifindational- or intermediate-level profice | vel should be beyond" diagr ication of thes | able to recogniz soses would de e diagnoses wo | ze these diagno monstrate an a | ses. With ap dditional lev | propriate el of mastery |
| Please no diagnosis | ote that a "Neutral" vote will not contri | bute towards a | a consensus on | the inclusion o | r exclusion o | f that specific |
| Facial Sit | es: Dermoscopic Features of the Fac | e (i.e., pseud | onetwork) | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 1) | Dermoscopic features of the face should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 2) | Dermoscopic features of the face should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 3) | Dermoscopic features of the face should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Acral Site | es: Benign Patterns of Acral Nevi | | | | | |
| | | Strongly | Disagree | Neutral | Agree | Strongly agre |
| 4) | Benign patterns of acral nevi should be included in Level 1 (Foundational) | | 0 | 0 | 0 | 0 |
| 5) | Benign patterns of acral nevi should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 6) | Benign patterns of acral nevi should NOT be included at either level | 0 | 0 | 0 | 0 | |
| Nails: Le | ntigo of the Nail (melanotic macule | of the nail) | | | | |
| | | Strongly | 66 | | | 2 0 |
| 7) | Lentigo of the Nail should be included in Level 1 (Foundational) | disagree | Disagree | Neutral | Agree | Strongly agre |
| 8) | Lentigo of the Nail should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 9) | Lentigo of the Nail should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Nails: Me | lanoma of the Nail | | | | | |
| | | Strongly | | | | |
| 10) | Melanoma of the Nail should be included in Level 1 (Foundational) | disagree | Disagree | Neutral | Agree | Strongly agre |
| 11) | Melanoma of the Nail should be included in Level 2 (Intermediate) | 0 | 0 | 0.0 | 0 | 0 |
| 12) | Melanoma of the Nail should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Nails: Su | bungual Hemorrhage | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 13) | Subungual Hemorrhage should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 14) | Subungual Hemorrhage should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 15) | Subungual Hemorrhage should NOT be included at either level | 0 | 0 | .0. | 0 | 0 |
| 16) | Please include your suggestions fo diagnoses and any comments here | | Optio | inal | | |
| | | Subn | nit | | | |
| | | Save & Retu | ırn Later | | | |
| | | | | | | |

| | on 5: Other (including sl | XIII IIII CC | cions & n | restation | 13) | AAA |
|---|--|---|---|--|---|---|
| | d like to identify the dermatologic diagn towards PCPs. | oses that sho | ould be included | d in dermoscopy | y education (| programs |
| diagnosi | ate how strongly you would agree or dis s. Given the diversity of interest, bandwi to sort each diagnosis into three choices | idth, and eng | | | | |
| Le de tra be No for | vel 1 (Foundational) — PCPs who desir plications for the detection of skin canc ining. vel 2 (Intermediate) — PCPs who are I rmoscopy beyond the Foundational Lev ining, recognition of these "above and I yond Level 1 (Foundational). bt appropriate — Dermoscopic identificational control in the proficial control in the proficial control in the profice of the profice | er should be sighly interest el should be seyond" diagn cation of thes ency for PCPs | able to recognized in dermosco able to recognizeoses would de- e diagnoses wo | re these diagno opy and desire f re these diagno monstrate an ai ould not be refle | urther traini ses. With ap dditional levi ctive of eithi | ropriate ng in propriate el of mastery |
| Please n diagnosi | ote that a "Neutral" vote will not contrib s. | ute towards a | consensus on | the inclusion of | r exclusion o | f that specific |
| Scables | | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 1) | Scables should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 2) | Scabies should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 3) | Scables should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Mollusco | um Contagiosum | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| | Molluscum Contagiosum should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 4) | included in cever I (roundational) | | | | | |
| | Molluscum Contagiosum should be included in Level 2 (Intermediate) | | 0 | | 0 | |
| | Molluscum Contagiosum should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 5) | Molluscum Contagiosum should be included in Level 2 (Intermediate) Molluscum Contagiosum should NOT be included at either level | | | | | |
| 5) | Molluscum Contagiosum should be included in Level 2 (Intermediate) Molluscum Contagiosum should NOT be included at either level | | | | | 0 |
| 5) 6) Verruca | Molluscum Contagiosum should be included in Level 2 (Intermediate) Molluscum Contagiosum should NOT be included at either level | Strongly | 0 | 0 | 0 | |
| 5) 6) Verruca 7) | Molluscum Contagiosum should be included in Level 2 (Intermediate) Molluscum Contagiosum should NOT be included at either level (Warts) Verruca should be included in Level 1 | Strongly | 0 | Neutral | Agree | Strongly agree |

| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
|--------------|--|-------------------|----------|---------|-------|---------------|
| | nous Lake should be included in vel 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| | nous Lake should be included in vel 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| | nous Lake should NOT be included either level | 0 | 0 | 0 | 0 | 0 |
| Radiation Ta | ttoo | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| | diation Tattoo should be included Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| | diation Tattoo should be included Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| | diation Tattoo should NOT be luded at either level | 0 | 0 | 0 | 0 | 0 |
| Dermoscopio | : Features of Scars | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| | rmoscopic features of scars should included in Level 1 | 0 | 0 | 0 | 0 | 0 |
| | rmoscopic features of scars should included in Level 2 | 0 | 0 | 0 | 0 | 0 |
| | rmoscopic features of scars should IT be included at either level | 0 | 0 | 0 | 0 | 0 |
| | ease include your suggestions for | | | | | |
| dia | agnoses and any comments here: | | Opti | ional | | |
| | | Subm | it | | | |
| | | Save & Retu | rn Later | | | |







| Secti | on 1: Nonmelanocytic I | Lesions | | | | AAA |
|---------------------|--|-----------------|--------------------------------|---|--|--------------------------------|
| targetec | ld like to identify the dermatologic diag i towards PCPs. The panel has reached h a consensus, we ask you to re-vote. | | | | | |
| | und 1, we ask you to rate how strongly ig a specific diagnosis for a particular le | | | with each of the | e following st | atements |
| • Le | evel 1 (Foundational) — PCPs who des splications for the detection of skin can aining. evel 2 (Intermediate) — PCPs who are ermoscopy beyond the Foundational Le aining, recognition of these "above and eyond Level 1 (Foundational). | highly interest | able to recognized in dermosco | te these diagno opy and desire it te these diagno | ses with app further traini ses. With ap | ropriate ng in propriate |
| Please n diagnos | ote that a "Neutral" vote will not contri is. | bute towards | consensus on | the inclusion o | r exclusion o | f that specific |
| | Basal Cell Carcinoma Consensus: Basal Cell Carcinoma s | hould be incl | uded in Level 1 | (Foundationa | l) | |
| | Actinic Keratosis Consensus: Actinic Keratosis shou | ld be included | in Level 1 (Fo | undational) | | |
| | Squamous Cell Carcinoma Consensus: Squamous Cell Carcino | oma should be | included in L | evel 1 (Founda | tional) | |
| | Simple Lentigo Consensus: Simple Lentigo should | be included in | Level 1 (Four | dational) | | |
| | Solar Lentigo Consensus: Solar Lentigo should b | e included in | Level 1 (Found | ational) | | |
| | Seborrheic Keratosis Consensus: Seborrheic Keratosis s | hould be inclu | ided in Level 1 | (Foundationa | 1) | |
| | Angioma Consensus: Angioma should be inc | luded in Leve | l 1 (Foundation | nal) | | |
| | Dermatofibroma Consensus: Dermatofibroma shou | ld be included | l in Level 1 (Fo | undational) | | |
| | ous Hyperplasia sus: Sebaceous Hyperplasia should a tional) | t least be incl | uded in Level 2 | 2 (Intermediat | e) if not incl | uded in Level |
| Should: | Sebaceous Hyperplasia be included i | | ndational) or l | evel 2 (Interm | ediate)? | |
| | | Strongly | Disagree | Neutral | Agree | Strongly agre |
| 1) | Sebaceous Hyperplasia should be included in Level 1 (Foundational) | 0 | Ó | 0 | 0 | 0 |
| | Sebaceous Hyperplasia should be | 0 | 0 | 0 | 0 | 0 |

| | out Level 2 (Intermediate)? | | | | | |
|----------------------------------|---|---|--------------------|------------------------|-------------|------------------------|
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 3) | Pigmented Actinic Keratosis should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 4) | Pigmented Actinic Keratosis should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| | lanus-Like Keratosis (Benign Licheno us: Lichen Planus-Like Keratosis sho | | | el 1 (Foundatio | nal) | |
| What ab | out Level 2 (Intermediate)? | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 5) | Lichen Planus-Like Keratosis should be included in Level 2 (Intermediate) | | | 0 | 0 | 0 |
| 6) | Lichen Planus-Like Keratosis should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Angioke | ratoma us: Angiokeratoma should NOT be in | duded to the | unt d /Foundate | lanal) | | |
| | out Level 2 (Intermediate)? | cidded iii ce | rei i (roulluat | Ollary | | |
| | | Strongly | 24.0000 | Neutral | 1000000 | - 02.01 (0.27 (0.48)) |
| 7) | Angiokeratoma should be included in Level 2 (Intermediate) | disagree | Disagree | Neutral | Agree | Strongly agree |
| 8) | Angiokeratoma should NOT be | (0) | 0 | 0 | 0 | 0 |
| | included at either level | | | .0. | 0 | |
| | included at either level Il Acanthoma us: Clear Cell Acanthoma should NO | T | 9000 SANSON | A 100 11 100 | | |
| Consens | Il Acanthoma | T | 9000 SANSON | A 100 11 100 | | |
| Consens | ll Acanthoma us: Clear Cell Acanthoma should NOT | T | 9000 SANSON | A 100 11 100 | Agree | Strongly agree |
| Consens | ll Acanthoma us: Clear Cell Acanthoma should NO1 out Level 2 (Intermediate)? | be included | l in Level 1 (Fo | undational) | | |
| Consens What ab | Il Acanthoma us: Clear Cell Acanthoma should NO1 out Level 2 (Intermediate)? Clear Cell Acanthoma should be | Strongly disagree | l in Level 1 (Fo | undational) Neutral | Agree | Strongly agree |
| What ab 9) 10) Squamo | Il Acanthoma us: Clear Cell Acanthoma should NO! out Level 2 (Intermediate)? Clear Cell Acanthoma should be included in Level 2 (Intermediate) Clear Cell Acanthoma should NOT be | Strongly disagree | I in Level 1 (Fo | Neutral | Agree | Strongly agree |
| What ab 9) 10) Squamo | Il Acanthoma us: Clear Cell Acanthoma should NO1 out Level 2 (Intermediate)? Clear Cell Acanthoma should be included in Level 2 (Intermediate) Clear Cell Acanthoma should NOT be included at either level us Cell Carcinoma in situ (Bowen's di | Strongly disagree | I in Level 1 (Fo | Neutral | Agree | Strongly agre |
| What ab 9) 10) Squamo Consens | Il Acanthoma us: Clear Cell Acanthoma should NO1 out Level 2 (Intermediate)? Clear Cell Acanthoma should be included in Level 2 (Intermediate) Clear Cell Acanthoma should NOT be included at either level us Cell Carcinoma in situ (Bowen's di | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 9) 10) Squamo Consens | Il Acanthoma us: Clear Cell Acanthoma should NOI out Level 2 (Intermediate)? Clear Cell Acanthoma should be included in Level 2 (Intermediate) Clear Cell Acanthoma should NOT be included at either level us Cell Carcinoma in situ (Bowen's di us: none Squamous Cell Carcinoma in situ should be included in Level 1 | Strongly disagree Strongly disagree Strongly disagree | Disagree Disagree | Neutral | Agree Agree | Strongly agree |




| | 7 | c Lesion | | | | AAA |
|---|--|---|--|--|---|---------------------|
| targetec | d like to identify the dermatologic diagn towards PCPs. The panel has reached a h a consensus, we ask you to re-vote. | | | | | |
| | und 1, we ask you to rate how strongly yi g a specific diagnosis for a particular levi | | | with each of the | following st | tatements |
| • Le de | vel 1 (Foundational) — PCPs who desir plications for the detection of skin cance ining. vel 2 (Intermediate) — PCPs who are h rmoscopy beyond the Foundational Lev ining, recognition of these "above and b yyond Level 1 (Foundational). | er should be eighly interest el should be | able to recognized in dermosco | re these diagno opy and desire f re these diagno | ses with app further trainingses. With app | ing in propriate |
| Please r diagnos | ote that a "Neutral" vote will not contribe s. | ute towards a | consensus on | the inclusion o | r exclusion o | f that specific |
| | Overview of benign nevi patterns (e Consensus: An overview of benign n | .g., globular nevi patterns | pattern, retice should be inc | ular network) luded in Level | 1 (Foundati | onal) |
| | Intradermal Nevi Consensus: Intradermal Nevi should | d be included | d in Level 1 (Fo | undational) | | |
| | Congenital Melanocytic Nevi | | | | | |
| | Consensus: Congenital Melanocytic Consensus: Congenital Melanocytic | | | | | al) |
| Blue Ne | Consensus: Congenital Melanocytic Consensus: Congenital Melanocytic Spitz Nevi Consensus: Spitz Nevi should NOT b Consensus: Spitz Nevi should be included. | Nevi should e included ir luded in Lev | be included in Level 1 (Foun el 2 (Intermed | Level 2 (Interdictional) | mediate) | |
| | Consensus: Congenital Melanocytic Consensus: Congenital Melanocytic Spitz Nevi Consensus: Spitz Nevi should NOT b Consensus: Spitz Nevi should be including Vi us: Blue Nevi should at least be including us: Blue Nevi should at least be including us: Blue Nevi should at least be including processed to the should at least be including us: Blue Nevi should at least be including processed to the should at least be including us: Blue Nevi should at least be including processed to the should be including processed to the should be included processed to the should processed to the should processed processed processed processed processed processed processed processed processed processed processed processed processed processed processed processed processed processed proce | Nevi should e included ir luded in Lev | be included in Level 1 (Foun el 2 (Intermed | Level 2 (Interdictional) | mediate) | |
| Consent (Foundate | Consensus: Congenital Melanocytic Consensus: Congenital Melanocytic Spitz Nevi Consensus: Spitz Nevi should NOT b Consensus: Spitz Nevi should be including Vi us: Blue Nevi should at least be including us: Blue Nevi should at least be including us: Blue Nevi should at least be including processed to the should at least be including us: Blue Nevi should at least be including processed to the should at least be including us: Blue Nevi should at least be including processed to the should be including processed to the should be included processed to the should processed to the should processed processed processed processed processed processed processed processed processed processed processed processed processed processed processed processed processed processed proce | Nevi should e included ir luded in Lev ded in Level | be included in a Level 1 (Found of 2 (Intermed 2 (Intermediat | dational) iate) | mediate) | |
| Consent (Foundate | Consensus: Congenital Melanocytic Consensus: Congenital Melanocytic Spitz Nevi Consensus: Spitz Nevi should NOT b Consensus: Spitz Nevi should be included vi sus: Blue Nevi should at least be included tional) | Nevi should be included in luded in Level ded in Level dational) or Strongly | be included in a Level 1 (Foun el 2 (Intermed 2 (Intermedial Level 2 (Intern | dational) iate) | mediate) | s i |
| Consens (Founda Should | Consensus: Congenital Melanocytic Consensus: Congenital Melanocytic Spitz Nevi Consensus: Spitz Nevi should NOT b Consensus: Spitz Nevi should be included vi us: Blue Nevi should at least be included tional) | Nevi should be included in luded in Lev ded in Level dational) or | be included in a Level 1 (Found el 2 (Intermed 2 (Intermediat | dational) iate) (e) if not include nediate)? | mediate) ded in Level | |
| Consens (Founda Should I | Consensus: Congenital Melanocytic Consensus: Congenital Melanocytic Spitz Nevi Consensus: Spitz Nevi should NOT b Consensus: Spitz Nevi should be include it ius: Blue Nevi should at least be include tional) Blue Nevi be included in Level 1 (Found Blue Nevi should be included in Level | Nevi should be included in luded in Level ded in Level dational) or Strongly disagree | be included in Level 1 (Foun el 2 (Intermed 2 (Intermedial Level 2 (Intern Disagree | dational) iate) (e) if not include nediate)? | mediate) ded in Level Agree | s i |
| Consent (Foundate Should 1) 1) 2) Recurre | Consensus: Congenital Melanocytic Consensus: Congenital Melanocytic Spitz Nevi Consensus: Spitz Nevi should NOT b Consensus: Spitz Nevi should be include included in Level 1 (Found Blue Nevi should be included in Level 1 (Foundational) Blue Nevi should be included in Level 1 (Foundational) Blue Nevi should be included in Level 2 (Intermediate) Interview included in Level 2 (Intermediate) | Nevi should se included in Level ded in Level dational) or Strongly disagree | be included in Level 1 (Found el 2 (Intermediat 2 (Intermediat Level 2 (Intern Disagree | dational) (ate) (ce) if not include (nediato)? Neutral | Mediate) Jed in Level Agree | Strongly agre |
| Consens (Foundar Should 1) 2) Recurre Consens | Consensus: Congenital Melanocytic Consensus: Congenital Melanocytic Spitz Nevi Consensus: Spitz Nevi should NOT b Consensus: Spitz Nevi should be included included in Level 1 (Found Blue Nevi should at least be included in Level 1 (Foundational) Blue Nevi should be included in Level 2 (Intermediate) | Nevi should se included in Level ded in Level dational) or Strongly disagree | be included in Level 1 (Found el 2 (Intermediat 2 (Intermediat Level 2 (Intern Disagree | dational) (ate) (ce) if not include (nediato)? Neutral | Mediate) Jed in Level Agree | Strongly agre |
| Consens (Foundar Should 1) 2) Recurre Consens | Consensus: Congenital Melanocytic Consensus: Congenital Melanocytic Spitz Nevi Consensus: Spitz Nevi should NOT be Consensus: Spitz Nevi should NOT be consensus: Spitz Nevi should be included in Level tional) Blue Nevi should at least be included in Blue Nevi should be included in Level 1 (Foundational) Blue Nevi should be included in Level 2 (Intermediate) int Nevi (Persistent Nevi) use: Recurrent Nevi should NOT be included in Level Recurrent Nevi should NOT be included in Level Recurrent Nevi should NOT be included in Level Recurrent Nevi should NOT be included. | Nevi should se included in Level ded in Level dational) or Strongly disagree | be included in Level 1 (Found el 2 (Intermediat 2 (Intermediat Level 2 (Intern Disagree | dational) (ate) (ce) if not include (nediato)? Neutral | Mediate) Jed in Level Agree | Strongly agre |
| Consens (Foundated Should In 1982) Should In 1982 Consens What at | Consensus: Congenital Melanocytic Consensus: Congenital Melanocytic Spitz Nevi Consensus: Spitz Nevi should NOT be Consensus: Spitz Nevi should NOT be consensus: Spitz Nevi should be included in Level tional) Blue Nevi should at least be included in Blue Nevi should be included in Level 1 (Foundational) Blue Nevi should be included in Level 2 (Intermediate) int Nevi (Persistent Nevi) use: Recurrent Nevi should NOT be included in Level Recurrent Nevi should NOT be included in Level Recurrent Nevi should NOT be included in Level Recurrent Nevi should NOT be included. | Nevi should in included in Level ded in Level dational) or Strongly disagree | be included in Level 1 (Foundation Disagree | adational) iate) ce) if not include mediate)? Neutral | ded in Level | Strongly agre |

| | | disagree | Disagree | Neutral | Agree | Strongly agre |
|----------|--|----------------------|--------------------------|---------|--------|---------------|
| 5) | Halo Nevi should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 6) | If Halo Nevi do not reach consensus for Level 1 (Foundational), they should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 7) | Halo Nevi should NOT be included in either level | 0 | 0 | 0 | 0 | 0 |
| Combine | ed Nevi (NEW) | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 8) | Combined Nevi should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 9) | If Combined Nevi do not reach consensus for Level 1, they should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 10) | Combined Nevi should be NOT included at either level | 0 | 0 | 0 | 0 | 0 |
| | | | | | | |
| Ink Spot | Lentigo (Reticulated Black Solar Lent | igo) (NEW) | | | | |
| Ink Spot | Lentigo (Reticulated Black Solar Lent | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| | Lentigo (Reticulated Black Solar Lent Ink Spot Lentigo should be included in Level 1 (Foundational) | Strongly | Disagree | Neutral | Agree | Strongly agre |
| 11) | Ink Spot Lentigo should be included | Strongly disagree | The street of the street | | 110311 | |
| 11) | Ink Spot Lentigo should be included in Level 1 (Foundational) If Ink Spot Lentigo does not reach consensus for Level 1 (Foundational), it should be included in Level | Strongly disagree | 0 | 0 | 0 | 0 |
| 11) | Ink Spot Lentigo should be included in Level 1 (Foundational) I ink Spot Lentigo does not reach consensus for Level 1 (Foundational), it should be included in Level 2 (Intermediate) Ink Spot Lentigo should NOT be included at either level Please include your suggestions for | Strongly disagree | 0 | 0 | 0 | 0 |
| 11) | Ink Spot Lentigo should be included in Level 1 (Foundational) If Ink Spot Lentigo does not reach consensus for Level 1 (Foundational), it should be included in Level 2 (Intermediate) Ink Spot Lentigo should NOT be Included at either level | Strongly disagree | 0 | 0 | 0 | 0 |
| 11) | Ink Spot Lentigo should be included in Level 1 (Foundational) I ink Spot Lentigo does not reach consensus for Level 1 (Foundational), it should be included in Level 2 (Intermediate) Ink Spot Lentigo should NOT be included at either level Please include your suggestions for | Strongly disagree | Optio | 0 | 0 | 0 |
| 11) | Ink Spot Lentigo should be included in Level 1 (Foundational) I ink Spot Lentigo does not reach consensus for Level 1 (Foundational), it should be included in Level 2 (Intermediate) Ink Spot Lentigo should NOT be included at either level Please include your suggestions for | Strongly disagree | Optio | 0 | 0 | 0 |

| | | | | | | AAA |
|--------------------------------------|---|--|---|---|---|--------------------------------|
| targeted | d like to identify the dermatologic diagn towards PCPs. The panel has reached a h a consensus, we ask you to re-vote. | | | | | |
| | und 1, we ask you to rate how strongly y g a specific diagnosis for a particular lev | | | with each of the | e following st | atements |
| • Le de tra | vel 1 (Foundational) — PCPs who desir plications for the detection of skin canc ining. vvel 2 (Intermediate) — PCPs who are I rmoscopy beyond the Foundational Lev ining, recognition of these "above and b tyyond Level 1 (Foundational). | er should be nighly interest rel should be | able to recognized in dermosco | ze these diagno opy and desire i ze these diagno | ses with app further traini ses. With ap | ropriate ng in propriate |
| Please n diagnosi | ote that a "Neutral" vote will not contrib s. | ute towards a | a consensus on | the inclusion o | r exclusion o | f that specific |
| | Overview of melanoma patterns (e. Consensus: An overview of melanor | | | | | inal) |
| | Acral Lentiginous Melanoma Consensus: Acral Lentiginous Melar Consensus: Acral Lentiginous Melar | | | | | al) |
| | Lentigo Maligna Melanoma (melano Consensus: Lentigo Maligna Melano Consensus: Lentigo Maligna Melano otic/Hypomelanotic Melanoma | oma should to | NOT be include be included in | ed in Level 1 (Fe Level 2 (Intern | oundational nediate) |) |
| Consens | Consensus: Lentigo Maligna Melano Consensus: Lentigo Maligna Melano | oma should to | NOT be include be included in | ed in Level 1 (Fe Level 2 (Intern | oundational nediate) |) |
| Consens | Consensus: Lentigo Maligna Melano Consensus: Lentigo Maligna Melano otic/Hypomelanotic Melanoma uus: Amelanotic/Hypomelanotic Melan | oma should to oma should to noma should Strongly | NOT be include be included in I | ed in Level 1 (Fe Level 2 (Intern | oundational nediate) (Foundation | al) |
| Consens What ab | Consensus: Lentigo Maligna Melano Consensus: Lentigo Maligna Melano otic/Hypomelanotic Melanoma uus: Amelanotic/Hypomelanotic Melan | oma should t oma should t noma should | NOT be include be included in | ed in Level 1 (F Level 2 (Intern ded in Level 1 (| oundational nediate) | al) |
| Consens What ab | Consensus: Lentigo Maligna Melano Consensus: Lentigo Maligna Melano tic/Hypomelanotic Melanoma tus: Amelanotic/Hypomelanotic Melano tus: Amelanotic/Hypomelanotic Melanotic/Hypomelanotic Melanotic/Hypomelanotic Melanoma should be included in | oma should to oma should b noma should Strongly disagree | NOT be included in I | ed in Level 1 (Fi Level 2 (Intern ded in Level 1 (Neutral | oundational nediate) (Foundation Agree |) |
| Consens What ab | Consensus: Lentigo Maligna Melano Consensus: Lentigo Maligna Melano tic/Hypomelanotic Melanoma sus: Amelanotic/Hypomelanotic Melano tus: Amelanotic/Hypomelanotic Melanoma tus: Amelanotic/Hypomelanotic Melanoma should be included in Level 2 (Intermediate) Amelanotic/Hypomelanotic Melanoma should NOT be included at | oma should to noma should strongly disagree | NOT be included in land to the included in land to the included in land to the included land | ed in Level 1 (F Level 2 (Internated in Level 1 (| eundational nediate) (Foundation Agree | Strongly agre |
| Consens What ab | Consensus: Lentigo Maligna Melano Consensus: Lentigo Maligna Melano tic/Hypomelanotic Melanoma sus: Amelanotic/Hypomelanotic Melano tout Level 2? Amelanotic/Hypomelanotic Melanoma should be included in Level 2 (Intermediate) Amelanotic/Hypomelanotic Melanoma should NOT be included at either level | oma should to more should to more should to strongly disagree | NOT be included in la NOT be included in la NOT be included in la NOT be included. Disagree | Neutral | Agree | Strongly agre |
| Consens What ab | Consensus: Lentigo Maligna Melano Consensus: Lentigo Maligna Melano otic/Hypomelanotic Melanoma use: Amelanotic/Hypomelanotic Melano oout Level 2? Amelanotic/Hypomelanotic Melanoma should be included in Level 2 (Intermediate) Amelanotic/Hypomelanotic Melanoma should NOT be included at either level Melanoma (NEW) | oma should broad s | NOT be included in land to the included in land to the included in land to the included land | ed in Level 1 (F Level 2 (Internated in Level 1 (| eundational nediate) (Foundation Agree | Strongly agr |
| Consens What ab 1) 2) Nevoid I | Consensus: Lentigo Maligna Melano Consensus: Lentigo Maligna Melano tic/Hypomelanotic Melanoma sus: Amelanotic/Hypomelanotic Melano tus: Amelanotic/Hypomelanotic Melanoma tus: Amelanotic/Hypomelanotic Melanoma should be included in Level 2 (Intermediane) Amelanotic/Hypomelanotic Melanoma should NOT be included at either level Melanoma (NEW) Nevold Melanoma should be included | sma should brown a sh | NOT be included in i | Neutral | oundational rediate) (Foundation Agree | Strongly agre |
| Consens What ab 1) 2) Nevoid I 3) | Consensus: Lentigo Maligna Melano Consensus: Lentigo Maligna Melano tic/Hypomelanotic Melanoma us: Amelanotic/Hypomelanotic Melano out Level 2? Amelanotic/Hypomelanotic Melanoma should be included in Level 2 (Intermediate) Amelanotic/Hypomelanotic Melanoma should NOT be included at either level Melanoma (NEW) Nevoid Melanoma should be included in Level 1 (Foundational) If Nevoid Melanoma does not reach consensus for inclusion in Level 1 (Foundational), it should be included | oma should to ma should to ma should to make the more should to more should to more should the | NOT be included in i | Neutral | Agree Agree | Strongly agre |

| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
|---------|---|-------------------|----------|---------|-------|----------------|
| 6) | Desmoplastic Melanoma should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 7) | If Desmoplastic Melanoma does not reach consensus for inclusion in Level 1 (Foundational), it should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 8) | Desmoplastic Melanoma should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| /erruco | us Melanoma (NEW) | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 9) | Verrucous Melanoma should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 10) | If Verrucous Melanoma does not reach consensus for inclusion in Level 1 (Foundational), it should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 11) | Verrucous Melanoma should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| 12) | Please include your suggestions for | additional | | | | |
| | diagnoses and any comments here: | | Optio | onal | | |
| | | Subm | it | | | |
| | | Save & Retu | rn Later | | | |


| | | | | | | AAA |
|---|--|--|---|--|--|---|
| targeted | d like to identify the dermatologic diagn towards PCPs. The panel has reached a h a consensus, we ask you to re-vote. | | | | | |
| | und 1, we ask you to rate how strongly y g a specific diagnosis for a particular lev | | | with each of the | e following st | atements |
| • Le de tra be | vel 1 (Foundational) — PCPs who desir plications for the detection of skin canci- lining. vel 2 (Intermediate) — PCPs who are h rmoscopy beyond the Foundational Lev plining, recognition of these "above and b yond Level 1 (Foundational). | er should be nighly interess el should be peyond" diagr | able to recognized in dermosco able to recognize noses would de | ppy and desire te these diagno monstrate an a | ses with app further traini ses. With ap dditional levi | ropriate ng in propriate el of mastery |
| Please no diagnosis | ote that a "Neutral" vote will not contrib s. | ute towards | a consensus on | the inclusion o | r exclusion o | f that specific |
| | Subungual Hemorrhage Consensus: Subungual Hemorrhage | should be i | ncluded in Lev | el 1 (Foundatio | onal) | |
| | Facial Sites: Dermoscopic features of Consensus: Dermoscopic features of Consensus: Dermoscopic features of | f the face sh | ould NOT be in | ncluded in Lev | | |
| Level 1 (| rus: Benign patterns of acral nevi shou Foundational) Denign patterns of acral nevi be includ | ded in Level | | | | |
| Level 1 (I | Foundational) penign patterns of acral nevi be includ | Strongly disagree | 1 (Foundational | al) or Level 2 (I | ntermediate Agree | e)? |
| Level 1 (I Should b | Foundational) benign patterns of acral nevi be included Benign patterns of acral nevi should be included in Level 1 (Foundational) | ded in Level | 1 (Foundationa | Neutral | ntermediate | Strongly agre |
| Level 1 (I Should b | Foundational) penign patterns of acral nevi be included the second of t | Strongly disagree | 1 (Foundational | al) or Level 2 (I | ntermediate Agree | e)? |
| Level 1 (i Should b | Foundational) Benign patterns of acral nevi be included Benign patterns of acral nevi should be included in Level 1 (Foundational) Benign patterns of acral nevi should | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 1) 2) Nails: Le Consens | Foundational) Benign patterns of acral nevi be included. Benign patterns of acral nevi should be included in Level 1 (Foundational). Benign patterns of acral nevi should be included in Level 2 (Intermediate) acraige of the Nail (melanotic macule of the Nail (melanotic macu | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 1) 2) Nails: Le Consens | Foundational) Benign patterns of acral nevi be included in Level 1 (Foundational) Benign patterns of acral nevi should be included in Level 1 (Foundational) Benign patterns of acral nevi should be included in Level 2 (Intermediate) entigo of the Nail (melanotic macule outs: Lentigo of the Nail should NOT be | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| Level 1 (I Should b 1) 2) Nails: Le Consens What ab | Foundational) Benign patterns of acral nevi be included in Level 2 (Intermediate)? Benign patterns of acral nevi should be included in Level 1 (Foundational). Benign patterns of acral nevi should be included in Level 2 (Intermediate) intigo of the Nail (melanotic macule outs: Lentigo of the Nail should NOT be lout Level 2 (Intermediate)? Lentigo of the Nail should be included in Level 2 (Intermediate) | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| Level 1 (I Should b 1) 2) Nails: Le Consens What ab | Foundational) Benign patterns of acral nevi be included in Level 1 (Foundational) Benign patterns of acral nevi should be included in Level 1 (Foundational) Benign patterns of acral nevi should be included in Level 2 (Intermediate) entigo of the Nail (melanotic macule of usc. Lentigo of the Nail should NOT be rout Level 2 (Intermediate)? Lentigo of the Nail should be | Strongly disagree | Disagree | Neutral | Agree Agree | Strongly agre |
| Level 1 (I Should b 1) 2) Nails: Le Consens What ab 3) 4) | Foundational) Benign patterns of acral nevi be included in Level 1 (Foundational) Benign patterns of acral nevi should be included in Level 1 (Foundational) Benign patterns of acral nevi should be included in Level 2 (Intermediate) entigo of the Nail (melanotic macule outs: Lentigo of the Nail should NOT be be included in Level 2 (Intermediate)? Lentigo of the Nail should be included in Level 2 (Intermediate) Lentigo of the Nail should be included in Level 2 (Intermediate) | Strongly disagree of the nail) included in Strongly disagree | Disagree Level 1 (Found | Neutral Interpretation of the second of the | Agree | Strongly agre |
| Level 1 (I Should b 1) 2) Nails: Le Consens What ab 3) 4) Nails: Mc Consens | Foundational) Benign patterns of acral nevi be included in Level 1 (Foundational) Benign patterns of acral nevi should be included in Level 2 (Intermediate) entige of the Nail (melanotic macule caus: Lentigo of the Nail should NOT be included in Level 2 (Intermediate)? Lentigo of the Nail should be included in Level 2 (Intermediate). Lentigo of the Nail should be included in Level 2 (Intermediate). | Strongly disagree of the nail) included in Strongly disagree | Disagree Level 1 (Found | Neutral Interpolation Neutral Neutral Neutral | Agree | Strongly agre |
| Level 1 (I Should b 1) 2) Nails: Le Consens What ab 3) 4) Nails: Mc Consens | Benign patterns of acral nevi be included in Level 2 (intermediate)? Lentigo of the Nail should be included in Level 2 (intermediate) eus: Lentigo of the Nail should NOT be included in Level 2 (intermediate)? Lentigo of the Nail should NOT be included in Level 2 (intermediate)? | Strongly disagree of the nail) included in Strongly disagree | Disagree Level 1 (Found | Neutral Interpolation Neutral Neutral Neutral | Agree | Strongly agre |
| 1) 2) Nails: Leconsens What ab 3) 4) Nails: Mat ab | Benign patterns of acral nevi be included in Level 2 (intermediate)? Lentigo of the Nail should be included in Level 2 (intermediate) eus: Lentigo of the Nail should NOT be included in Level 2 (intermediate)? Lentigo of the Nail should NOT be included in Level 2 (intermediate)? | Strongly disagree of the nail) included in Strongly disagree Strongly disagree | Disagree Level 1 (Foundations Disagree Disagree | Neutral Istional) Neutral Neutral undational) | Agree Agree | Strongly agree |





| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
|-----------|---|-------------------|----------------|----------|-------|---------------|
| 8) | Molluscum Contagiosum should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 9) | If Molluscum Contagiosum does not reach consensus for inclusion in Level 1 (Foundational), it should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 10) | Molluscum Contagiosum should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Venous L | ake (example of a nonmelanocytic le | sion on mu | cocutaneous ju | inction) | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 11) | Venous Lake should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 12) | If Venous Lake does not reach consensus for inclusion in Level 1 (Foundational), it should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 13) | Venous Lake should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Psoriasis | (NEW) | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 14) | Psoriasis should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 15) | If Psoriasis does not reach consensus for inclusion in Level 1 (Foundational), it should be included in Level 2 (Intermediate) | 0 | 0 | 0 | | 0 |
| 16) | Psoriasis should NOT be included at either level | 0 | 0 | 0 | 0 | |
| Atopic D | ermatitis (Eczema) (NEW) | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 17) | Atopic Dermatitis should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 18) | If Atopic Dermatitis does not reach consensus for inclusion in Level 1 (Foundational), it should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 19) | Atopic Dermatitis should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| 20) | Please include your suggestions for diagnoses and any comments here: | | Optio | inal | | |
| | | Subn | nit | | | |
| | | Save & Retr | urn Later | | | |
| | | Save & Retr | urn Later | | | |






| | | AAA |
|--|---|---|
| We would like to identify the dermatologic diagnotargeted towards PCPs. | ses that should be included in den | noscopy training programs |
| As in Round 2, we ask you to vote whether you ag specific diagnosis for a particular level of proficier | | wing statements regarding a |
| Level 1 (Foundational) — PCPs who desire applications for the detection of skin cance training. Level 2 (Intermediate) — PCPs who are hi dermoscopy beyond the Foundational Leve training, recognition of these "above and be beyond Level 1 (Foundational). | r should be able to recognize these ghly interested in dermoscopy and I should be able to recognize these | diagnoses with appropriate desire further training in diagnoses, With appropriate |
| For all diagnoses from earlier rounds that did not interest of reaching a final consensus. | reach a clear consensus, we will no | ow conduct a majority vote in the |
| SECTION 1 | | |
| Majority Vote: - Level 1 (Foundational) - Level 2 (Intermediate) | | |
| Benign patterns of acral nevi Consensus: Benign patterns of acral nevi shou | ld be included in Level 2 if not in | luded in Level 1. |
| *** | Level 1 (Foundational) | Level 2 (Intermediate) |
| Should benign patterns of acral nevi be included in Level 1 or 2? | Level 1 (Foundational) | Level 2 (Intermediate) |
| Mollsucum Contagiosum Consensus: Molluscum Contagiosum should be | included in Level 2 if not include | ed in Level 1. |
| | Level 1 (Foundational) | Level 2 (Intermediate) |
| | | 0 |
| Should Molluscum Contagiosum be included in Level 1 or 2? | | |
| | 0 | |
| included in Level 1 or 2? | 0 | |
| included in Level 1 or 2? SECTION 2 Majority Vote: - Level 2 (Intermediate) - Neither Level 1 nor 2 Lichen Planus-Like Keratosis (Benign Lichenoid | ł Keratosis) | |
| included in Level 1 or 2? SECTION 2 Majority Vote: - Level 2 (Intermediate) - Neither Level 1 nor 2 | ł Keratosis) | |
| included in Level 1 or 2? SECTION 2 Majority Vote: - Level 2 (intermediate) - Neither Level 1 nor 2 Lichen Planus-Like Keratosis (Benign Lichenoic Consensus: Lichen Planus-Like Keratosis shoul | ł Keratosis) | |
| included in Level 1 or 2? SECTION 2 Majority Vote: - Level 2 (intermediate) - Neither Level 1 nor 2 Lichen Planus-Like Keratosis (Benign Lichenoic Consensus: Lichen Planus-Like Keratosis shoul | I Keratosis) d NOT be included in Level 1 (Foo | endational) |
| included in Level 1 or 2? SECTION 2 Majority Vote: - Level 2 (intermediate) - Neither Level 1 nor 2 Lichen Planus-Like Keratosis (Benign Lichenoic Consensus: Lichen Planus-Like Keratosis shoul What about Level 2? 3) Should Lichen Planus-Like Keratosis be included in Level 2 (intermediate) | I Keratosis) d NOT be included in Level 1 (For Level 2 (Intermediate) | endational) |
| included in Level 1 or 2? SECTION 2 Majority Vote: - Level 2 (Intermediate) - Neither Level 1 nor 2 Lichen Planus-Like Keratosis (Benign Lichenoic Consensus: Lichen Planus-Like Keratosis shoul What about Level 2? 3) Should Lichen Planus-Like Keratosis be included in Level 2 (Intermediate) or neither Level 1 nor 2? | I Keratosis) d NOT be included in Level 1 (For Level 2 (Intermediate) | endational) |
| included in Level 1 or 2? SECTION 2 Majority Vote: - Level 2 (intermediate) - Neither Level 1 nor 2 Lichen Planus-Like Keratosis (Benign Lichenoic Consensus: Lichen Planus-Like Keratosis shoul What about Level 2? 3) Should Lichen Planus-Like Keratosis be included in Level 2 (intermediate) or neither Level 1 nor 2? Talon Noir Consensus: Talon Noir should NOT be included | I Keratosis) d NOT be included in Level 1 (For Level 2 (Intermediate) | endational) |

| what ab | out Level 2? | | | | | |
|---------|--|----------------------|------------------|--|----------------|----------------|
| | | Level | 2 (Intermediate) | | Neither Lev | el 1 nor 2 |
| 5) | Should Radiation Tattoo be included in Level 2 (Intermediate) or neither Level 1 nor 2? | | 0 | | | N |
| | copic features of scars us: Dermoscopic features of scars sh | ould NOT be | included in Le | vel 1 | | |
| What ab | out Level 2? | | | | | |
| | | Level | 2 (Intermediate) | | Neither Lev | el 1 nor 2 |
| 6) | Should Dermoscopic features of scars be included in Level 2 (Intermediate) or neither Level 1 nor 2? | | 0 | | 0 | |
| | SECTION 3 | | | | | |
| | New Suggestions: - Level 1 (Foundational) - Level 2 (Intermediate) - Neither Level 1 nor Level 2 | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 7) | Poroma should be included in Level 1 (Foundational) | 100 | 0 | | 0 | 0 |
| 8) | If Poroma does not reach consensus for inclusion in Level 1 (Foundational), it should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 9) | Poroma should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| Xanthog | ranuloma (NEW) | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 10) | Xanthogranuloma should included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | 0 |
| 11) | If Xanthogranuloma does not reach consensus for inclusion in Level 1 (Foundational), it should included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 12) | Xanthogranuloma should NOT be included at either level | 10 | 0 | (0) | 0 | 0 |
| 13) | Please include any comments here: | | | | | |
| | | | We w | ill not be taking s oses at this time | uggestions for | additional |
| | | Subr | nit | | | |
| | | Save & Reti | urn Later | | | |








| Level 1: 5 | iolar Lentigo | | | | | |
|------------|---|----------------------|----------|---------|-------|----------------|
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 19) | Moth-eaten (sharply demarcated) borders | 0 | 0 | 0 | 0 | 0 |
| 20) | Homogenous light brown pigmentation | 0 | 0 | 0 | 0 | 0 |
| 21) | Network-like structures | 0 | 0 | 0 | 0 | 0 |
| 22) | Fingerprint-like structures (parallel lines) | 0 | 0 | 0 | 0 | 0 |
| 23) | Uniform brown perifollicular pigmentation | 0 | 0 | 0 | 0 | 0 |
| 24) | Fingerprint-like structures/pattern (parallel-lines) duplicate question | 0 | 0 | 0 | 0 | 0 |
| 25) | Please include any comments here: | | | | | |
| | | | Optio | onal | | |
| Louis de l | Basal Cell Carcinoma (BCC) | | | | | |
| Level I. | Jasar Cen Carcinoma (OCC) | | | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 26) | Leaf-like structures/areas | 0 | 0 | 0 | 0 | 0 |
| 27) | Blue-gray ovoid nests | 0 | 0 | 0 | 0 | 0 |
| 28) | Multiple blue-gray dots and globules (buckshot scatter) | 0 | 0 | 0 | 0 | 0 |
| 29) | Spoke-wheel-like structures/areas / concentric structures | 0 | 0 | 0 | 0 | 0 |
| 30) | Ulceration / erosion | 0 | 0 | 0 | 0 | 0 |
| 31) | Shiny white blotches and strands / structures | 0 | 0 | 0 | 0 | 0 |
| 32) | Arborizing vessels | 0 | 0 | 0 | 0 | 0 |
| 33) | Short fine telangiectasias (superficial BCC) | 0 | 0 | 0 | 0 | 0 |
| 341 | Please include any comments here: | | | | | |
| | | | Optio | onal | | |
| Level 1: / | Actinic Keratosis | | 100000 | | | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 35) | Rosettes | 0 | 0 | 0 | 0 | 0 |
| 36) | Surface scale | 0 | 0 | 0 | 0 | 0 |
| 37) | Strawberry pattern (pink-red pseudonetwork +/- fine wavy vessels [straight or coiled] surrounding hair follicles +/- white circles with central yellow clod [targetoid hair follicles]) | 0 | 0 | 0 | 0 | 0 |
| 38) | Please include any comments here: | | | | | |
| -01 | , | | Optio | mal | | |








| 1) Diffuse reticular network 2) Patchy reticular network 3) Peripheral reticular network with central hypopigmentation 4) Peripheral reticular network with central hypopigmentation 5) Peripheral reticular network with central hypopigmentation 6) Homogenous (tan, brown, blue, or pink) 7) Central network with evenly distributed peripheral globules 8) Globular pattern 10) Symmetric multicomponent pattern 11) Please Include any comments here: Optional Level 1: Intradermal Nevi Strongly disagree Disagree Neutral Agree Strongl Please include any comments here: Optional Level 2: Congenital Melanocytic Nevi | ould be | n 2: Benign Melanocyti f the following dermatologic diagnose included in dermoscopy education tar garding the inclusion of each of the fo | s, we would li | ike to identify o | | | |
|--|-----------|--|----------------|-------------------|---------|-------|----------------|
| 1) Diffuse reticular network 2) Patchy reticular network 3) Peripheral reticular network with central hypopligmentation 4) Peripheral reticular network with central hypopligmentation 5) Peripheral reticular network with central dispoplismentation 5) Peripheral reticular network with central globules 6) Homogenous (tan, brown, blue, or pink) 7) Central network with evenly distributed peripheral globules 8) Globular pattern 9) Two-component pattern 10) Symmetric multicomponent pattern 11) Please include any comments here: Optional Disagree Neutral Agree Strongly disagree Disagree Neutral Agree Strongly 12) Comma-shaped (curved) vessels 13) Homogenous (structureless) Disagree Neutral Agree Strongly 14) Peripheral network 15) Globules 16) Please include any comments here: | vel 1: O | verview of Benign Nevi Patterns | | | | | |
| 1) Diffuse reticular network 2) Patchy reticular network 3) Peripheral reticular network with central hypopigmentation 4) Peripheral reticular network with central hypopigmentation 5) Peripheral reticular network with central plobules 6) Homogenous (tan, brown, blue, or pink) 7) Central network with evenly distributed peripheral globules 8) Globular pattern 10) Symmetric multicomponent pattern 11) Please include any comments here: Optional Level 1: Intradermal Nevi Strongly disagree Disagree Neutral Agree Strongly Disagree Include any comments here: Optional Level 2: Congenital Melanocytic Nevi | | | | Disagree | Neutral | Agree | Strongly agre |
| 3) Peripheral reticular network with central hypoplgmentation 4) Peripheral reticular network with central hyperplgmentation 5) Peripheral reticular network with central globules 6) Homogenous (tan, brown, blue, or pink) 7) Central network with evenly distributed peripheral globules 8) Globular pattern 9) Two-component pattern 10) Symmetric multicomponent pattern 11) Please include any comments here: Optional Disagree Neutral Agree Strongly Strongly Disagree Neutral Agree Strongly Disagree Disagree Neutral Agree Strongly Disagree | 1) | Diffuse reticular network | | | | - | 0 |
| central hypopigmentation 4) Peripheral reticular network with central hyperpigmentation 5) Peripheral reticular network with central globules 6) Homogenous (tan, brown, blue, or pink) 7) Central network with evenly distributed peripheral globules 8) Globular pattern 10) Symmetric multicomponent pattern 11) Please include any comments here: Optional Level 1: Intradermal Nevi Strongly disagree 12) Comma-shaped (curved) vessels 13) Homogenous (structureless) prown/tan/pink pigmentation 14) Peripheral network 15) Globules 16) Please include any comments here: Optional Level 2: Congenital Melanocytic Nevi | 2) | Patchy reticular network | 101 | 0 | 0 | | 0 |
| central hyperpigmentation 5) Peripheral reticular network with central globules 6) Homogenous (tan, brown, blue, or pink) 7) Central network with evenly distributed peripheral globules 8) Globular pattern 9) Two-component pattern 10) Symmetric multicomponent pattern 11) Please include any comments here: Optional Level 1: Intradermal Nevi Strongly disagree Disagree Neutral Agree Strongly prown/tan/pink pigmentation 14) Peripheral network 15) Globules 16) Please include any comments here: Optional Level 2: Congenital Melanocytic Nevi | | | 0 | 0 | 0 | 0 | 0 |
| central globules 6) Homogenous (tan, brown, blue, or pink) 7) Central network with evenly distributed peripheral globules 8) Globular pattern 9) Two-component pattern 10) Symmetric multicomponent pattern 11) Please include any comments here: Strongly disagree Disagree Neutral Agree Strongly disagree Disagree Neutral Agree Strongly disagree | | | 0 | 0 | 0 | 0 | 0 |
| pink) 7) Central network with evenly distributed peripheral globules 8) Globular pattern 9) Two-component pattern 10) Symmetric multicomponent pattern 11) Please include any comments here: Optional Level 1: Intradermal Nevi Strongly disagree Disagree Neutral Agree Strongly brown/tan/pink pigmentation 14) Peripheral network 15) Globules 16) Please include any comments here: Optional Level 2: Congenital Melanocytic Nevi | | | 0 | 0 | 0 | 0 | 0 |
| distributed peripheral globules 8) Globular pattern 9) Two-component pattern 10) Symmetric multicomponent pattern 11) Please include any comments here: Optional | | | 0 | 0 | 0 | 0 | 0 |
| 9) Two-component pattern 10) Symmetric multicomponent pattern 11) Please include any comments here: Optional Level 1: Intradermal Nevi Strongly disagree Disagree Neutral Agree Strongly Disagree Neutral Agree Strongly Disagree Neutral N | | | 0 | 0 | 0 | 0 | 0 |
| 10) Symmetric multicomponent pattern 11) Please Include any comments here: Optional Level 1: Intradermal Nevi Strongly disagree Disagree Neutral Agree Strongly Disagree Neutral Agree Strongly Disagree Neutral Disagree Neutral Disagree Neutral Disagree Neutral Strongly Disagree Neutral Disagree Neutral Strongly Disagree Neutral Strongly Disagree Neutral Strongly Disagree Disagree Neutral Agree Strongly Disagree Disagree Neutral Agree Strongly Disagree Neutral Neu | 8) | Globular pattern | 0 | 0 | 0 | 0 | 0 |
| Level 1: Intradermal Nevi Strongly disagree Disagree Neutral Agree Strongly Disagree Neutral Disagree Neutral Disagree Neutral Strongly Disagree Neutral Disagree Neutral Disagree Neutral Disagree Neutral Disagree Neutral Disagree Neutral Strongly Disagree Neutral Disagree Strongly Disagree Neutral Disagree Strongly Disagree Neutral Disagree Strongly Disagree Neutral Disagree Neutral Disagree Strongly Disagree Neutral Disagree Strongly Disagree Neutral Disagree Strongly Disagree Neutral Disagree Neutral Disagree Strongly Disagree Neutral Disagr | 9) | Two-component pattern | 0 | 0 | 0 | 0 | 0 |
| Comma-shaped (curved) vessels Disagree Disagree Neutral Agree Strongly disagree Disagree Disagree Neutral Agree Strongly Disagree Disagre | 10) | Symmetric multicomponent pattern | 0 | 0 | 0 | 0 | 0 |
| disagree Disagree Neutral Agree Strong 12) Comma-shaped (curved) vessels 13) Homogenous (structureless) brown/tan/pink pigmentation 14) Peripheral network 15) Globules 16) Please include any comments here: Optional Level 2: Congenital Melanocytic Nevi | | | | Optio | inal | | |
| 12) Comma-shaped (curved) vessels 13) Homogenous (structureless) brown/tan/pink plgmentation 14) Peripheral network 15) Globules 16) Please include any comments here: Optional Level 2: Congenital Melanocytic Nevi | | | | Disagree | Neutral | Agree | Strongly agre |
| brown/tan/pink pigmentation 14) Peripheral network 15) Globules 16) Please include any comments here: Optional Level 2: Congenital Melanocytic Nevi | 12) | Comma-shaped (curved) vessels | | | 0 | 0 | .0 |
| 15) Globules 16) Please include any comments here: Optional Level 2: Congenital Melanocytic Nevi Strongly disagree Disagree Neutral Agree Strongly | | | 0 | 0 | 0 | 0 | |
| 16) Please include any comments here: Optional Level 2: Congenital Melanocytic Nevi Strongly disagree Disagree Neutral Agree Strong | 14) | Peripheral network | 0 | 0 | 0 | 0 | 0 |
| Optional Level 2: Congenital Melanocytic Nevi Strongly disagree Disagree Neutral Agree Strong | 15) | Globules | 0 | 0 | 0 | 0 | 0 |
| Optional Level 2: Congenital Melanocytic Nevi Strongly disagree Disagree Neutral Agree Strong | 16) | Please include any comments here: | | | | | |
| Strongly disagree Disagree Neutral Agree Strong | | | | Optio | inal | | |
| disagree Disagree Neutral Agree Strong | vel 2: Co | ngenital Melanocytic Nevi | | | | | |
| | | | | Disagree | Neutral | Apren | Strongly agree |
| pattern | | | 0 | 0 | 0 | 0 | 0 |
| 18) Reticular network | 18) | Reticular network | 0 | 0 | 0 | 0 | 0 |
| 19) Homogenous background OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO | | | 0 | 0 | 0 | 0 | 0 |
| 20) Hypertrichosis | 20) | Hypertrichosis | 0 | 0 | 0 | 0 | 0 |
| 21) Perifollicular hyper-/hypopigmentation | | | 0 | 0 | 0 | 0 | 0 |


















| 4) | Homogenous brown background coloration Uniform band thickness, color (including blue), and spacing with parallel band configuration Please include any comments here: | 0 | Optio | 0 | Agree | Strongly agree |
|---|--|--|---|--|---|--|
| 4) | coloration Uniform band thickness, color (including blue), and spacing with | 0 | 0 | 0 | 0 | |
| 4) | coloration | | O | | Agree | |
| Dermosc | | uisagree | Disagree | tagarran | Agree | Strongly agre |
| Dermoso | | Strongly disagree | Disagree | Neutral | | |
| | opic Features: Nevus of the Nail | | | | | |
| 3) | Nevus of the Nail should NOT be included at either level | 0 | 0 | 0 | 0 | 0 |
| 2) | Nevus of the Nail should be included in Level 2 (Intermediate) | 0 | 0 | 0 | 0 | 0 |
| 1) | Nevus of the Nail should be included in Level 1 (Foundational) | 0 | 0 | 0 | 0 | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| tra Lei de tra be No for Please no diagnosis | ining, eela 2 (intermediate) — PCPs who are it moscopy beyond the Foundational Lew ining, recognition of these "above and it or in the properties of the properties of the properties of the profice of t | nighly interest el should be beyond" diagr cation of thes ency for PCP: ute towards | ed in dermosci able to recogni ioses would de e diagnoses wo i. | opy and desire to ge these diagnormonstrate an ar- puld not be refle the inclusion of | further traini ses. With ap dditional leve ective of either r exclusion o | ng in propriate el of mastery er f that specific |
| • Le | rel 1 (Foundational) — PCPs who desir plications for the detection of skin canci | e a basic yet | practical under | standing of der | moscopy an | d its |
| engagem | wing diagnosis was inadvertently left of with each of the following statements in ent with dermoscopy across the PCP sp | egarding this | diagnosis. Give | en the diversity | of interest, b | andwidth, and |
| disagree | | | | | | ⊕ 😑 |








| Should | | | | | | |
|--|--|---------------------------------------|---------------------------|---------------|-------|----------------|
| J.II. | the following feature(s) also be included | ed in PCP-ta | rgeted dermos | copy educatio | n? | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 7 | Shiny white blotches and strands / structures | 0 | 0 | 0 | 0 | 0 |
| 8 | Short fine telangiectasias (superficial BCC) | 0 | 0 | 0 | 0 | 0 |
| 9) | Please include any comments here | | | | | |
| | | | Optio | nal | | |
| | ent dark homogenous (uniform) reti | | | copy educatio | n? | |
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 10 | Chicken-wire fence | 0 | 0 | 0 | 0 | 0 |
| | | | | | | |
| 441 | Diago include any comments have | | | | | |
| | e sign | | Optio | nal | | |
| Level 2: Consens - Rosett - Surfac | Pigmented Actinic Keratosis sus: e sign | | | ** | n? | |
| Level 2: Consens - Rosett - Surfac | Pigmented Actinic Keratosis sus: e sign e scale | led in PCP-ta | | ** | n? | Strongly agree |
| Level 2: Consens - Rosett - Surfac Should | Pigmented Actinic Keratosis sus: e sign e scale | led in PCP-ta | rgeted dermos | copy educatio | | Strongly agree |
| Level 2: Consens - Rosett - Surfac Should | Pigmented Actinic Keratosis sus: e sign e scale the following feature(s) also be includ | led in PCP-ta Strongly disagree | rgeted dermos Disagree | copy educatio | Agree | |
| Level 2: Consens - Rosett - Surfac Should 1 | Pigmented Actinic Keratosis us: e scign e scale the following feature(s) also be includ Gray dots Annular-granular pattern (gray dots | led in PCP-ta Strongly disagree | rgeted dermos Disagree | Neutral | Agree | 0 |
| Level 2: Consens - Rosett - Surfac Should 1 | Pigmented Actinic Keratosis sus: e sign e sign the following feature(s) also be included Gray dots Annular-granular pattern (gray dots around follicular openings) | led in PCP-ta Strongly disagree | rgeted dermos Disagree | Neutral | Agree | 0 |
| Level 2: Consensers - Rosett - Surface Should in 12: 13: 14: Level 2: Consensers - Surface - Irregul | Pigmented Actinic Keratosis sus: e sign e sign the following feature(s) also be included Gray dots Annular-granular pattern (gray dots around follicular openings) Please include any comments here Squamous Cell Carcinoma in situ (Bo | led in PCP-ta Strongly disagree | Disagree Option | Neutral | Agree | 0 |
| Level 2: Consensers - Rosett - Surface Should in 12: 13: 14: Level 2: Consensers - Surface - Irregul | Pigmented Actinic Keratosis us: e sign e scale the following feature(s) also be included Gray dots Annular-granular pattern (gray dots around follicular openings) Please include any comments here Squamous Cell Carcinoma in situ (Bouss: es scale arly arranged glomerular (coiled) / do | led in PCP-ta Strongly disagree | Disagree Option | Neutral | Agree | 0 |


| (FETANOSTI) | | | • | copy educatio | | |
|--------------|---|-------------------|-----------|---------------|-------|---------------|
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 17) | Coarse gray granularity | 0 | 0 | 0. | 0 | 0 |
| 18) | Peppering (evenly spaced gray dots) | 0 | 0 | 0 | 0 | 0 |
| 19) | Sharp cut-off borders (scalloped/moth-eaten) | 0 | 0 | 0 | 0 | 0 |
| 20) | Blue-gray/blue-white structures (NEW) | 0 | 0 | 0 | 0 | 0 |
| 21) | Please include any comments here: | | | | | |
| | | | Optio | nal | | |
| | | Subn | nit | | | |
| | | Save & Retu | ırn Later | | | |







| | NES VESS | | | | | |
|---------------------------------|--|----------------------|---------------------------|----------------|-------|---------------|
| | | Strongly disagree | Disagree | Neutral | Agree | Strongly agre |
| 8) | Brown to black dots/globules associated with longitudinal lines | 0 | 0 | 0 | 0 | 0 |
| 9) | Please include any comments here | : | Optio | | | |
| | | | | | | |
| | Total Male | | 8 | | | |
| | Talon Noir | | | | | |
| Consens | | | | | | |
| Consens - Homog | us: enous red-brown coloration | | 2 | | | |
| Consens - Homog | us: | led in PCP-ta | 2 | scopy educatio | n? | |
| Consens - Homog | us: enous red-brown coloration | Strongly | rgeted dermo: | scopy educatio | ** | Strongly agre |
| Consens - Homog | us: enous red-brown coloration he following feature(s) also be inclu | | 2 | | n? | Strongly agre |
| Consens - Homog Should t | us: enous red-brown coloration he following feature(s) also be included Peripheral red-brown dots/globules | Strongly disagree | rgeted dermos Disagree | Neutral | Agree | Strongly agre |
| Consens - Homog Should ti | us: enous red-brown coloration he following feature(s) also be included Peripheral red-brown dots/globules | Strongly disagree | rgeted dermos Disagree | Neutral | Agree | Strongly agre |
| Consens - Homog Should ti | us: enous red-brown coloration he following feature(s) also be included Peripheral red-brown dots/globules | Strongly disagree | priced dermos | Neutral | Agree | Strongly agre |
| Consens - Homog Should ti | us: enous red-brown coloration he following feature(s) also be included Peripheral red-brown dots/globules | Strongly disagree | Disagree Optic | Neutral | Agree | Strongly agre |
| Consens Homog Should t | us: enous red-brown coloration he following feature(s) also be included Peripheral red-brown dots/globules | Strongly disagree | Disagree Optic | Neutral | Agree | Strongly agre |



| Demographics Survey | |
|--|---|
| We sincerely appreciate your input. | |
| In this initial survey, we will collect demographic of involvement in dermoscopy education to PCPs | |
| What is your practice specialty? | Family Medicine Internal Medicine Medicine-Pediatrics Dermatology Other |
| If you answered "Other" above, please describe: | |
| Do you use dermoscopy in your practice? | ○ Yes ○ No |
| How long have you used dermoscopy in your practice for? | <pre> < 1 year</pre> |
| Are you specialized in pigmented lesions, dermoscopy, or melanoma? | ○ Yes ○ No |
| How long have you specialized in pigmented lesions and melanoma for (as an attending physician)? | <pre> < 1 year</pre> |
| Are you directly involved in dermoscopy training for PCPs? | ○ Yes ○ No |
| Do you provide dermoscopy training for PCPs in the clinic and/or through the lecture format? | ☐ In the clinic ☐ Lectures ☐ Other (Please check all that apply.) |
| If you answered "Other" above, please describe: | |

Appendix C. Dictionary of dermoscopic features for included diagnoses with annotations and references

Sections

| 1. | Nonmelanocytic Lesions | Page 2 |
|----|--|--------|
| 2. | Benign Melanocytic Lesions | Page 5 |
| 3. | <u>Melanoma</u> | Page 7 |
| 4. | Special Sites | Page 8 |
| 5. | Other (including skin infections & infestations) | Page 9 |

Section 1: Nonmelanocytic Lesions

| Diagnosis (Level) | Dermoscopic Features | References |
|--------------------------------|---|---|
| Hemangioma (Level 1) | Red, blue-red, red-purple, or maroon lacunae/lagoons with white septae Blue-black coloring (when thrombosed) | Wolf IH. Dermoscopic diagnosis of vascular lesions. <i>Clin Dermatol</i> . 2002;20(3):273-275. |
| Seborrheic keratosis (Level 1) | Milia-like cysts (cloudy or starry) and comedo-like openings "Fissures and ridges" / "gyri and sulci" / cerebriform pattern Moth-eaten (sharply demarcated) borders Fat fingers Fingerprint-like structures (parallel lines) Hairpin (looped) vessels, usually with whitish hale | Braun RP, Rabinovitz HS, Krischer J, Kreusch J, Oliviero M, Naldi L, Kopf AW, Saurat JH. Dermoscopy of pigmented seborrheic keratosis: a morphological study. <i>Arch Dermatol</i> . 2002;138(12):1556-1560. |
| Dermatofibroma (Level 1) | Central scar-like white patch/depigmentation Fine/delicate surrounding/peripheral network-like structures Central shiny white lines/streaks (optional to include) Ring-like globules Central-pink-blueh Detted-vessels | Agero AL, Taliercio S, Dusza SW, Salaro C, Chu P, Marghoob AA. Conventional and polarized dermoscopy features of dermatofibroma. Arch Dermatol. 2006;142(11):1431-1437. Zaballos P, Puig S, Llambrich A, Malvehy J. Dermoscopy of dermatofibromas: a prospective morphological study of 412 cases. Arch Dermatol. 2008;144(1):75-83. |
| Solar lentigo (Level 1) | Moth-eaten (sharply demarcated) borders Fingerprint-like structures (parallel lines) Homogenous light brown pigmentation Uniform brown perifollicular pigmentation (optional to include) Network-like structures | Bollea-Garlatti LA, Galimberti GN, Galimberti RL. Lentigo maligna: keys to dermoscopic diagnosis. <i>Actas</i> <i>Dermo-Sifiliogr</i> . 2016;107(6):489-497. |
| Basal cell carcinoma (Level 1) | Arborizing vessels Ulceration / erosion Leaf-like structures/areas Blue-gray ovoid nests Spoke-wheel-like structures/areas / concentric structures Multiple blue-gray dots and globules (buckshot scatter) Shiny white blotches and strands / structures Short fine telangiectasias (superficial BCC) | Balagula Y, Braun RP, Rabinovitz HS, et al. The significance of crystalline/chrysalis structures in the diagnosis of melanocytic and nonmelanocytic lesions. <i>J Am Acad Dermatol</i> . 2012;67(2):194.e1-194.e1948. |

Key: black, from the dermatology resident Delphi study; purple, from ISIC database; green, from An Atlas of Dermoscopy, yellow, from Dermoscopedia; red, from other literature; blue, feature or text added by steering committee; yellow highlight, feature or text added by panel; strikelhrough, text removed by panel or feature excluded by panel consensus

| Diagnosis (Level) | Dermoscopic Features | References |
|---------------------------------|---|--|
| Squamous cell carcinoma | Yellow keratin mass / scale-crust | |
| (Level 1) | Ulceration / blood spots / hemorrhage | |
| | White circles ("keratin pearls") | |
| | Glomerular (coiled) vessels | |
| | Rosettes sign | |
| | Hairpin vessels , usually with whitish halo | |
| Actinic keratosis (Level 1) | Surface scale | Zalaudek I, Giacomel J, Argenziano G, et |
| | Rosettes-sign | Dermoscopy of facial nonpigmented actinic keratosis. Br. J Dermatol. |
| | Strawberry pattern (pink-red pseudonetwork +/- fine wavy vessels [straight or coiled] surrounding hair follicles +/- white circles with central yellow clod [targetoid hair follicles]) | 2006;155(5):951-956. |
| Sebaceous hyperplasia (Level 2) | Pale yellow lobules (popcorn-like structures) around a central follicular | |
| | opening Crown vessels <mark>, out of focus</mark> | |
| Pigmented actinic keratosis | Surface scale | Casari A, Chester J, Pellacani G. Actinic |
| (Level 2) | Rosettes-sign | keratosis and non-invasive diagnostic techniques: an update. Biomedicines. |
| | (optional to include) Annular-granular pattern (gray dots around follicular openings) | 2018;6(1):8. Kelati A, Baybay H, Moscarella E, |
| | (optional to include) Red pseudonetwork | Argenziano G, Gallouj S, Mernissi FZ. |
| | (optional to include) Patent/evident follicles | Dermoscopy of pigmented actinic keratosis of the face: a study of 232 |
| | Gray dots | cases. Actas Dermo-Sifilioar. |
| | White circles | 2017;108(9):844-851. |
| Squamous cell carcinoma in | Irregularly arranged glomerular (coiled) / dotted vessels | |
| situ (Level 2) | Surface scale | |
| | Peripheral brown/gray dots arranged linearly (pigmented squamous cell carcinoma in situ) | |
| Keratoacanthoma (Level 2) | Central keratin mass | |
| | Hairpin (looped) or serpentine (linear-irregular) vessels, usually at the periphery, with white-yellow halo | |
| Angiokeratoma (Level 2) | Red/purple/black ("dark") lacunae Hemorrhagic crust | Wolf IH. Dermoscopic diagnosis of vascular lesions. Clin Dermatol. |
| | Tierrormagie orașt | 2002;20(3):273-275. |

| Diagnosis (Level) | Dermoscopic Features | References | |
|------------------------------|--|------------|--|
| Lichen planus-like keratosis | Features of a lentigo or a seborrheic keratosis in an area | | |
| (Level 2) | (optional to include) Peppering (evenly spaced gray dots) | | |
| | (optional to include) Sharp cut-off borders (scalloped/moth-eaten) | | |
| | (optional to include) Coarse gray granularity | | |
| Ink spot lentigo* (Level 2) | Prominent dark homogenous (uniform) reticular network | | |
| | (optional to include) Chicken-wire fence | | |

^{*} Diagnosis suggested by a panelist during Round 1 of the Dermatologic Diagnoses survey series

Section 2: Benign Melanocytic Lesions

| Diagnosis (Level) | Dermoscopic Features | References |
|-----------------------------|--|--|
| Overview of benign nevi | Diffuse reticular network | |
| patterns (Level 1) | Peripheral reticular network with central hypopigmentation | |
| | Peripheral reticular network with central hyperpigmentation | |
| | Globular pattern | |
| | Patchy reticular network | |
| | Homogenous (tan, brown, blue, or pink) | |
| | Peripheral reticular network with central globules | |
| | Central network with evenly distributed peripheral globules | |
| | Symmetric two-component pattern | |
| | (optional to include) Symmetric multicomponent pattern | |
| Intradermal nevi (Level 1) | Comma-shaped (curved) vessels | |
| | Homogenous (structureless) brown/tan/pink pigmentation | |
| | Peripheral network | |
| | Globules | |
| Blue nevi (Level 2) | Homogenous blue/blue-gray pigmentation | |
| | Well-circumscribed lesion | |
| Spitz nevi (Level 2) | Starburst pattern with tiered globules/streaks and regularly spaced | Zalaudek I, Kittler H, Hofmann-Wellenhof |
| | pseudopods at the periphery (radial streaming) Vascular pattern (pink homogenous with dotted vessels) | R, et al. "White" network in Spitz nevi and early melanomas lacking |
| | Negative pigment network (reticular depigmentation) | significant pigmentation. J Am Acad |
| | Shiny white lines (crystalline structures) | Dermatol. 2013;69(1):56-60. Marchell R, Marghoob AA, Braun RP, |
| | Globular with negative network or blue white veil | Argenziano G. Dermoscopy of |
| | Globalar with negative network of blue write veil | Pigmented Spitz and Reed Nevi: The |
| | | Starburst Pattern. Arch Dermatol. 2005;141(8):1060. |
| | | 2005, 141(0). 1000. |
| Congenital melanocytic nevi | Cobblestone pattern/globular pattern | |
| (Level 2) | Reticular network | |
| | Homogenous/diffuse background pigmentation | |
| | Hypertrichosis | |
| | (optional to include) Perifollicular hyper-/hypo-pigmentation | |

| Diagnosis (Level) | Dermoscopic Features | References | | |
|--|---|---|--|--|
| Recurrent/persistent nevi (Level 2) | Pigment within the scar, not extending beyond | | | |
| Halo nevi* (Level 2) | Encircling/surrounding depigmentation/pallor Central reticulation with peripheral white depigmentation Benign nevi patterns, globular, homogenous | Kolm I, Di Stefani A, Hofmann-Wellenhof R, et al. Dermoscopy patterns of halo nevi. Arch Dermatol. 2006;142(12):1627-1632. | | |

^{*} Diagnosis suggested by a panelist during Round 1 of the Dermatologic Diagnoses survey series

Section 3: Melanoma

| Diagnosis (Level) | Dermoscopic Features | References |
|---|---|---|
| Overview of melanoma patterns (Level 1) | Blue structures (blue-white veil, blue-gray structures) Shiny white lines/structures (crystalline structures) Atypical pigment network Atypical/irregular streaks (radial streaming, pseudopods) Atypical/irregular dots/globules Regression structures (white scar-like area and/or peppering) Negative pigment network Atypical vascular pattern/structures, polymorphous vessels (2+ types of blood vessels) Peripheral brown/tan structureless area Angulated lines (extrafacial) / polygons / zig-zag pattern Atypical off-center blotch(es) | Balagula Y, Braun RP, Rabinovitz HS, et al. The significance of crystalline/chrysalis structures in the diagnosis of melanocytic and nonmelanocytic lesions. J Am Acad Dermatol. 2012;67(2):194.e1–194.e1948. Marghoob NG, Liopyris K, Jaimes N. Dermoscopy: A Review of the Structures That Facilitate Melanoma Detection. J Am Osteopath Assoc. 2019;119(6):380-390. |
| Acral melanoma (Level 2) | Parallel ridge pattern Ulceration Irregular diffuse pigmentation or blotch Multicomponent pattern, asymmetry of structures/colors Atypical fibrillar pattern Neo-vascularization, milky red | Popa A, Dumitraş cu MC, Sandru F. Acral Melanoma mimicking a non-healing arterial ulcer. <i>Medical Image Database</i> . 2022;4(1):11-12. |
| Lentigo maligna melanoma (Level 2) | Annular-granular pattern (gray dots around follicular openings) Asymmetric pigmentation around follicular openings / asymmetrical follicular openings Rhomboidal structures (angulated lines) / zig-zag pattern Dark blotches +/- obliterated hair follicles (optional to include) Circle within a circle (isobar) | Schiffner R, Schiffner-Rohe J, Vogt T, et al. Improvement of early recognition o lentigo maligna using dermatoscopy. Am Acad Dermatol. 2000;42(1 Pt 1):25-32. Slutsky JB, Marghoob AA. The Zig-Zag Pattern of Lentigo Maligna. Arch Dermatol. 2010;146(12):1444. |
| Melanoma of the nail (Level 2) | Pigmentation of periungual skin (micro-Hutchinson's sign) Triangular shape of pigment band (band diameter wider at proximal end) Longitudinal brown/black lines with irregular spacing, width, coloration, or parallelism Band width >3 mm or ² / ₃ of nail plate width (optional to include) Brown to black dots/globules associated with longitudinal lines | |

| Amelanotic/hypomelanotic melanoma (Level 2) | Milky red areas Shiny white lines (crystalline structures) Atypical vascular pattern, polymorphous vessels (2+ types of blood vessels) Scar-like depigmentation | Balagula Y, Braun RP, Rabinovitz HS, et al. The significance of crystalline/chrysalis structures in the diagnosis of melanocytic and nonmelanocytic lesions. J Am Acad Dermatol. 2012;67(2):194.e1- |
|--|---|---|
| | | 194.e1948. |

Section 4: Special Sites

| Diagnosis (Level) | Dermoscopic Features | References |
|--|--|---|
| Subungual hemorrhage (Level 1) | Well-circumscribed red-black dots or blotches / blood spots | |
| | Discontiguous with the cuticle (not connected to the proximal nailfold or edge of nail) | |
| | Distal streaks of red-brown coloration ("filamentous" distal end) | |
| | (optional to include) Homogenous red/purple/black coloration without melanin granules | |
| Dermoscopic features of the face (Level 2) | Pseudonetwork | |
| Benign patterns of acral nevi (Level 2) | Parallel furrow pattern (with pattern variations including single line, double line, single dotted line, double-dotted line) | |
| | Lattice-like pattern | |
| | Fibrillar pattern (soles only) | |
| | Homogenous pattern | |
| | (optional to include) Peas in a pod pattern (parallel furrow + globules on ridges) (acral congenital melanocytic nevi) | |
| Nevus of the nail (Level 2) | Homogenous brown background coloration | |
| | Uniform band thickness, color (including blue), and spacing with parallel band configuration | |
| Lentigo of the nail (Level 2) | Multiple thin homogenous gray lines (or single gray band) +/- gray background | |
| | (optional to include) Regular light brown lines | |
| Talon noir* (Level 2) | Homogenous or parallel-ridge red-brown coloration | Zalaudek I, Argenziano G, Soyer HP, |
| | (optional to include) Cracks (lightning bolt sign) Peripheral red-brown dots/globules | Saurat JH, Braun RP. Dermoscopy of subcorneal hematoma. <i>Dermatol Surg.</i> 2004;30(9):1229-1232. |

^{*} Diagnosis suggested by a panelist during Round 1 of the Dermatologic Diagnoses survey series

Section 5: Other (including skin infections & infestations)

| Diagnosis (Level) | Dermoscopic Features | References |
|------------------------------------|---|--|
| Verruca (Level 1) | Papilliform structures Tiny red-black dots (papillary capillaries) | Al Rudaisat M, Cheng H. Dermoscopy features of cutaneous warts. Int J Gen Med. 2021;14:9903-9912. |
| Scabies (Level 1) | Delta-wing jet with contrail sign (small dark brown triangular structure located at the end of whitish structureless curved/wavy lines) | Park JH, Kim CW, Kim SS. The diagnostic accuracy of dermoscopy for scabies. <i>Ann Dermatol.</i> 2012;24(2):194-199. doi:10.5021/ad.2012.24.2.194 |
| Molluscum contagiosum (Level 2) | Central pore or umbilication Polylobular white-yellow amorphous structures | lanhez M, Cestari Sda C, Enokihara MY, Seize MB. Dermoscopic patterns of |
| ` ' | (optional to include) Linear or branched vessels (red corona) / crown vessels | molluscum contagiosum: a study of 211 lesions confirmed by histopathology. <i>An Bras Dermatol</i> . 2011;86(1):74-79. |
| Radiation tattoo (Level 2) | Homogenous blue or black coloration | Nazarian RS, Amin B, Papalezova K, Ohri N, McLellan BN. Radiation tattoos mimicking melanoma: a clinical observation. <i>Acta Oncologica</i> . 2019;58(9):1283-1285. |
| Scars (Level 2) | White depigmentation | Yoo MG, Kim IH. Keloids and hypertrophic |
| | Arborizing, linear irregular, or comma vessels in keloids | scars: characteristic vascular structures visualized by using dermoscopy. <i>Ann Dermatol</i> . 2014;26(5):603-609. |
| Venous lake (Level 2) | Homogenous purple/blue/red coloration +/- globule/clods | Lee JS, Mun JH. Dermoscopy of venous lake on the lips: A comparative study with labial melanotic macule. <i>PLoS One</i> . 2018;13(10):e0206768. |
| Psoriasis* (Level 2) | Red or pink color with white-yellow scales / light red background | Golińska J, Sar-Pomian M, Rudnicka. |
| | Dotted vessels in a regular distribution | Dermoscopic features of psoriasis of the skin, scalp and nails – a |
| | Twisted red loops in a homogenous distribution | systematic review. J Eur Acad |
| | Glomerular vessels | Dermatol Venereol. 2019;33(4):648-660. |

^{*} Diagnosis suggested by a panelist during Round 1 of the Dermatologic Diagnoses survey series

Additional References

- Braun RP LA, Marghoob AA, et al, eds. Dermoscopedia. International Dermoscopy Society. Accessed December 2021.
- https://dermoscopedia.org/Main_Page
 Fried LJ, Tan A, Berry EG, et al. Dermoscopy proficiency expectations for US dermatology resident physicians: results of a modified Delphi survey of pigmented lesion experts. JAMA Dermatol. 2021;157(2):189-197.
- Kittler H, Marghoob AA, Argenziano G, Carrera C, Curiel-Lewandrowski C, Hofmann-Wellenhof R, et al. Standardization of terminology in dermoscopy/dermatoscopy: Results of the third consensus conference of the International Society of Dermoscopy. *J Am Acad Dermatol.* 2016;74(6):1093–106.

 Marghoob AA, Malvehy J, Braun RP, eds. *An Atlas of Dermoscopy.* 2nd ed. CRC Press. 2012.

Appendix D. Results summaries for the diagnoses survey series (3 rounds) and features survey series (2 rounds)

| Dermatologic Diagnoses Survey Series | |
|---|---------|
| Round 1 | Page 2 |
| Round 2 | Page 14 |
| Round 3 | Page 24 |
| Dermoscopic Features Survey Series | |
| Round 1 | Page 29 |
| Round 2 | Page 42 |

Results summary for Round 1 of the diagnoses survey series (initial round)

Development of an Expert Consensus on Core Dermoscopy Proficiencies for **PCPs Who Use Dermoscopy**

Dermatologic Diagnoses: Round 1

Preliminary Results

October 20, 2021

I. Study Objective

The objective of this study is to develop and refine an expert consensus statement regarding key learning objectives deemed appropriate for dermoscopy educational interventions targeted towards primary care providers (PCPs). These interventions seek to support early skin cancer detection and accurate skin cancer diagnosis by PCPs.

By reaching a consensus on the dermoscopic diagnoses and features that PCPs who use dermoscopy should know, we can develop effective educational interventions that meet the needs of practicing physicians and advanced practice providers.

II. Survey Overview

The objective of this initial diagnoses survey series is to develop an expert-approved list of common dermatologic diagnoses with characteristic dermoscopic features that should be included in dermoscopy training programs for PCPs.

In Round 1, panelists reviewed a list of diagnoses and considered whether each specific diagnosis should be included in the learning objectives for PCP-targeted dermoscopy education. The list of diagnoses in Round 1 was largely derived from a consensus-based list of dermoscopic diagnoses considered reflective of an appropriate foundational proficiency for dermatology residents.¹

Given the diversity of interest in and engagement with dermoscopy across the PCP spectrum, panelists were also instructed to sort each diagnosis into three choices:

- Level 1 (Foundational) PCPs who desire a basic yet practical understanding of dermoscopy and its applications for the detection of skin cancer should be able to recognize these diagnoses with sufficient training.
- Level 2 (Intermediate) PCPs who are highly interested in dermoscopy and desire
 further training in dermoscopy beyond Level 1 should be able to recognize these
 diagnoses. With sufficient training, recognition of these "above and beyond" diagnoses
 would demonstrate an additional level of mastery beyond Level 1.
- Not appropriate Dermoscopic identification of these diagnoses would not be reflective of either foundational- or intermediate-level proficiency for PCPs.

III. Survey Methods

This study protocol follows the two-phase modified Delphi method. In the first phase, a steering committee develops a statement (i.e., list of dermoscopic diagnoses) to present to the panel, and in the second phase, an expert panel refines this statement through sequential rounds of voting. In each round, panelists may propose changes to the statement, which are then presented to and voted on by the panel in a subsequent round.

By using a web-based platform, panelists' responses, suggestions, and comments remain anonymous. This process is intended to ensure that the outcomes most closely represent the collective viewpoints of the panelists.

For the diagnoses survey series, a steering committee (comprised of 3 PCPs who use dermoscopy and 2 dermatologists who are highly engaged in dermoscopy education for PCPs) approved a list of diagnoses and provided input on the design of the survey instrument, which was subsequently developed on REDCap. In recruiting panelists for the second phase, the steering committee drafted a list of potential candidates consisting of PCPs known to use dermoscopy and dermatologists known to be directly involved in dermoscopy education for PCPs.

On October 1, 2021, the Round 1 survey was distributed via e-mail to panel invitees. The survey instrument included a consent statement and a list of diagnoses divided into 5 sections:

- 1. Non-melanocytic lesions
- 2. Benign melanocytic lesions
- 3. Melanoma

- Special sites
- Other (including skin infections & infestations)

For each specific diagnosis, panelists considered the following questions:

- Should the diagnosis be included in a Level 1 (Foundational) proficiency standard for PCPs?
- Should the diagnosis be included in a Level 2 (Intermediate) proficiency standard for PCPs?
- Should the diagnosis not be included at either Level 1 or Level 2?

Panelists also had the opportunity to write in suggestions for additional diagnoses that will be voted on by the panel in Round 2 per the modified Delphi method.

Of the 40 colleagues invited to join the panel, 35 (85.7%) voluntarily consented to participate and completed the survey instrument. In this initial round, panelists also completed a demographics survey that asked about their area of expertise, use of dermoscopy, and experience with dermoscopy training for PCPs.

The collection of completed surveys ended on October 19, 2021. Responses were de-identified, and data analyses were performed using REDCap and Excel. Incomplete survey responses were excluded from data analyses.

IV. Results Preview

The dermoscopic diagnoses that achieved consensus, or >70% agreement (defined as selection of "strongly agree" or "agree" on the Likert scale), are listed below. Tables 1 and 2 includes the diagnoses that panelists agreed should be included in Levels 1 and 2, respectively. Table 3 includes the diagnoses that panelists agreed should not be included in either Level 1 or Level 2.

Table 1. Dermoscopic diagnoses that >70% panelists agreed should be included in Level 1.

| Nonmelanocytic lesions | Benign melanocytic lesions | Melanoma | Special sites | Other |
|---|--|-------------------------------------|-------------------------|---------|
| Basal cell carcinoma Actinic keratosis Squamous cell carcinoma Simple lentigo Solar lentigo Seborrheic keratosis Angioma Dermatofibroma | Overview of benign nevi patterns Intradermal nevi | Overview of melanoma patterns | Subungual hemorrhage | Verruca |

Table 2. Dermoscopic diagnoses that >70% panelists agreed should be included in Level 2.

| Nonmelanocytic lesions | Benign melanocytic lesions | Melanoma | Special sites | Other |
|--|--|--|---|--------|
| Pigmented actinic keratosis Sebaceous hyperplasia | Congenital melanocytic nevi Blue nevi Spitz nevi | Acral melanoma Lentigo maligna melanoma | Dermoscopic features of the face Benign patterns of acral nevi Melanoma of the nail | (none) |

Table 3. Dermoscopic diagnoses that >70% panelists agreed should <u>not</u> be included in <u>either</u> Level 1 or Level 2.

| Nonmelanocytic lesions | Benign melanocytic lesions | Melanoma | Special sites | Other |
|------------------------|----------------------------------|----------|---------------|--------|
| (none) | (none) | (none) | (none) | (none) |

V. Results

For Round 1, panelists were instructed to rate on a Likert scale whether they agree that a diagnosis should be included in Level 1 (Foundational), should be included in Level 2 (Intermediate), or should not be included at either level. For each survey item, the options for the Likert scale were:

- 1. Strongly disagree
- Disagree 2.
- 3. Neutral

- 4. Agree
- 5. Strongly agree

Panelists' responses on the Likert scale were converted to a numerical format with 1 representing "strongly disagree" and 5 representing "strongly agree," as above. The selection of strongly agree" (5) or "agree" (4) was considered a "positive response" and contributed towards a survey item reaching consensus.

Tables 4-8, corresponding to the 5 different sections, summarize the results of Round 1. Panelists' suggestions for additional diagnoses and comments are also included. Panelists will vote on these suggested diagnoses in Round 2.

Suggestions that were addressed in a subsequent section on the survey (e.g., "intradermal nevus," "verruca," etc.) were excluded from this report, and suggestions that were more applicable to a different section (e.g., "talon noir," "mucous membranes," etc.) were moved to the appropriate section.

For each diagnosis, the aggregate of panelists' responses resulted in one of the following designations for the "next step":

- "include in Level 1" as a learning objective
 - The diagnosis reached a clear consensus for inclusion in Level 1 with >70% of panelists voting "strongly agree" (5) or "agree" (4).
 - The diagnosis is deemed appropriate for PCPs who desire a basic yet practical understanding of dermoscopy.
- "exclude from Level 1" / "include in Level 2" as a learning objective
 - The diagnosis did not reach a clear consensus for inclusion in Level 1. However, the diagnosis reached a clear consensus for inclusion in Level 2.
 - The diagnosis is deemed appropriate for PCPs who are highly interested in dermoscopy and desire further training beyond Level 1.
- "exclude from Level 2" as a learning objective
 - The diagnosis is not deemed appropriate for either Level 1 or Level 2.
- "re-vote in round 2"
 - The diagnosis did not reach a clear consensus for a particular level with >50% of panelists voting "strongly agree" (5) or "agree" (4).

Table 4. Results for diagnoses representing nonmelanocytic lesions (n=35 panelists). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis Level | Level response % positive average responses* | | Comments | |
|---------------------------|--|-------------|--------------------------------|--|
| Basal cell carcinoma | | | | |
| Level 1 | 4.77 | 94.3% | include in Level 1 | (none) |
| Level 2 | - | | | |
| Neither | | | | |
| Actinic keratosis | | | | |
| Level 1 | 3.97 | 71.4% | include in Level 1 | (none) |
| Level 2 | | - | | |
| Neither | _ | | | |
| Pigmented actinic ke | eratosis | | 0.4197 (0.253) (0.277) (0.277) | |
| Level 1 | 2.69 | 25.7% | exclude from Level 1 | (none) |
| Level 2 | 3.97 | 77.1% | include in Level 2 | |
| Neither | | | | |
| Squamous cell carci | inoma in situ | | | |
| Level 1 | 3.97 | 65.7% | re-vote in Round 2 | (none) |
| Level 2 | 3.80 | 68.6% | re-vote in Round 2 | Acceptable 1 |
| Neither | 1.34 | 0% | | |
| Keratoacanthoma | | | | |
| Level 1 | 3.49 | 51.4% | re-vote in Round 2 | (none) |
| Level 2 | 3.74 | | re-vote in Round 2 | (1.51.5) |
| Neither | 1.49 | 0% | TO TOLO III TROUNG E | |
| Squamous cell carci | - All Annual Control | 0,0 | | |
| Level 1 | 4.23 | 74.3% | include in Level 1 | (none) |
| Level 2 | 4.20 | 74.570 | include in Level 1 | (none) |
| Neither | _ | _ | | |
| Simple Lentige | (2007) | 2-1 | | |
| Level 1 | 4.17 | 80.0% | | diagnosis later removed by |
| Level 2 | 4.17 | 00.070 | | steering committee due to |
| Neither | | | | overlap with solar lentigo |
| Solar lentigo | | | | Version in the Control of the Contro |
| Level 1 | 4.26 | 85.7% | include in Level 1 | (none) |
| Level 2 | 4.20 | 03.7 % | include in Level 1 | (none) |
| Neither | _ | _ | | |
| I N. N. C. CONTINUES | | === | | |
| Seborrheic keratosis | | 400.00/ | technological designation | () |
| Level 1 | 4.94 | 100.0% | include in Level 1 | (none) |
| Level 2 | _ | - | | |
| Neither | | | | |
| Lichen planus-like k | | | | was the second of the second o |
| Level 1 | 2.40 | | exclude from Level 1 | "LPLK is a very tricky lesion |
| Level 2 | 3.63 | 57.1% | re-vote in Round 2 | that is even difficult for seasoned dermoscopists. It |
| Neither | 1.97 | 17.1% | | is often included discussions/ controversies at national dermoscopy meetings as the great masquerade lesion." |
| Angioma | | | | orber 4 Stemporth |
| Level 1 | 4.80 | 100.0% | include in Level 1 | (none) |
| Level 2 | _ | | | |
| Neither | _ | _ | | |

| Level | Round 1: response average | Round 1: % positive responses* | Next step | Comments |
|----------------------|---------------------------------|--------------------------------------|-------------------------------------|----------|
| Angiokeratoma | | | | |
| Level 1 | 3.11 | 37.1% | exclude from Level 1 | (none) |
| Level 2 | 3.80 | 62.9% | re-vote in Round 2 | |
| Neither | 1.57 | 2.9% | | |
| Dermatofibroma | | | | |
| Level 1 | 4.71 | 94.3% | include in Level 1 | (none) |
| Level 2 | _ | _ | | |
| Neither | _ | | | |
| Clear cell acanthoma | | 1977.7773 | | |
| Level 1 | 2.17 | 11.4% | exclude from Level 1 | (none) |
| Level 2 | 3.69 | 65.7% | re-vote in Round 2 | |
| Neither | 2.09 | 22.9% | | |
| Sebaceous hyperplas | sia | | A CONTRACTOR OF STREET, STREET, ST. | 101 (59 |
| Level 1 | 3.66 | 54.3% | re-vote in Round 2 | (none) |
| Level 2 | 4.03 | 77.1% | include in Level 2 | |
| Neither | _ | | if not included in Level 1 | |

"Merkel cell carcinoma" → vote in Round 2

Additional Comments

"If a provider determines to use dermoscopy to aid in diagnosis, it should be essential that they can recognize common skin cancers and ailments."

"I feel that BCC, SCC, SK, etc., should be taught at a foundational level but can be taught in more detail in Level 1.

"Having much experience teaching medical students, residents, and practicing PCPs, I have found that triage of lesions for biopsy or not (instead of diagnosing the lesion) using the TADA (Triage Amalgamated Dermoscopy Algorithm where only dermatofibroma, angioma, and seborrheic keratosis are the only lesions truly diagnosed with TADA) to be vastly superior when teaching at the foundational level to PCP. Using TADA, I can rapidly (in an hour) teach learners to achieve demonstrable confidence and skill in lesion triage. Before TADA, my first attempts at teaching utilized modified pattern analysis to 'diagnose' lesions and skill and confidence acquisition with learners was very difficult in a short session. Thus, I think any dermoscopy curriculum should have the TADA algorithm as foundational work, and then select diagnoses at the intermediate level using modified pattern analysis."

[&]quot;porokeratosis" → vote in Round 2

[&]quot;ink spot lentigo" → vote in Round 2

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 5. Results for diagnoses representing benign melanocytic lesions (n=34-35 panelists). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis Level | Round 1: response average | Round 1: % positive responses* | Next step | Comments |
|---------------------------|---------------------------------|--------------------------------------|----------------------------|--------------------------|
| Overview of benig | n nevi patterns (| (n=35) | | |
| Level 1 | 4.43 | 91.4% | include in Level 1 | (none) |
| Level 2 | _ | _ | | |
| Neither | _ | _ | | |
| Congenital meland | ocytic nevi | | | |
| Level 1 (n=34) | 3.34 | 45.7% | exclude from Level 1 | (none) |
| Level 2 (n=35) | 4.00 | 73.5% | include in Level 2 | |
| Neither (n=34) | | | | |
| Intradermal nevi (r | 1=34) | | | |
| Level 1 | 3.94 | 70.6% | include in Level 1 | (none) |
| Level 2 | _ | <u> </u> | | |
| Neither | _ | _ | | |
| Blue nevi (n=34) | 1.0000000 | | | |
| Level 1 | 3.53 | 52.9% | re-vote in Round 2 | (none) |
| Level 2 | 3.97 | 76.5% | include in Level 2 | |
| Neither | _ | _ | | |
| Spitz nevi (n=34) | | | | |
| Level 1 | 2.44 | 17.6% | exclude from Level 1 | (none) |
| Level 2 | 3.88 | 76.5% | include in Level 2 | Secretary representation |
| Neither | _ | | | |
| Recurrent/persiste | nt nevi (n=34) | | era ann east an an an an a | |
| Level 1 | 2.50 | 14.7% | exclude from Level 1 | (none) |
| Level 2 | 3.82 | 64.7% | re-vote in Round 2 | |
| Neither | 2.00 | 2.9% | | |

"halo nevi" → vote in Round 2

Additional Comments

"I do not understand the category of persistent nevi."

[&]quot;combined nevi" → vote in Round 2

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 6. Results for diagnoses representing melanoma (n=34-35 panelists). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis Level | Round 1: response average | Round 1: % positive responses* | Next step | Comments |
|--------------------|---------------------------------|--------------------------------------|---------------------------------|--|
| Overview of mel | anoma patterns (n= | :35) | | |
| Level 1 | 4.66 | 91.4% | include in Level 1 | (none) |
| Level 2 | _ | _ | | |
| Neither | _ | _ | | |
| Acral melanoma | (n=35) | | | |
| Level 1 | 3.40 | 48.6% | exclude from Level 1 | "I would be very hesitant to |
| Level 2 | 3.94 | 80.0% | include in Level 2 | encourage someone who has a |
| Neither | her — — | | | basic level of training in dermoscopy to manage and interpret acral lesions. They are difficult to interpret and high risk." |
| Lentigo maligna | melanoma (n=34) | | | |
| Level 1 | 3.26 | 45.7% | exclude from Level 1 | (none) |
| Level 2 | 4.00 | 74.3% | include in Level 2 | |
| Neither | _ | | CONTROL OF MANAGEMENT PROPERTY. | |
| Amelanotic/hypo | melanotic melanor | ma (n=34) | | |
| Level 1 | 2.66 | 28.6% | exclude from Level 1 | "Even for the most advanced |
| Level 2 | 3.71 | 65.7% | re-vote in Round 2 | physician that has a mastered |
| Neither | 1.97 | 1.97 8.6% | | dermoscopy, diagnosis of an amelanotic melanoma should always be confirmed with biopsy." |

Additional Comments

(none)

[&]quot;nevoid melanoma" → vote in Round 2

[&]quot;desmoplastic melanoma" → vote in Round 2

[&]quot;verrucous melanoma" → vote in Round 2

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 7. Results for diagnoses related to special sites (n=35 panelists). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis Level | Round 1: response average | Round 1: % positive responses* | Next step | Comments |
|---------------------------|---------------------------------|--------------------------------------|----------------------|--|
| Dermoscopic | features of the fa | ace | | Second State Control of Control o |
| Level 1 | 2.97 | 42.9% | exclude from Level 1 | (none) |
| Level 2 | 3.91 | 77.1% | include in Level 2 | |
| Neither | | | | |
| Benign patter | rns of acral nevi | * 1111 | | |
| Level 1 | 3.11 | 51.4% | re-vote in Round 2 | (none) |
| Level 2 | 3.86 | 74.3% | include in Level 2 | |
| Neither | _ | _ | | |
| Lentigo of the | nail . | - | | |
| Level 1 | 2.46 | 20.0% | exclude from Level 1 | (none) |
| Level 2 | 3.71 | 62.9% | re-vote in Round 2 | |
| Neither | 2.11 | 8.6% | | |
| Melanoma of | the nail | | | |
| Level 1 | 2.89 | 31.4% | exclude from Level 1 | (none) |
| Level 2 | 3.89 | 74.3% | include in Level 2 | |
| Neither | <u> </u> | _ | | |
| Subungual H | emorrhage | 525.27 3212.04 | | 75 |
| Level 1 | 3.91 | 77.1% | include in Level 1 | (none) |
| Level 2 | _ | _ | | |
| Neither | - | _ | | |

Additional Comments

"Except for subungual hemorrhage, distinguishing among the above in my opinion is not 'basic yet practical understanding of dermoscopy and its applications for the detection of skin cancer."

[&]quot;talon noir" → vote in Round 2

[&]quot;mucous membranes" → vote in Round 2

[&]quot;mucocutaneous junction (MCJ) nevi" → vote in Round 2

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 8. Results for other diagnoses, including skin infections and infestations (n=35 panelists). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis Level | | | Comments | |
|---------------------------|-------|-------|----------------------|----------------|
| Scabies | | | | |
| Level 1 | 3.66 | 68.6% | re-vote in Round 2 | (none) |
| Level 2 | 3.46 | 51.4% | re-vote in Round 2 | |
| Neither | 1.77 | 8.6% | | |
| Molluscum contagi | iosum | | | 40 |
| Level 1 | 3.59 | 52.9% | re-vote in Round 2 | (none) |
| Level 2 | 3.59 | 58.8% | re-vote in Round 2 | |
| Neither | 1.71 | 2.9% | | |
| Verruca | 4,000 | | | |
| Level 1 | 4.00 | 77.1% | include in Level 1 | (none) |
| Level 2 | _ | _ | | |
| Neither | _ | _ | | |
| Venous lake | | | | |
| Level 1 | 3.34 | 51.4% | re-vote in Round 2 | (none) |
| Level 2 | 3.51 | 51.4% | re-vote in Round 2 | |
| Neither | 1.80 | 2.9% | | |
| Radiation tattoo | | | NAMES OF THE OWNERS | |
| Level 1 | 2.83 | 31.4% | exclude from Level 1 | (none) |
| Level 2 | 3.60 | 54.3% | re-vote in Round 2 | (8) alim |
| Neither | 2.11 | 5.7% | | |
| Scars | | | | |
| Level 1 | 2.74 | 25.7% | exclude from Level 1 | (none) |
| Level 2 | 3.43 | 54.3% | re-vote in Round 2 | edicación (PD) |
| Neither | 2.11 | 8.6% | | |

Suggestions → vote in Round 2

Additional Comments

(none)

[&]quot;psoriasis"

[&]quot;atopic dermatitis"

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

VI. Next Steps for Panelists

All panelists who completed Round 1 will be invited to complete Round 2. The purpose of Round 2 will be to vote on diagnoses without a clear consensus for a particular level of proficiency (>50% but <70% "strongly agree" or "agree") and to vote on suggestions for additional diagnoses that were written in by panelists.

The deadline for the Round 2 survey is Friday, November 5, 2021 5:00 PM CST.

Following the conclusion of the diagnoses survey series, we will then poll panelists on the dermoscopic structures corresponding to each consensus-based diagnosis that would be appropriate for PCPs who use dermoscopy to recognize.

In closing, the research team greatly appreciates all panelists' time and effort in participating in this process. Panelists who complete all required survey instruments and who review the final study manuscript will be included as a co-author for publication.

VII. References

 Fried LJ, Tan A, Berry EG, et al. Dermoscopy Proficiency Expectations for US Dermatology Resident Physicians: Results of a Modified Delphi Survey of Pigmented Lesion Experts. *JAMA Dermatol*. 2021;157(2):189-197. doi:10.1001/jamadermatol.2020.5213

If you have any questions or comments related to this study or your rights as a research participant, please e-mail Tiffaney Tran at

Development of an Expert Consensus on Core Dermoscopy Proficiencies for **PCPs Who Use Dermoscopy**

Dermatologic Diagnoses: Round 2

Preliminary Results

November 15, 2021

I. Survey Objective

The objective of this survey series is to develop an expert-approved list of common dermosopic diagnoses plus characteristic dermoscopic features that should be included in dermoscopy training programs for PCPs.

Given the diversity of interest in and engagement with dermoscopy across the PCP spectrum, dermoscopic diagnoses will be sorted into the following two levels of dermoscopy proficiency:

- Level 1 (Foundational) PCPs who desire a basic yet practical understanding of dermoscopy and its applications for the detection of skin cancer should be able to recognize these diagnoses with sufficient training.
- Level 2 (Intermediate) PCPs who are highly interested in dermoscopy and desire
 further training in dermoscopy beyond Level 1 should be able to recognize these
 diagnoses. With sufficient training, recognition of these "above and beyond" diagnoses
 would demonstrate an additional level of mastery beyond Level 1.

In Round 1, panelists reviewed a list of diagnoses approved by the steering committee and considered whether each diagnosis should be included in the learning objectives for PCP-targeted dermoscopy education and, if so, in Level 1 or Level 2. The list of diagnoses in Round 1 was largely derived from a consensus-based list of dermoscopic diagnoses considered reflective of an appropriate foundational proficiency for dermatology residents.¹

The purpose of Round 2 was to re-vote on diagnoses without a clear consensus for a particular level of proficiency (>50% but <70% "strongly agree" or "agree") and to vote on panelists' suggestions for additional diagnoses.

II. Survey Methods

On October 25, 2021, the Round 2 survey was distributed via e-mail to all panelists who completed Round 1. The survey instrument included a consent statement and a list of diagnoses divided into the following 5 sections:

- 1. Non-melanocytic lesions
- 2. Benign melanocytic lesions
- 3. Melanoma

- 4. Special sites
- Other (including skin infections & infestations)

For each specific diagnosis, panelists considered the following questions:

- Should the diagnosis be included in Level 1 (Foundational)?
- Should the diagnosis be included in Level 2 (Intermediate) if not included in Level 1?
- Should the diagnosis <u>not</u> be included at <u>either</u> Level 1 or Level 2?

Panelists also had the opportunity to write in suggestions for additional diagnoses that will be voted on by the panel in Round 3 per the modified Delphi method.

Of the 35 colleagues who completed Round 1, 34 (97.1 %) voluntarily consented to continue to participate and completed the survey instrument. The collection of completed surveys ended on

November 12, 2021. Responses were de-identified, and data analyses were performed using REDCap and Excel.

III. Results Preview

The dermoscopic diagnoses that achieved consensus, or >70% agreement, are listed below. Tables 1 and 2 include the diagnoses that panelists agreed should be included in Levels 1 and 2, respectively.

Table 1. Dermoscopic diagnoses that >70% panelists agreed should be included in Level 1. No new diagnoses were added in Round 2.

| Nonmelanocytic lesions | Benign melanocytic lesions | Melanoma | Special sites | Other |
|--|--|-------------------------------------|----------------------------------|---------|
| Basal cell carcinoma Actinic keratosis Squamous cell carcinoma Simple lentigo Solar lentigo Seborrheic keratosis Angioma Dermatofibroma | Overview of benign nevi patterns Intradermal nevi | Overview of melanoma patterns | Subungual hemorrhage Scabies | Verruca |

Table 2. Dermoscopic diagnoses that >70% panelists agreed should be included in Level 2. Diagnoses in **bold** are new additions to the list based on consensus outcomes from Round 2.

| Nonmelanocytic lesions | Benign melanocytic lesions | Melanoma | Special sites | Other |
|---|---|--|--|--|
| Pigmented actinic keratosis Sebaceous hyperplasia Squamous cell carcinoma in situ Keratoacanthoma Angiokeratoma Ink spot lentigo | Congenital melanocytic nevi Blue nevi Spitz nevi Recurrent/ persistent nevi Halo nevi | Acral lentiginous melanoma Lentigo maligna melanoma Amelanotic/ hypomelanotic melanoma | Dermoscopic features of the face Benign patterns of acral nevi (if not included in Level 1) Melanoma of the nail Lentigo of the nail | Molluscum contagiosum (if not included in Level 1) Venous lake Psoriasis |

IV. Results

Panelists were instructed to rate on a Likert scale whether they agree that a diagnosis should be included in Level 1 (Foundational), included in Level 2 (Intermediate), or <u>not</u> be included at either level.

Panelists' responses on the Likert scale were converted to a numerical format with 1 representing "strongly disagree" and 5 representing "strongly agree." The selection of strongly agree" (5) or "agree" (4) was considered a "positive response" and contributed towards a survey item reaching consensus.

Tables 3-7, corresponding to the 5 different sections of the survey, summarize the results of Round 2. Panelists' suggestions for additional diagnoses and comments are also included. Panelists will vote on these suggested diagnoses in Round 3.

For each diagnosis, the aggregate of panelists' responses resulted in one of the following designations for the "next step":

- · "include in Level 1" as a learning objective
 - The diagnosis reached a clear consensus for inclusion in Level 1 with >70% of panelists voting "strongly agree" (5) or "agree" (4).
 - The diagnosis is deemed appropriate for PCPs who desire a basic yet practical understanding of dermoscopy.
- "exclude from Level 1" / "include in Level 2" as a learning objective
 - The diagnosis did not reach a clear consensus for inclusion in Level 1. However, the diagnosis reached a clear consensus for inclusion in Level 2.
 - The diagnosis is deemed appropriate for PCPs who are highly interested in dermoscopy and desire further training beyond Level 1.
- "exclude from Level 1" / "exclude from Level 2" as a learning objective
 - The diagnosis is <u>not</u> deemed appropriate for either Level 1 or Level 2.
- "re-vote in Round 3"
 - The diagnosis did not reach a clear consensus for a particular level with >60% but <70% of panelists voting "strongly agree" (5) or "agree" (4).

Table 3. Results for diagnoses representing nonmelanocytic lesions (n=34 panelists). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis Level | Round 1: response average | Round 1: % positive responses* | Round 2: response average | Round 2: % positive responses* | Next step |
|------------------------|---------------------------------|--------------------------------------|---------------------------------|--------------------------------------|--|
| Squamous cell carcin | noma in situ | | | | |
| Level 1 | 3.97 | 65.7% | 3.38 | ↓ 55.9% | exclude from Level 1 |
| Level 2 | 3.80 | 68.6% | 4.35 | ↑ 94.1% | include in Level 2 |
| Neither | 1.34 | 0% | i 1 | | TOTAL STATE OF THE |
| Keratoacanthoma | | | | | |
| Level 1 | 3.49 | 51.4% | 3.09 | ↓ 44.1% | exclude from Level 1 |
| Level 2 | 3.74 | 65.7% | 4.15 | ↑ 82.4% | include in Level 2 |
| Neither | 1.49 | 0% | _ | _ | |
| Lichen planus-like ke | ratosis | | | | |
| Level 1 | 2.40 | 14.3% | _ | _ | exclude from Level 1 |
| Level 2 | 3.63 | 57.1% | 3.59 | 61.8% | re-vote in Round 3 |
| Neither | 1.97 | 17.1% | 2.65 | 29.4% | |
| Angiokeratoma | | | | | |
| Level 1 | 3.11 | 37.1% | _ | _ | exclude from Level 1 |
| Level 2 | 3.80 | 62.9% | 3.74 | ↑ 73.5% | include in Level 2 |
| Neither | 1.57 | 2.9% | _ | 3 | |
| Clear cell acanthoma | | | | | |
| Level 1 | 2.17 | 11.4% | .— | _ | exclude from Level 1 |
| Level 2 | 3.69 | 65.7% | 3.35 | 1 58.8% | exclude from Level 2 |
| Neither | 2.09 | 22.9% | | _ | |
| Sebaceous hyperplas | sia | | | | |
| Level 1 | 3.66 | 54.3% | 3.53 | 1 58.8% | exclude from Level 1 |
| Level 2 | 4.03 | 77.1% | 4.00 | ↑ 82.4% | include in Level 2 |
| Neither | | _ | - | _ | |
| Merkel cell carcinoma | (new) | | | | |
| Level 1 | _ | _ | 1.41 | 0.0% | exclude from Level 1 |
| Level 2 | _ | _ | 2.82 | 35.3% | exclude from Level 2 |
| Neither | - | - | 3.12 | 50.0% | |
| Porokeratosis (new) | | | | | |
| Level 1 | | - | 1.88 | 11.8% | exclude from Level 1 |
| Level 2 | - | _ | 3.24 | 47.1% | exclude from Level 2 |
| Neither | - | _ | 2.88 | 41.2% | |
| Ink spot lentigo (new) |) | | | | |
| Level 1 | _ | _ | 2.68 | 35.3% | exclude from Level 1 |
| Level 2 | _ | _ | 4.00 | 79.4% | include in Level 2 |
| Neither | - | _ | 2.15 | 14.7% | |

Additional Comments

"I think the goal for Level 2 for PCPs should be dermoscopy mastery to the level of a board-certified dermatologist."

[&]quot;poroma" → vote in Round 3

[&]quot;xanthogranuloma" → vote in Round 3

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 4. Results for diagnoses representing benign melanocytic lesions (n=34 panelists). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis Level | Round 1: response average | Round 1: % positive responses* | Round 2: response average | Round 2: % positive responses* | Next step |
|---------------------------|---------------------------------|--------------------------------------|---------------------------------|--------------------------------------|----------------------|
| Blue Nevi | | | | | |
| Level 1 | 3.53 | 52.9% | 3.38 | 58.8% | exclude from Level 1 |
| Level 2 | 3.97 | 76.5% | 3.94 | ↑ 79.4% | include in Level 2 |
| Neither | _ | * 141.41 | _ | _ | |
| Recurrent/persisten | t nevi | | | | |
| Level 1 | 2.50 | 14.7% | _ | - | exclude from Level 1 |
| Level 2 | 3.82 | 64.7% | 2.26 | ↑ 73.5% | include in Level 2 |
| Neither | 2.00 | 2.9% | 2.62 | 32.4% | |
| Halo nevi (new) | | | | | |
| Level 1 | _ | _ | 2.62 | 32.4% | exclude from Level 1 |
| Level 2 | _ | _ | 3.85 | 79.4% | include in Level 2 |
| Neither | _ | _ | _ | - | |
| Combined nevi (nev | v) | | | | |
| Level 1 | _ | _ | 2.06 | 14.7% | exclude from Level 1 |
| Level 2 | _ | _ | 3.59 | 58.8% | exclude from Level 2 |
| Neither | _ | _ | 2.26 | 20.6% | |

(none)

Additional Comments

(none)

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 5. Results for diagnoses representing melanoma (n=34 panelists). Responses were converted to a numerical scale with a minimum of 1 representing "strongly disagree" and a maximum of 5 representing "strongly agree."

| Diagnosis Level | Round 1: response average | Round 1: % positive responses* | Round 2: response average | Round 2: % positive responses* | Next step |
|---------------------------|---------------------------------|--------------------------------------|---------------------------------|--------------------------------------|----------------------|
| Amelanotic/hypor | melanotic melanom | na | | | |
| Level 1 | 2.66 | 28.6% | _ | _ | exclude from Level 1 |
| Level 2 | 3.71 | 65.7% | 3.97 | ↑ 76.5% | include in Level 2 |
| Neither | 1.97 | 8.6% | - | - | |
| Nevoid melanom | a (new) | | | | |
| Level 1 | | _ | 2.00 | 14.7% | exclude from Level 1 |
| Level 2 | _ | _ | 3.26 | 50.0% | exclude from Level 2 |
| Neither | _ | · · | 2.79 | 38.2% | |
| Desmoplastic me | lanoma (new) | | | | |
| Level 1 | ` _ | _ | 1.91 | 11.8% | exclude from Level 1 |
| Level 2 | _ | _ | 2.97 | 38.2% | exclude from Level 2 |
| Neither | _ | _ | 2.94 | 41.2% | |
| Verrucous melan | oma (new) | | | | . 11 11-2 |
| Level 1 | | _ | 1.85 | 11.8% | exclude from Level 1 |
| Level 2 | _ | - | 2.85 | 35.3% | exclude from Level 2 |
| Neither | _ | _ | 3.21 | 47.1% | |

(none)

Additional Comments

"The reason for including melanoma is to make sure anyone trained in dermoscopy is not missing the chance to diagnose a melanoma. The consequences of a miss are too high."

"In clinical practice, many of these diagnoses/subtypes are not as relevant as the decision to excise or

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 6. Results for diagnoses related to special sites. Responses were converted to a numerical scale with a minimum of 1 representing "strongly disagree" and a maximum of 5 representing "strongly agree."

| Diagnosis Level | Round 1: response average | Round 1: % positive responses* | Round 2: response average | Round 2: % positive responses* | Next step |
|---------------------------|---------------------------------|--------------------------------------|---------------------------------|--------------------------------------|----------------------|
| Benign patterns of a | cral nevi | | | | |
| Level 1 | 3.11 | 51.4% | 3.53 | 64.7% | re-vote in Round 3 |
| Level 2 | 3.86 | 74.3% | 4.03 | ↑ 82.4% | include in Level 2 |
| Neither | | _ | _ | | if not in Level 1 |
| Lentigo of the nail | | | | | |
| Level 1 | 2.46 | 20.0% | _ | _ | exclude from Level 1 |
| Level 2 | 3.71 | 62.9% | 3.91 | ↑ 76.5% | include in Level 2 |
| Neither | 2.11 | 8.6% | _ | _ | |
| Talon noir (new) | 00000000 | experiosic | | | |
| Level 1 | _ | _ | 2.62 | 32.4% | exclude from Level 1 |
| Level 2 | _ | _ | 3.76 | 67.6% | re-vote in Round 3 |
| Neither | | | 2.26 | 17.6% | |
| Nevi of the mucosa | (new) | | | | |
| Level 1 | | _ | 1.79 | 11.8% | exclude from Level 1 |
| Level 2 | _ | _ | 3.29 | 55.9% | exclude from Level 2 |
| Neither | _ | _ | 2.74 | 29.4% | |
| Nevi of the mucocuta | aneous junction (| new) | | | |
| Level 1 | _ | _ | 1.68 | 5.9% | exclude from Level 1 |
| Level 2 | _ | _ | 3.00 | 44.1% | exclude from Level 2 |
| Neither | _ | _ | 2.85 | 41.2% | |

Suggestions (none)

Additional Comments

"Talon noir and mucocutaneous lesions are quite rare. I would have no problem if they are omitted."

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 7. Results for other diagnoses, including skin infections and infestations (n=34 panelists). Responses were converted to a numerical scale with a minimum of 1 representing "strongly disagree" and a maximum of 5 representing "strongly agree."

| Diagnosis Level | Round 1: response average | Round 1: % positive responses* | Round 2: response average | Round 2: % positive responses* | Next step |
|---------------------------|---------------------------------|--------------------------------------|---------------------------|--------------------------------------|----------------------|
| Scabies | | | | | |
| Level 1 | 3.66 | 68.6% | 3.74 | ↑ 70.6% | include in Level 1 |
| Level 2 | 3.46 | 51.4% | | | exclude from Level 2 |
| Neither | 1.77 | 8.6% | _ | | |
| Molluscum contagiosum | | | | | |
| Level 1 | 3.59 | 52.9% | 3.56 | 64.7% | re-vote in Round 3 |
| Level 2 | 3.59 | 58.8% | 4.00 | ↑ 76.5% | include in Level 2 |
| Neither | 1.71 | 2.9% | _ | _ | if not in Level 11 |
| Venous lake | | | | | |
| Level 1 | 3.34 | 51.4% | 3.06 | 1 44.1% | exclude from Level 1 |
| Level 2 | 3.51 | 51.4% | 3.85 | ↑ 79.4% | include in Level 2 |
| Neither | 1.80 | 2.9% | _ | Carriotation Carrio | |
| Radiation tattoo | | | | | |
| Level 1 | 2.83 | 31.4% | _ | _ | exclude from Level 1 |
| Level 2 | 3.60 | 54.3% | 3.62 | 67.6% | re-vote in Round 3 |
| Neither | 2.11 | 5.7% | 2.26 | 20.6% | |
| Scars | | 2.272.00 | | | |
| Level 1 | 2.74 | 25.7% | _ | | exclude from Level 1 |
| Level 2 | 3.43 | 54.3% | 3.62 | 67.6% | re-vote in Round 3 |
| Neither | 2.11 | 8.6% | 2.38 | 20.6% | |
| Psoriasis (new) | | | | | |
| Level 1 | _ | _ | 2.65 | 32.4% | exclude from Level 1 |
| Level 2 | _ | _ | 3.68 | 70.6% | include in Level 2 |
| Neither | _ | _ | _ | _ | |
| Atopic dermatitis (new) | | | | | |
| Level 1 | | _ | 2.65 | 35.3% | exclude from Level 1 |
| Level 2 | _ | _ | 3.24 | 52.9% | exclude from Level 2 |
| Neither | _ | | 2.76 | 38.2% | |

(none)

Additional Comments

[&]quot;I have never thought of atopic dermatitis as a dermatitis [dermoscopic?] diagnosis. I guess except on the palms or soles with its spongiotic findings."

[&]quot;I do not find dermoscopy necessary for eczema or psoriasis, so [I] am not familiar with their dermoscopic features or utility."

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

V. Next Steps for Panelists

All panelists who completed Round 2 will be invited to complete Round 3. The purpose of Round 3 will be to re-vote on diagnoses without a clear consensus for a particular level of proficiency (>60% but <70% "strongly agree" or "agree") and to vote on two additional diagnoses.

The deadline for the Round 3 survey is Tuesday, November 23, 2021 5:00 PM CST prior to the U.S. Thanksgiving holiday.

In the near future, panelists will vote on dermoscopic structures corresponding to each consensus-based diagnosis that would be appropriate for PCPs who use dermoscopy to recognize. The list of dermoscopic features will be largely derived from a consensus-based list of dermoscopic diagnoses considered reflective of an appropriate foundational proficiency for dermatology residents.1 For additional diagnoses not on this list, we will consult Dermoscopedia² and other sources for relevant dermoscopic features.

In closing, the research team greatly appreciates all panelists' time and effort in participating in this process. Panelists who complete all required survey instruments and who review the final study manuscript will be included as a co-author for publication.

VI. References

- Fried LJ, Tan A, Berry EG, et al. Dermoscopy Proficiency Expectations for US Dermatology Resident Physicians: Results of a Modified Delphi Survey of Pigmented Lesion Experts. JAMA Dermatol. 2021;157(2):189-197. doi:10.1001/jamadermatol.2020.5213
- Dermoscopedia. International Dermosocpy Society (IDS). https://dermoscopedia.org/Main_Page

If you have any questions or comments related to this study or your rights as a research participant, please e-mail Tiffaney Tran at

Development of an Expert Consensus on Core Dermoscopy Proficiencies for **PCPs Who Use Dermoscopy**

Dermatologic Diagnoses: Round 3

Preliminary Results

December 13, 2021

I. Survey Objective

The objective of this survey series is to develop an expert-approved list of common dermosopic diagnoses plus characteristic dermoscopic features that should be included in dermoscopy training programs for PCPs.

Given the diversity of interest in and engagement with dermoscopy across the PCP spectrum, dermoscopic diagnoses were sorted into the following two levels of dermoscopy proficiency:

- Level 1 (Foundational) PCPs who desire a basic yet practical understanding of dermoscopy and its applications for the detection of skin cancer should be able to recognize these diagnoses with sufficient training.
- Level 2 (Intermediate) PCPs who are highly interested in dermoscopy and desire
 further training in dermoscopy beyond Level 1 should be able to recognize these
 diagnoses. With sufficient training, recognition of these "above and beyond" diagnoses
 would demonstrate an additional level of mastery beyond Level 1.

In Round 1, panelists reviewed a list of diagnoses approved by the steering committee and considered whether each diagnosis should be included in the learning objectives for PCP-targeted dermoscopy education and, if so, in Level 1 or 2.

In Rounds 2, panelists re-voted on diagnoses without a clear consensus for a particular level of proficiency (>50% but <70% "strongly agree" or "agree") and voted on panelists' suggestions for additional diagnoses. The purpose of Round 3 was to conduct a simple majority vote on diagnoses still without a clear consensus for a particular level of proficiency (>60% but <70% "strongly agree" or "agree") and vote on panelists' suggestions.

II. Survey Methods

On November 15, 2021, the Round 3 survey was distributed via e-mail to all panelists who completed Round 2. The survey instrument included a consent statement and a list of 8 diagnoses, 2 of which represented newly suggested diagnoses.

Of the 35 colleagues who completed Round 1, 33 (94.3%) voluntarily consented to continue to participate and completed Round 3. Data collection concluded on December 2, 2021. Responses were de-identified, and data analyses were performed using REDCap and Excel.

III. Results Preview

The dermoscopic diagnoses that achieved <u>consensus</u>, or >70% agreement, are listed below. **Tables 1 and 2** include the diagnoses that panelists agreed should be included in **Level 1** and **Level 2**, respectively.

Table 1. Dermoscopic diagnoses that >70% panelists agreed should be included in Level 1. No new diagnoses were added in Round 3.

| Nonmelanocytic lesions | Benign melanocytic lesions | Melanoma | Special sites | Other |
|--|--|-------------------------------------|-------------------------|---------------------|
| Basal cell carcinoma Actinic keratosis Squamous cell carcinoma Simple lentigo Solar lentigo Seborrheic keratosis Angioma Dermatofibroma | Overview of benign nevi patterns Intradermal nevi | Overview of melanoma patterns | Subungual hemorrhage | Scabies Verruca |

Table 2. Dermoscopic diagnoses that >70% panelists agreed should be included in Level 2. Diagnoses in **bold** are new additions to the list based on consensus outcomes from Round 3.

| Nonmelanocytic lesions | Benign melanocytic lesions | Melanoma | Special sites | Other |
|---|---|--|--|--|
| Pigmented actinic keratosis Sebaceous hyperplasia Squamous cell carcinoma in situ Kerato-acanthoma Angio-keratoma Ink spot lentigo Lichen planus-like keratosis | Congenital melanocytic nevi Blue nevi Spitz nevi Recurrent nevi (persistent nevi) Halo nevi | Acral lentiginous melanoma Lentigo maligna melanoma Amelanotic/ hypomelanotic melanoma | Dermoscopic features of the face Melanoma of the nail Lentigo of the nail Benign patterns of acral nevi Talon noir | Venous lake Psoriasis Molluscum contagiosum Radiation tattoo Scars |

IV. Results Breakdown

A simple majority vote was conducted for diagnoses from previous rounds still without a clear consensus for a particular level of proficiency. Table 1 summarizes these results in Round 3.

For new diagnoses, panelists were instructed as before to rate on a Likert scale whether they agree that a diagnosis should be included in Level 1 (Foundational), included in Level 2 (Intermediate), or not be included at either level. Table 2 summarizes the results for new diagnoses in Round 3.

Table 3. Results for diagnoses previously without a clear consensus (n=33 panelists), based on a simple majority vote.

| Category: <i>Diagnosis</i> Level | Round 3: # responses* | Round 3: % responses* | Next Step | |
|-------------------------------------|-----------------------------|-----------------------|-----------------------|--|
| Benign Nonmelanocytic Lesions | : Lichen planus-like kerato | sis | | |
| Level 1 | _ | _ | exclude from Level 1* | |
| Level 2 | 22 | 66.7% | include in Level 2 | |
| Neither | 11 | 33.3% | | |
| Special Sites: Benign patterns of a | acral nevi | | | |
| Level 1 | 15 | 45.5% | | |
| Level 2 | 18 | 54.5% | include in Level 2 | |
| Neither | _ | _ | | |
| Special Sites: Talon noir | | | | |
| Level 1 | <u> </u> | | exclude from Level 1* | |
| Level 2 | 20 | 60.6% | | |
| Neither | 13 | 39.4% | include in Level 2 | |
| Other: Molluscum contagiosum | | | | |
| Level 1 | 13 | 39.4% | include in Level 2 | |
| Level 2 | 20 | 60.6% | | |
| Neither | _ | _ | | |
| Other: Radiation tattoo | | | | |
| Level 1 | | _ | exclude from Level 1* | |
| Level 2 | 22 | 66.7% | include in Level 2 | |
| Neither | 11 | 33.3% | | |
| Other: Dermoscopic features of sc | ars | | | |
| Level 1 | _ | _ | exclude from Level 1* | |
| Level 2 | 19 | 57.6% | include in Level 2 | |
| Neither | 14 | 42.4% | | |

Comments

"Not certain [regarding] some of these [diagnoses], as dermoscopy not used for them, but format required an answer."

[&]quot;I think only lesions that could be tumors or need to be distinguished from tumors should be in a basic [Level 1] or Level 2 dermoscopy. More unusual conditions are for advanced training, more for dermatologists."

^{*} This result was based on previous rounds of surveys.

Table 4. Results for additional diagnoses suggested in Round 2 (n=33 panelists). For a diagnosis to be included in Level 1 or Level 2, >70% of panelists must vote "strongly agree" (5) or "agree" (4) for that particular level.

| Diagnosis Level | Round 3: response average | | Next step | |
|---------------------------|---------------------------------|-----------------|----------------------|--|
| Poroma (new) | | | | |
| Level 1 | 1.61 | 3.0% | exclude from Level 1 | |
| Level 2 [†] | 3.09 | 47.1% | exclude from Level 2 | |
| Neither | 2.97 | 45.5% | | |
| Xanthogranuloma (new) | 50 EVALUE | alocoles system | 195 | |
| Level 1 | 1.39 | 0.0% | exclude from Level 1 | |
| Level 2 [†] | 2.64 | 30.3% | exclude from Level 2 | |
| Neither | 3.39 | 60.6% | | |

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

V. Next Steps for Panelists

All panelists who completed Round 3 of the diagnoses survey series will be invited to complete Round 1 of the features survey series.

In the upcoming features survey series, panelists will consider dermoscopic structures corresponding to each consensus-based diagnosis and vote on whether each would be appropriate for PCPs who use dermoscopy to recognize.

The list of dermoscopic features will be largely derived from a consensus-based list of dermoscopic diagnoses considered reflective of an appropriate foundational proficiency for dermatology residents. For additional diagnoses not on this list, we will consult Dermoscopedia² and other sources for relevant dermoscopic features.

The deadline for the next survey is Wednesday, January 12, 2022 5:00 PM CST.

In closing, the research team greatly appreciates all panelists' time and effort in participating in this process. Panelists who complete all required survey instruments and who review the final study manuscript will be included as a co-author for publication.

VI. References

- Fried LJ, Tan A, Berry EG, et al. Dermoscopy Proficiency Expectations for US Dermatology Resident Physicians: Results of a Modified Delphi Survey of Pigmented Lesion Experts. JAMA Dermatol. 2021;157(2):189-197. doi:10.1001/jamadermatol.2020.5213
- Dermoscopedia. International Dermoscopy Society (IDS). https://dermoscopedia.org/Main Page

If you have any questions or comments related to this study or your rights as a research participant, please e-mail Tiffaney Tran at

[†] Panelists were asked whether the specific diagnosis should be included in Level 2 if not included in Level 1.

Development of an Expert Consensus on Core Dermoscopy Proficiencies for PCPs Who Use Dermoscopy

Dermoscopic Features: Round 1

Preliminary Results

January 24, 2022

I. Survey Objective

The objective of this features survey series is to develop an expert-approved list of characteristic dermoscopic features that should be included in dermoscopy training programs for PCPs.

The goal is to capture the dermoscopic structures that are highly characteristic and important to recognize. This also includes commonly seen structures that may not be specific to one diagnosis.

II. Survey Methods

On December 16, 2021, the Round 1 survey was distributed via e-mail to all panelists who completed the dermoscopic survey series. The survey instrument included a consent statement and a consensus-based list of dermoscopic diagnoses divided into five sections:

- 1. Nonmelanocytic lesions
- Benign melanocytic lesions
- Melanoma

- 4. Special sites
- 5. Other
- Miscellaneous

A miscellaneous section was included to solicit input on a new addition to the list of consensusbased diagnoses, namely nevus of the nail. This diagnosis was inadvertently left off the diagnoses survey series.

For each diagnosis, panelists reviewed a number of dermoscopic features approved by the steering committee and considered whether each feature should be included as a learning objective for PCP-targeted dermoscopy education.

Of the 33 colleagues who completed the diagnoses survey series, 33 (100%) voluntarily consented to continue to participate and completed Round 1 of the features survey series.

Data collection concluded on January 24, 2022. Responses were de-identified, and data analyses were performed using REDCap and Excel.

III. Results

For each dermoscopic feature, panelists were asked to rate on a Likert scale whether they agree that the feature should be included in dermoscopy education for PCPs who use dermoscopy. For each survey item, the options for the Likert scale were:

- 1. Strongly disagree
- 2. Disagree
- 3. Neutral

- 4. Agree
- 5. Strongly agree

Panelists' responses on the Likert scale were converted to a numerical format with 1 representing "strongly disagree" and 5 representing "strongly agree," as above. The selection of strongly agree" (5) or "agree" (4) was considered a "positive response" and contributed towards a survey item reaching consensus.

Tables 1-6, corresponding to the 5 different sections plus the miscellaneous section, summarize the results of Round 1. Panelists' suggestions for additional features and comments are also included. Panelists will vote on these suggested features in Round 2.

For each feature, the aggregate of panelists' responses resulted in one of the following designations for the "next step":

- · "include" as a learning objective
 - The feature reached a clear consensus for <u>inclusion</u> in PCP-targeted dermoscopy education with >70% of panelists voting "strongly agree" (5) or "agree" (4).
- · "exclude" as a learning objective
 - The feature reached a clear consensus for <u>exclusion</u> from PCP-targeted dermoscopy education with <50% panelists voting "strongly agree" (5) or "agree" (4). In other words, >50% of panelists voted "neutral" (3), "disagree" (2), or "strongly disagree" (1).
- "re-vote in Round 2"
 - The feature did not reach a clear consensus for inclusion with >60% but <70% of panelists voting "strongly agree" (5) or "agree" (4).

Table 1. Results for diagnoses representing nonmelanocytic lesions (n=33). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Survey Item | Round 1: response average | Round 1: % positive responses* | Next step | Round 1: comments | |
|---|--|---|-------------------------------|---|--|
| Angioma (Level 1) | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | "Blue-black coloring: okay if in lacunae in | |
| Red, blue-red, red-purple, or maroon lacunae/lagoons with white septae | 4.91 | 72.7% | include | absence of other structures." – added "Not sure PCPs need to correctly identify a thrombosed angioma/angio- | |
| Blue-black coloring in lacunae (when thrombosed) in absence of other structures | 4.03 | 72.7% | include re-vote in Round 2 | keratoma." – re-vote in Round 2 "Not sure a thrombosed angioma needs to be included. I think they are easily identified as unimportant on gross exam." – re-vote in Round 2 | |
| Dermatofibroma (Level 1) | | | | "Shiny white lines: with polarization." - | |
| Central scar-like white patch/depigmentation | 4.94 | 100.0% | include | added "Blood vessels are not a major | |
| Fine/delicate surrounding/peripheral | 4.79 | 100.0% | include | component." – excluded by consensus "Lesion needs to be firm and dimple." – | |
| network-like structures | 2.07 | 00 70/ | as costs in Decord 0 | clinical feature | |
| Ring-like globules Central shiny white lines/streaks | 3.97 4.42 | 66.7% 84.8% | re-vote in Round 2 include | - Cimiour reactive | |
| under polarized dermoscopy | 4.42 | 04.8% | liicidde | | |
| Dotted vessels | 3.27 | 39.4% | exclude | | |
| Central pink blush | 3.30 | 42.4% | exclude | | |
| Seborrheic keratosis (Level 1) | | | | "Milia-like cysts AND comedo-like | |
| Milia-like cysts (cloudy or starry) and comedo-like openings | ilia-like cysts (cloudy or starry) 4.79 93.9% includ | | include | openings together (DD; dermal nevus)." – combined | |
| Comedo-like-openings | 4.79 | 93.9% | include | "Whitish halo: difficult to see in daily | |
| Moth-eaten (sharply demarcated) borders | 4.45 | 87.9% | include | practice." – updated "I would just include fingerprint-like | |
| 'Fissures and ridges' / 'gyri and sulci' / cerebriform pattern | 4.70 | 93.9% | include | structures in lentigo as below." – updated | |
| Fat fingers | 4.18 | 78.8% | include | | |
| Fingerprint-like structures/pattern (parallel lines) | 4.27 | 78.8% | include | | |
| Hairpin (looped) vessels, usually with whitish halo | 3.97 | 78.8% | include | | |
| Solar lentigo (Level 1) | 111111111111111111111111111111111111111 | -11-7 | Arman are | (none) | |
| Moth-eaten (sharply demarcated) borders | 4.58 | 90.9% | include | E E | |
| Homogenous light brown pigmentation | 4.52 | 87.9% | include | | |
| Network-like structures | 3.97 | 63.6% | re-vote in Round 2 | | |
| Fingerprint-like structures (parallel lines) Uniform brown perifollicular | 4.42 | 90.9% 75.8% | include | | |
| pigmentation | 4.00 | 75.070 | include | | |
| Basal cell carcinoma (Level 1) | | | | "From the dermoscopy-using PCP's point | |
| Leaf-like structures/areas | 4.58 | 90.9% | include | of view, knowing it is a BCC is not as | |
| Blue-gray ovoid nests | 4.55 | 87.9% | include | important as knowing it is cancer and | |
| Multiple blue-gray dots and globules (buckshot scatter) | 4.45 | 84.8% | include | must be removed." "Please decide if we use leaf-like or spoke wheel, not both. Or use one as a main | |
| Spoke-wheel-like structures/areas / concentric structures | 4.36 | 87.9% | include | description and the other as 'AKA." – descriptions adapted from Fried et | |
| Ulceration / erosion | 4.64 | 93.9% | include | al., 2021 | |
| Shiny white blotches and strands / structures | 4.06 | 69.7% | re-vote in Round 2 | | |
| Arborizing vessels | 4.88 | 97.0% | include | | |

| Survey Item | Round 1: response average | Round 1: % positive responses* | Next step | Round 1: comments |
|---|---------------------------------|--------------------------------------|--------------------|---|
| Short fine telangiectasias (superficial BCC) | 4.03 | 69.7% | re-vote in Round 2 | |
| Actinic keratosis (Level 1) | | | | "Agree the strawberry pattern should be |
| Rosettes | 4.33 | 81.8% | include | included, but the description is much |
| Surface scale | 4.67 | 97.0% | include | too long and somewhat confusing for a |
| Strawberry pattern (pink-red | 4.30 | 78.8% | include | non-expert." – description adapted from Fried et al., 2021 |
| pseudonetwork +/- fine wavy vessels [straight or coiled] surrounding hair follicles +/- white circles with central yellow clod [targetoid hair follicles]) | | | | |
| Squamous cell carcinoma (Level 1) | | | | "I usually think of the hairpin vessels with |
| Yellow keratin mass / scale-crust | 4.73 | 100.0% | include | white halo as more suggestive of ISK, |
| Ulceration / blood spots / hemorrhage | 4.61 | 93.9% | include | whereas SCCs have less of a halo." – updated |
| White circles ('keratin pearls') | 4.48 | 90.9% | include | 300 |
| Rosettes | 4.15 | 75.8% | include | |
| Glomerular (coiled) vessels | 4.42 | 90.9% | include | |
| Hairpin vessels, usually with +/- whitish halo | 4.15 | 78.8% | include | |
| Sebaceous hyperplasia (Level 2) | | | | "Suggest crown vessels—out of focus— |
| Pale yellow lobules (popcorn-like | 4.82 | 100.0% | include | when compared to telangiectasia in |
| structures) around a central | 4.02 | 100.070 | IIICidde | BCC." - added |
| follicular opening | | | | |
| Crown vessels, out of focus | 4.61 | 90.9% | include | |
| Ink spot lentigo (Level 1) | | | | "Suggest: Prominent dark homogenous |
| Prominent dark homogenous (uniform) reticular network | 4.64 | 93.9% | include | (uniform) reticular network." – added |
| Chicken-wire fence | 3.85 | 63.6% | re-vote in Round 2 | |
| Pigmented actinic keratosis (Level | 2) | | | "Pigmented AK vs lentigo maligna or SCO |
| Gray dots | 3.82 | 69.7% | re-vote in Round 2 | is too complex for PCP level." |
| Annular-granular pattern (gray dots around follicular | 3.82 | 66.7% | re-vote in Round 2 | "The pigmented AK is relatively rare and a very difficult diagnosis. I am not sure if this belongs in a PCP curriculum at all |
| openings) | 4.00 | 75 00/ | lankida | because in my opinion, it is more |
| Rosettes | 4.00 | 75.8% | include | confusing than anything else." |
| Surface scale | 4.48 | 90.9% | include | "Tough call to make for beginning |
| Red pseudonetwork | 3.67 | 57.6% | exclude | dermoscopy." |
| White circles Patent/evident follicles | 3.48 3.67 | 42.4% 57.6% | exclude exclude | inclusion in Level 2 based on panel consensus |
| Squamous cell carcinoma in situ (l | evel 2) | 7.00 | | "It's a tall ask to have PCPs diagnose |
| Surface scale | 4.52 | 87.9% | include | pigmented Bowen's." - re-vote in |
| Peripheral brown/gray dots arranged linearly (pigmented | 3.85 | 60.6% | re-vote in Round 2 | Round 2 "The peripheral dots are extremely rare and not very typical. I would leave this |
| SCCIS) Irregularly arranged glomerular (coiled) / dotted vessels | 4.55 | 93.9% | include | out." – excluded "Glomerular vessels 'irregularly arranged to differentiate from psoriasis with regular spacing and arrangement of |
| | | | | dotted/coiled/glomerular vessels." – added |
| Keratoacanthoma (Level 2) | | | | (none) |
| Central keratin mass | 4.73 | 93.9% | include | 100 50 |
| Hairpin (looped) or serpentine (linear-irregular) vessels, usually at the periphery, with white-yellow halo | 4.52 | 87.9% | include | |

| Survey Item | Round 1: response average | Round 1: % positive responses* | Next step | Round 1: comments |
|--|---|--------------------------------------|--------------------|--|
| Angiokeratoma (Level 2) | | | | "Not sure PCPs should be asked to |
| Red/purple/black ('dark') lacunae | urple/black ('dark') lacunae 4.61 93.9% include | | include | diagnose this lesion." – inclusion in |
| Hemorrhagic crust | | | include | Level 2 based on panel consensus |
| Lichen planus-like keratosis (Leve | 12) | | | |
| Coarse gray granularity | 3.88 | 63.6% | re-vote in Round 2 | "Not sure PCPs should be asked to |
| Peppering (evenly spaced gray dots) | 4.03 | 69.7% | re-vote in Round 2 | identify these lesions." – inclusion in Level 2 based on panel consensus |
| Sharp cut-off borders (scalloped/moth-eaten) | 4.06 | 69.7% | re-vote in Round 2 | "It gets pretty complicated, and I am liking TADA more and more for teaching." |
| Features of a lentigo or a seborrheic keratosis in an area | 4.15 | 72.7% | include | "I would like PCPs to see gray granularity and stop and think carefully. I worry they will miss melanomas with regression thinking they are LPLKs." "Please include blue-grey/blue-white structures." – vote in Round 2 |

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 2. Results for diagnoses representing benign melanocytic lesions (n=33). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis (Level classification) Feature, added, removed | Round 1: response average | Round 1: % positive response* | Next step | Round 1: comments | | | |
|---|--|-------------------------------------|--------------------|--|--|--|--|
| Overview of benign nevi patterns | Overview of benign nevi patterns (Level 1) | | | | | | |
| Diffuse reticular network | 4.85 | 100.0% | include | complex nevi from melanoma." | | | |
| Patchy reticular network | 4.70 | 97.0% | include | | | | |
| Peripheral reticular network with central hypopigmentation | 4.76 | 100.0% | include | | | | |
| Peripheral reticular network with central hyperpigmentation | 4.76 | 100.0% | include | | | | |
| Peripheral reticular network with central globules | 4.61 | 90.9% | include | | | | |
| Homogenous (tan, brown, blue, or pink) | 4.64 | 93.9% | include | | | | |
| Central network with evenly distributed peripheral globules | 4.55 | 87.9% | include | | | | |
| Globular pattern | 4.82 | 100.0% | include | | | | |
| Two-component pattern | 4.06 | 69.7% | re-vote in Round 2 | | | | |
| Symmetric multicomponent pattern | 4.15 | 75.8% | include | | | | |
| Intradermal nevi (Level 1) | | | | "wobble sign" - clinical feature | | | |
| Comma-shaped (curved) vessels | 4.58 | 93.9% | include | 194-0 | | | |
| Homogenous (structureless) brown/tan/pink pigmentation | 4.52 | 93.9% | include | | | | |
| Peripheral network | 4.03 | 72.7% | include | | | | |
| Globules | 4.36 | 87.9% | include | | | | |
| Congenital melanocytic nevi (Leve Cobblestone pattern/globular pattern | 4.64 | 93.9% | include | "Why are we asking PCPs to diagnose CMN?" – inclusion in Level 2 based on panel consensus | | | |
| Reticular network | 4.45 | 90.9% | include | "central hypo-pigmentation" – vote in | | | |
| Homogenous background pigmentation | 4.45 | 87.9% | include | Round 2 | | | |
| Hypertrichosis | 4.30 | 78.8% | include | | | | |
| Perifollicular hyper-/hypo- pigmentation | 4.06 | 69.7% | re-vote in Round 2 | | | | |
| Blue nevi (Level 2) | | | | "History is important." - clinical feature | | | |
| Homogenous blue/blue-gray pigmentation | 4.88 | 100.0% | include | "Need to be presented with photos of melanoma metastases to increase | | | |
| Well-circumscribed | 4.67 | 93.9% | include | suspicion of a blue/gray macule in a patient with a history of melanoma." – clinical feature "Must include clinical stability over time." - clinical feature | | | |
| Spitz nevi (Level 2) | | | | "Maybe include pseudopods as an option | | | |
| Vascular pattern (pink homogenous with dotted vessels) | 4.00 | 75.8% | include | in #27 [starburst pattern], regularly spaced at the periphery." – added "PCPs should not be asked to differentiate | | | |
| Starburst pattern with tiered globules/streaks and regularly spaced pseudopods at the periphery (radial streaming) | 4.55 | 87.9% | include | spitz from melanoma." "Some spitz nevi have several red flag features that I would want someone to think of melanoma. I would rather have | | | |
| Negative pigment network (reticular depigmentation) | 3.85 | 60.6% | re-vote in Round 2 | them biopsy spitz nevi than miss melanomas." | | | |
| Shiny white lines (crystalline structures) | 3.82 | 63.6% | re-vote in Round 2 | "These are important findings but very advanced skills." | | | |
| Globular with negative network or blue-white veil | 3.64 | 60.6% | re-vote in Round 2 | inclusion in Level 2 based on panel consensus | | | |

| Diagnosis (Level classification) Feature, added, removed | Round 1: response average | Round 1: % positive response* | Next step | Round 1: comments |
|---|---------------------------------|-------------------------------------|-----------|---|
| Recurrent/persistent nevi (Level 2) |) | | | SHEET CHANNES ON AN ANY SHEET LABOURN ON TH |
| Pigment within the scar, not extending beyond | 4.30 | 81.8% | include | "? adding starburst/radial pattern" – vote in Round 2 "Not sure that PCP should be asked to identify recurrent nevi." inclusion in Level 2 based on panel consensus |
| Halo nevi (Level 2) | | | | |
| Encircling/surrounding depigmentation/pallor | 4.52 | 93.9% | include | "The most common nevus that undergoes halo reaction are globular and |
| Central reticulation with peripheral white depigmentation | 4.03 | 78.8% | include | homogeneous." – added "Only globular pattern is acceptable. Everything else comes off." – added |
| Benign nevi patterns, globular, homogenous | 4.12 | 78.8% | include | "Need to make a note about doing a thorough skin exam to search for a melanoma." |

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 3. Results for diagnoses representing melanoma (n=33). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis (Level classification) Feature, added, removed | Round 1: response average | Round 1: % positive response* | Next step | Round 1: comments |
|--|---------------------------------|--|--------------------|---|
| Overview of melanoma patterns (Level | | response | | "Shiny white lines/structures |
| Atypical pigment network | 4.82 | 97.0% | include | (crystalline structures comes up in |
| Blue structures (blue-white veil, blue- gray structures) | 4.88 | 100.0% | include | several lesions and may cause confusion." – okay to include if |
| Shiny white lines/structures (crystalline structures) | 4.76 | 100.0% | include | "Would re-phrase off-center blotch." - |
| Negative pigment network | 4.55 | 87.9% | include | added |
| Atypical/irregular dots/globules | 4.67 | 93.9% | include | |
| Atypical/irregular streaks (radial streaming, pseudopods) | 4.76 | 97.0% | include | |
| Regression structures (white scar-like area and/or peppering) | 4.70 | 93.9% | include | |
| Peripheral brown/tan structureless area | 4.21 | 78.8% | include | |
| Angulated lines (extrafacial) / polygons / zig-zag pattern | 4.21 | 75.8% | include | |
| Atypical vascular pattern/structures, polymorphous vessels (2+ types of blood vessels) | 4.39 | 87.9% | include | |
| Atypical/off-center blotch | 4.18 | 69.7% | re-vote in Round 2 | |
| Acral melanoma (Level 2) | 45.000 | | | "pigment crossing normal ridge |
| Parallel ridge pattern | 4.76 | 93.9% | include | pattern" – vote in Round 2 |
| Irregular diffuse pigmentation or blotch | 4.39 | 84.8% | include | "#14 [irregular diffuse pigmentation] add blotch." – added |
| Multicomponent pattern, asymmetry of structures/colors | 4.36 | 84.8% | include | "Maybe change/add descriptors in multicomponent pattern: asymmetr of structures/colors." – added |
| Atypical fibrillar pattern | 4.15 | 72.7% | include | "neovascularization → milky red" – |
| Ulceration | 4.58 | 90.9% | include | added |
| Neo-vascularization, milky red | 4.00 | 72.7% | include | "Negative predictors of PFP [parallel furrow pattern] and fibrillar [pattern' to stay in line with BRAAFF checklist." |
| | | | | BRAAFF checklist: Lallas A, et al. The BRAAFF checklist: a new dermoscopic algorithm for diagnosing acral melanoma. J Dermatol. 2015;173(4):1041-1049. |
| Lentigo maligna melanoma (Level 2) | 22/22 | 2222029 | | (none) |
| Annular-granular pattern (gray dots around follicular openings) | 4.45 | 90.9% | include | |
| Asymmetric pigmentation around follicular openings / asymmetric follicular openings | 4.42 | 87.9% | include | |
| Rhomboidal structures (angulated lines) / zig-zag pattern | 4.39 | 81.8% | include | |
| Circle within a circle (isobar) | 3.94 | 60.6% | re-vote in Round 2 | |
| Dark blotches +/- obliterated hair follicles | 4.21 | 75.8% | include | |
| Amelanotic/hypomelanotic melanoma | (Level 2) | - Control of the Cont | | (none) |
| Scar-like depigmentation | 4.21 | 75.8% | include | |
| Milky red areas | 4.42 | 81.8% | include | |
| Shiny white lines (crystalline structures) | 4.39 | 81.8% | include | |
| Atypical vascular pattern, polymorphous vessels (2+ types of blood vessels) | 4.24 | 81.8% | include | |

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 4. Results for diagnoses related to special sites (n=33). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis (Level classification) Feature, added, removed | Round 1: response average | Round 1: % positive response* | Next step | Round 1: comments |
|--|---------------------------------|-------------------------------------|--------------------|--|
| Subungual hemorrhage (Level 1) | | | | "What about the lightning sign or white |
| Well-circumscribed red-black dots or blotches / blood spots | 4.58 | 90.9% | include | streaks?" – vote in Round 2 "The amount of info will be daunting fo |
| Distal streaks of red-brown coloration ('filamentous' distal end) | 4.27 | 81.8% | include | PCPs, so recommend keep teaching focused." |
| Homogenous red/purple/black coloration without melanin granules | 4.09 | 69.7% | re-vote in Round 2 | "Not so sure subungual hemorrhage needs a dermoscopic description." |
| Discontiguous with the cuticle (not connected to the proximal nailfold or edge of nail) | 4.42 | 87.9% | include | "For the 'discontinuous with the cuticle,' perhaps you mean not connected to the proximal nailfold/edge of nail?" – added |
| Dermoscopic features of the face (Leve | 12) | | | "Not sure what this section is about." |
| Pseudonetwork | 4.27 | 78.8% | include | VARIANTE DE LA SETTE PROPERTURA DE LA COMPUNITA DE LA COMPUNIT |
| Benign patterns of acral nevi (Level 2) | 1,000 | | | "#12 [peas in a pod pattern] is more |
| Parallel furrow pattern (with pattern variations including single line, double line, single dotted line, double-dotted line) | 4.73 | 93.9% | include | complex and not sure it's something the PCP needs to know." – re-vote in Round 2 "Does it make sense to teach the |
| Lattice-like pattern | 4.55 | 87.9% | include | benign patterns, or should we teach |
| Fibrillar pattern (soles only) | 4.48 | 84.8% | include | the malignant patterns and leave |
| Homogenous pattern | 4.21 | 75.8% | include | everything else in place?" – benign patterns included based on panel |
| Peas in a pod pattern (parallel furrow + globules on ridges) (congenital nevi) | 4.03 | 69.7% | re-vote in Round 2 | consensus "hard" |
| Lentigo of the nail (Level 2) | | | | "regular brown lines" - vote in Round |
| Multiple thin homogenous gray-lines (or single gray band) +/- gray background-homogenous gray band or lines +/- gray background | 4.18 | 78.8% | include | 2 "I would call it gray band. Multiple is ar exception." – updated |
| Melanoma of the nail (Level 2) | | | | *#19 [longitudinal brown/black lines |
| Triangular shape of pigment band (band diameter wider at proximal end) | 4.45 | 87.9% | include | with irregular spacing] add broken lines" – added "Nail dermoscopy is very advanced." |
| Pigmentation of periungual skin (micro-Hutchinson's sign) | 4.39 | 90.9% | include | "The ability to sort out benign acral nevi vs melanoma is very difficult. If |
| Brown to black dots/globules associated with longitudinal lines | 3.91 | 60.6% | re-vote in Round 2 | you can make this easier, it would be super." |
| Longitudinal brown/black broken lines with irregular spacing, width, coloration, or parallelism | 4.30 | 81.8% | include | |
| Band width >3 mm or 2/3 of nail plate width | 4.27 | 78.8% | include | |
| Talon noir (Level 2) | | | | "I feel like when you say parallel ridge, |
| Homogenous or parallel-ridge red- brown coloration | 4.15 | 78.8% | include | it has a connotation of melanoma, so perhaps just say homogenous red- |
| Peripheral red-brown dots/globules | 4.03 | 66.7% | re-vote in Round 2 | brown coloration?" - removed |
| Cracks (lightning bolt sign) | 3.76 | 51.5% | exclude | "parallel ridge" "I don't know the lightning bolt sign." – excluded by consensus "What about the possibility of scratching the lesion to remove the hemorrhage in the stratum corneum?" – clinical feature "ability to scrape off clinically" – clinical feature |

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 5. Results for other diagnoses, including skin infections and infestations (n=33). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis (Level classification) Feature, added, removed | Round 1: response average | Round 1: % positive response* | Next step | Round 1: comments |
|--|---------------------------------|-------------------------------------|--------------------|--|
| Scabies (Level 1) | | | | "Consider including burrows on its own |
| Delta-wing jet with contrail sign (small dark brown triangular structure located at the end of whitish structureless curved/wavy lines) | 4.52 | 90.9% | include | since they may not always see the mite?" – clinical feature |
| Verruca (Level 1) | | | | "Don't really need dermatoscope for |
| Papilliform structures | 4.67 | 93.9% | include | this." |
| Tiny red-black dots (papillary capillaries) | 4.61 | 90.9% | include | |
| Molluscum contagiosum (Level 1) | | | | "Don't really need dermatoscope for |
| Central pore or umbilication | 4.61 | 93.9% | include | this." |
| Polylobular white-yellow amorphous structures | 4.27 | 81.8% | include | "Not sure if we should dermoscopy of molluscum in this context." |
| Linear or branched vessels (red corona) / crown vessels | 3.97 | 63.6% | re-vote in Round 2 | |
| Venous Lake (Level 2) | | | | (none) |
| Homogenous purple/ blue/red coloration +/- globules/clods | 4.61 | 93.9% | include | |
| Psoriasis (Level 2) | | | | "Would agree strongly if 12 said white |
| Red or pink color with white yellow white scales / light red background | 4.03 | 75.8% | include | only not white-yellow." - changed to white |
| Dotted vessels in a regular distribution | 4.03 | 72.7% | include | "I'm not sure [if dermoscopy] is relevant to this effort." – based on |
| Twisted red loops in a homogenous distribution | 3.42 | 45.5% | exclude | consensus "I don't do dermoscopy on psoriasis." |
| Glomerular vessels | 3.42 | 45.5% | exclude | |
| Radiation tattoo (Level 2) | | | | (none) |
| Homogenous blue or black coloration | 4.33 | 84.8% | include | |
| Dermoscopic features of scars (Level 2) |) | | | (none) |
| Arborizing, linear irregular, or comma vessels in keloids | 3.58 | 45.5% | exclude | 300000000000000000000000000000000000000 |
| White depigmentation | 4.00 | 72.7% | include | |

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 6. Results for nevus of the nail, a diagnosis inadvertently left off on prior surveys (n=33). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis or feature | Round 1: response average | Round 1: % positive response* | Next step | Round 1: comments |
|--|---------------------------------|-------------------------------------|----------------------|--|
| Diagnosis: Nevus of the nail | | | | (none) |
| Level 1 | 2.58 | 21.2% | exclude from Level 1 | |
| Level 2 | 3.91 | 78.8% | include in Level 2 | |
| Neither | 2.30 | 15.2% | | Sec. 15. 11. 1995 Sec. 1995 |
| Feature: Nevus of the nail (Level 2) | | 3,953,70,930 | | "unbroken lines" - added |
| Homogenous brown background coloration | 4.15 | 84.8% | include | "Including blue is confusing." – removed |
| Uniform band thickness, color (including blue), and spacing with parallel band configuration and unbroken lines | 4.24 | 87.9% | include | |

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Next Steps for Panelists

All panelists who completed Round 1 of the features survey series will be invited to complete Round 2. The purpose of Round 2 will be to vote on feature without a clear consensus and to vote on suggestions for additional features that were written in by panelists.

The deadline for the next survey is Wednesday, February 9, 2022 5:00 PM CST.

In closing, the research team greatly appreciates all panelists' time and effort in participating in this process. Panelists who complete all required survey instruments and who review the final study manuscript will be included as a co-author for publication.

If you have any questions or comments related to this study or your rights as a research participant, please e-mail Tiffaney Tran at

Development of an Expert Consensus on Core Dermoscopy Proficiencies for PCPs Who Use Dermoscopy

Dermoscopic Features: Round 2

Preliminary Results

February 18, 2022

I. Survey Objective

The objective of this features survey series is to develop an expert-approved list of characteristic dermoscopic features that should be included in dermoscopy training programs for PCPs. The goal is to capture the dermoscopic structures that are highly characteristic and important to recognize. This also includes commonly seen structures that may not be specific to one diagnosis.

In Round 1, panelists reviewed a list of dermoscopic features approved by the steering committee and considered whether each feature should be included in the learning objectives for PCP-targeted dermoscopy education.

The purpose of Round 2 was to re-vote on features without a clear consensus for inclusion and to vote on panelists' suggestions for additional features.

II. Survey Methods

On January 26, 2021, the Round 2 survey was distributed via e-mail to all panelists who completed Round 1. The survey instrument included a consent statement and a consensusbased list of dermoscopic diagnoses divided into five sections:

- 1. Nonmelanocytic lesions
- 2. Benign melanocytic lesions
- 3. Melanoma

- 4. Special sites
- 5. Other (including skin infections & infestations)

Panelists re-voted on dermoscopic features without a clear consensus and voted on suggestions for additional features.

Of the 33 colleagues who completed Round 1, 30 (90.9%) voluntarily consented to continue to participate and completed Round 2. Data collection concluded on February 18, 2022. Responses were de-identified, and data analyses were performed using REDCap and Excel.

III. Results

For each dermoscopic feature, panelists were asked to rate on a Likert scale whether they agree that the feature should be included in dermoscopy education for PCPs who use dermoscopy. For each survey item, the options for the Likert scale were:

- 1. Strongly disagree
- 2. Disagree
- 3. Neutral

- 4. Agree
- 5. Strongly agree

Panelists' responses on the Likert scale were converted to a numerical format with 1 representing "strongly disagree" and 5 representing "strongly agree," as above. The selection of strongly agree" (5) or "agree" (4) was considered a "positive response" and contributed towards a survey item reaching consensus.

Tables 1-5, corresponding to the 5 different sections, summarize the results of Round 2. Panelists' comments are also included.

For each feature, the aggregate of panelists' responses resulted in one of the following designations for the "next step":

- · "include" as a learning objective for PCPs
 - >70% of panelists voted "strongly agree" (5) or "agree" (4) in Round 2.
- "potentially include" as a learning objective for PCPs depending on the skill level of the educational cohort (up to the discretion of the instructor)
 - <70% but >50% of panelists voted "strongly agree" (5) or "agree" (4) in both Round 1 and Round 2.
- "exclude" as a learning objective for PCPs
 - <50% of panelists voted "strongly agree" (5) or "agree" (4) in either Round 1 or Round 2.

Table 1. Results for diagnoses representing nonmelanocytic lesions (Round 1, n=33; Round 2, n=30). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis (Level classification) Feature, added, removed | Round 1: response average | Round 1: % positive responses* | Round 2: response average | Round 2: % positive responses* | Round 2: comments |
|---|---------------------------------|--------------------------------------|---------------------------------|--------------------------------------|--|
| Hemangioma (Level 1) | _,,,,,,,, | | | . ториново | "Lacunae of any color |
| Red, blue-red, red-purple, or maroon lacunae/lagoons with white septae | 4.91 | 72.7% | - | _ | including clear ones (lymphangioma) should included." – updated diagnosis to |
| Blue-black coloring in lacunae (when thrombosed) in absence of other structures | 4.03 | 72.7% | ↓ 3.97 | † 73.3% include | diagnosis to "hemangioma" to distinguish from lymphangioma and other angiomas "I worry this may be confused for a melanoma." |
| Dermatofibroma (Level 1) | | | | | "This is an important clue to |
| Central scar-like white patch/depigmentation | 4.94 | 100.0% | - | - | DF. Network can be seen in nevi and DF, but ring-like |
| Fine/delicate surrounding/peripheral network- like structures | 4.79 | 100.0% | _ | - | globules only in DF and not in nevi." – potentially include |
| Ring-like globules | 3.97 | 66.7% | ↓ 3.47 | ↓ 60.0% potentially include | "Not a common enough feature to be included." – potentially include |
| Central shiny white lines/streaks under polarized dermoscopy | 4.42 | 84.8% | · · | - | |
| Dotted vessels | 3.27 | 39.4% | _ | - | |
| Central pink blush | 3.30 | 42.4% | | - | 200 |
| Seborrheic keratosis (Level 1) | | | | | (none) |
| Milia-like cysts (cloudy or starry) and comedo-like openings | 4.79 | 93.9% 87.9% | _ | _ | |
| Moth-eaten (sharply demarcated) borders 'Fissures and ridges' / 'gyri and | 4.45 4.70 | 93.9% | - | _ | |
| sulci' / cerebriform pattern Fat fingers | 4.18 | 78.8% | _ | _ | |
| Fingerprint-like structures (parallel lines) | 4.27 | 78.8% | _ | _ | |
| Hairpin (looped) vessels | 3.97 | 78.8% | - | - | |
| Solar Lentigo (Level 1) | | | | | "Too ambiguous of term and |
| Moth-eaten (sharply demarcated) borders | 4.58 | 90.9% | - | - | feature for PCPs." – potentially include |
| Homogenous light brown pigmentation | 4.52 | 87.9% | _ | _ | "If you want to include ink spot lentigo, then need to include network-like structures." |
| Network-like structures | 3.97 | 63.6% | ↓ 3.57 | ↓ 63.3% potentially include | |
| Fingerprint-like structures (parallel lines) | 4.42 | 90.9% | _ | _ | |
| Uniform brown perifollicular pigmentation | 4.06 | 75.8% | 22-0 | 1 - 1 | |
| Basal Cell Carcinoma (Level 1) | | | | | "Shiny white blotches and |
| Leaf-like structures/areas | 4.58 | 90.9% | · · | · — | strands / structures only |
| Blue-gray ovoid nests | 4.55 | 87.9% | _ | _ | visible when polarized." – added "under polarized |
| Multiple blue-gray dots and globules (buckshot scatter) | 4.45 | 84.8% | _ | - | dermoscopy" "Consider updating 'shiny |
| Spoke-wheel-like structures/areas / concentric structures | 4.36 | 87.9% | - | _ | white blotches and strands / structures' to 'multiple |
| Ulceration / erosion | 4.64 | 93.9% | 2.5 | | |

| Diagnosis (Level classification) Feature, added, removed | Round 1: response average | Round 1: % positive responses* | Round 2: response average | Round 2: % positive responses* | Round 2: comments |
|---|---|---|---------------------------------|--------------------------------------|--|
| Shiny white blotches and strands / | 4.06 | 69.7% | 4.00 | † 76.7% | aggregated yellow-white |
| structures under polarized dermoscopy | 4.00 | 00.170 | 44.00 | include | globules." |
| Arborizing vessels | 4.88 | 97.0% | _ | _ | Multiple aggregated yellow- |
| Short fine telangiectasias (superficial BCC) | 4.03 | 69.7% | ↓ 3.63 | † 70.0% include | white globules: Navarrete- Dechent C, et al. Association of multiple aggregated yellow- white globules with nonpigmented basal cell carcinoma. <i>JAMA Dermatol</i> . 2020;156(8):882-890. |
| Actinic keratosis (Level 1) | | | | | (none) |
| Rosettes | 4.33 | 81.8% | _ | _ | |
| Surface scale | 4.67 | 97.0% | | _ | |
| Strawberry pattern (pink-red pseudonetwork +/- fine wavy vessels [straight or coiled] surrounding hair follicles +/- white circles with central yellow clod [targetoid hair follicles]) | 4.30 | 78.8% | _ | _ | |
| Squamous cell carcinoma (Level 1) | | | | | (none) |
| Yellow keratin mass / scale-crust | 4.73 | 100.0% | _ | _ | 8 1 |
| Ulceration / blood spots / hemorrhage | 4.61 | 93.9% | - | - | |
| White circles ('keratin pearls') | 4.48 | 90.9% | _ | _ | |
| Rosettes | 4.15 | 75.8% | _ | _ | |
| Glomerular (coiled) vessels | 4.42 | 90.9% | | _ | |
| Hairpin vessels | 4.15 | 78.8% | - | i — | |
| Sebaceous hyperplasia (Level 2) | | | | | (none) |
| Pale yellow lobules (popcorn-like structures) around a central follicular opening | 4.82 | 100.0% | _ | - | |
| Crown vessels, out of focus | 4.61 | 90.9% | 1 - 1 | - | |
| Ink spot lentigo (Level 2) | | | | | "Haven't heard this term." |
| Prominent dark homogenous (uniform) reticular network | 4.64 | 93.9% | _ | _ | |
| Chicken-wire fence | 3.85 | 63.6% | ↓ 3.33 | ↓ 50.0% potentially | |
| | | | | include | |
| Pigmented actinic keratosis (Level 2 | | | | | "Too difficult (including for |
| Gray dots | 3.82 | 69.7% | ↓ 3.13 | ↓ 46.7% | us)." "Overlap with lentigo maligna |
| Annular-granular pattern (gray | 3.82 | 66.7% | ↓ 3.37 | ¢xclude ↓53.3% | makes these hard to |
| dots around follicular openings) | 5.02 | 00.776 | ¥ 5.57 | potentially | advocate training PCPs to differentiate." |
| Rosettes | 4.00 | 75.8% | _ | - | |
| Surface scale | 4.48 | 90.9% | _ | _ | |
| Red pseudonetwork | 3.67 | 57.6% | - | _ | |
| White circles | 3.48 | 42.4% | _ | _ | |
| Patent/evident follicles | 3.67 | 57.6% | | - | |
| | | U 100 00 00 00 00 00 00 00 00 00 00 00 00 | | | "Best clue to pigmented |
| Squamous cell carcinoma in situ (L | | 87.9% | www.077 | _ | SCC." |
| Surface scale | 4.52 | | | 1 | |
| Surface scale Peripheral brown/gray dots arranged linearly (pigmented | 4.52 3.85 | 60.6% | ↓ 3.30 | ↓ 46.7% exclude | |
| Surface scale Peripheral brown/gray dots | 000000000000000000000000000000000000000 | | ↓3.30 — | | |
| Surface scale Peripheral brown/gray dots arranged linearly (pigmented SCCIS) Irregularly arranged glomerular | 3.85 | 60.6% | ↓ 3.30 — | | (none) |

| Diagnosis (Level classification) Feature, added, removed | Round 1: response average | Round 1: % positive responses* | Round 2: response average | Round 2: % positive responses* | Round 2: comments |
|--|---------------------------------|--------------------------------------|---------------------------------|--------------------------------------|--|
| Hairpin (looped) or serpentine (linear-irregular) vessels, usually at the periphery, with white-yellow halo | 4.52 | 87.9% | - | _ | |
| Angiokeratoma (Level 2) | | | | | (none) |
| Red/purple/black ('dark') lacunae | 4.61 | 93.9% | _ | _ | 1 PK |
| Hemorrhagic crust | 4.09 | 75.8% | _ | _ | |
| Lichen planus-like keratosis (Level 2 | 2) | | | | "Too much overlap with |
| Coarse gray granularity | 3.88 | 63.6% | ↓ 3.40 | ↓ 53.3% potentially include | melanoma to be differentiated by PCPs. This is not a diagnosis th |
| Peppering (evenly spaced gray dots) | 4.03 | 69.7% | ↓ 3.60 | ↓ 63.3% potentially include | most PCPs should be making on dermoscopy." "Too hard to trust a beginner |
| Sharp cut-off borders (scalloped/moth-eaten) | 4.06 | 69.7% | ↓ 3.60 | ↓ 63.3% potentially include | to know what blue-gray- white is 'fine' and what is melanoma." |
| Features of a lentigo or a seborrheic keratosis in an area | 4.15 | 72.7% | _ | - | |
| Blue-gray/blue-white structures (new) | A = 2 | - | 2.57 | 20.0% exclude | |

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 2. Results for diagnoses representing benign melanocytic lesions (Round 1, n=33; Round 2, n=30). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis (Level classification) Feature, added, removed | Round 1: response average | Round 1: % positive responses* | Round 2: response average | Round 2: % positive responses* | Round 2: comments |
|---|---------------------------------|---|---------------------------------|---|---|
| Overview of benign nevi patterns (Levi | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | "But only if symmetrical." - |
| Diffuse reticular network | 4.85 | 100.0% | 1-1 | _ | added "symmetric" "Benign' label can be misleading." |
| Patchy reticular network | 4.70 | 97.0% | _ | | |
| Peripheral reticular network with | 4.76 | 100.0% | _ | _ | |
| central hypopigmentation | 533555 | BESTERA | | | |
| Peripheral reticular network with central hyperpigmentation | 4.76 | 100.0% | · | | |
| Peripheral reticular network with central globules | 4.61 | 90.9% | _ | _ | |
| Homogenous (tan, brown, blue, or pink) | 4.64 | 93.9% | _ | _ | |
| Central network with evenly distributed peripheral globules | 4.55 | 87.9% | - | | |
| Globular pattern | 4.82 | 100.0% | _ | _ | |
| Symmetric two-component pattern | 4.06 | 69.7% | ↓ 3.40 | ↓ 60.0% potentially | |
| | | | | include | |
| Symmetric multicomponent pattern | 4.15 | 75.8% | - | _ | |
| Intradermal nevi (Level 1) | | | | | (none) |
| Comma-shaped (curved) vessels | 4.58 | 93.9% | 1-0 | _ | 2000 COO CO |
| Homogenous (structureless) | 4.52 | 93.9% | _ | _ | |
| brown/tan/pink pigmentation | | | | | |
| Peripheral network | 4.03 | 72.7% | 2- | 275 | |
| Globules | 4.36 | 87.9% | 1 - 1 | 550 | |
| Congenital melanocytic nevi (Level 2) Cobblestone pattern/globular pattern | 4.64 | 93.9% | 9420 | <u></u> | "I do not use these criteria in my evaluation, |
| Reticular network | 4.45 | 90.9% | | _ | therefore I would need the know the sensitivity and specificity to rate their usefulness." |
| Homogenous background | 4.45 | 87.9% | _ | | |
| pigmentation | 4.45 | 78.8% | - | = | |
| Hypertrichosis | | | 10.57 | 1 00 004 | 0-5 00350 |
| Perifollicular hyper-/hypo- pigmentation | 4.06 | 69.7% | ↓ 3.57 | ↓ 60.0% potentially | |
| Central hypopigmentation (new) | - | - | 3.10 | include 33.3% | |
| Central hypopignientation (new) | | | 3.10 | exclude | |
| Blue nevi (Level 2) | | | | | (none) |
| Homogenous blue/blue-gray pigmentation | 4.88 | 100.0% | - | _ | 55 5 |
| Well-circumscribed | 4.67 | 93.9% | - | - | |
| Spitz nevi (Level 2) Vascular pattern (pink homogenous | 4.00 | 75.8% | 1,1 | - | "Spitz nevus diagnosis is tough. Not sure how detailed you want to get with PCPs. The overlap with melanoma is huge. "These features are also melanoma-specific structures and could falsely reassure someor against biopsy." |
| with dotted vessels) Starburst pattern with tiered | 4.55 | 87.9% | _ | _ | |
| globules/streaks and regularly spaced pseudopods at the | | | | | |
| periphery (radial streaming) | 2.05 | 60.00/ | 1040 | 1 22 20 | |
| Negative pigment network (reticular depigmentation) | 3.85 | 60.6% | ↓ 3.10 | ↓ 33.3% exclude | |
| Shiny white lines (crystalline | 3.82 | 63.6% | ↓ 3.30 | ↓ 43.3% | |
| structures) | 1000 | | • | exclude | "I think I would want PCP |
| Globular with negative network or blue-white veil | 3.64 | 60.6% | ↓2.70 | ↓ 23.3% exclude | targeted dermoscopy to recognize that if there is any veil, think melanom and biopsy, rather than |
| | | | | | observe and monitor a Spitz nevus. I tend to |

| Diagnosis (Level classification) Feature, added, removed | Round 1: response average | Round 1: % positive responses* | Round 2: response average | Round 2: % positive responses* | Round 2: comments |
|--|---------------------------------|--------------------------------------|---------------------------------|--------------------------------------|--|
| | | | | | biopsy all spitz nevi in adults. So, as long as this is clarified, I could agree to add the features above." |
| Recurrent/persistent nevi (Level 2) | | | | | "Most of these things are |
| Pigment within the scar, not extending beyond | 4.30 | 81.8% | - | - | high-level, and risk of making mistake has |
| Starburst pattern (radial streaming) (new) | - | _ | 2.93 | 33.3% exclude | significant implications. I would not include these as part of routine dermoscopy for PCPs." |
| Halo nevi (Level 2) | | | | | (none) |
| Encircling/surrounding depigmentation/pallor | 4.52 | 93.9% | _ | - | |
| Central reticulation with peripheral white depigmentation | 4.03 | 78.8% | 1-0 | 7.50 | |
| Benign nevi patterns, globular, homogenous | 4.12 | 78.8% | _ | _ | |

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 3. Results for diagnoses representing melanoma (Round 1, n=33; Round 2, n=30). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis (Level classification) Feature, added, removed | Round 1: response average | Round 1: % positive responses* | Round 2: response average | Round 2: % positive responses* | Round 2: comments |
|--|---------------------------------|--------------------------------------|---------------------------------|--------------------------------------|---|
| Overview of melanoma patterns (Level | "black blotch" | | | | |
| Atypical pigment network | 4.82 | 97.0% | _ | 1 - | "Atypical blotch is an off- center blotch or the presence of multiple |
| Blue structures (blue-white veil, blue- gray structures) | 4.88 | 100.0% | _ | - | |
| Shiny white lines/structures (crystalline structures) | 4.76 | 100.0% | _ | 100 | blotches." - changed to "blotch" to |
| Negative pigment network | 4.55 | 87.9% | _ | _ | "blotch(es)" |
| Atypical/irregular dots/globules | 4.67 | 93.9% | _ | _ | |
| Atypical/irregular streaks (radial streaming, pseudopods) | 4.76 | 97.0% | _ | : | |
| Regression structures (white scar-like area and/or peppering) | 4.70 | 93.9% | _ | _ | |
| Peripheral brown/tan structureless area | 4.21 | 78.8% | _ | · - | |
| Angulated lines (extrafacial) / polygons / zig-zag pattern | 4.21 | 75.8% | _ | _ | |
| Atypical vascular pattern/structures, polymorphous vessels (2+ types of blood vessels) | 4.39 | 87.9% | _ | _ | |
| Atypical/off-center blotch(es) | 4.18 | 69.7% | † 4.33 | † 90.0% include | |
| Acral melanoma (Level 2) | | | | | "Not familiar with this |
| Parallel ridge pattern | 4.76 | 93.9% | _ | - | term." |
| Irregular diffuse pigmentation or blotch | 4.39 | 84.8% | _ | 1 - | |
| Multicomponent pattern, asymmetry of structures/colors | 4.36 | 84.8% | _ | _ | |
| Atypical fibrillar pattern | 4.15 | 72.7% | _ | - | |
| Ulceration | 4.58 | 90.9% | | _ | |
| Neo-vascularization, milky red | 4.00 | 72.7% | | _ | |
| Pigment crossing normal ridge pattern (new) | _ | - | 3.37 | 46.7% exclude | |
| Lentigo maligna melanoma (Level 2) | | | | | "I just have never used |
| Annular-granular pattern (gray dots around follicular openings) | 4.45 | 90.9% | _ | - | this as a diagnostic feature." |
| Asymmetric pigmentation around follicular openings / asymmetric follicular openings | 4.42 | 87.9% | _ | _ | |
| Rhomboidal structures (angulated lines) / zig-zag pattern | 4.39 | 81.8% | - | 71-0 | |
| Circle within a circle (isobar) | 3.94 | 60.6% | ↓ 3.57 | ↓ 56.7% potentially include | |
| Dark blotches +/- obliterated hair follicles | 4.21 | 75.8% | _ | _ | |
| Amelanotic/hypomelanotic melanoma | (Level 2) | | | | (none) |
| Scar-like depigmentation | 4.21 | 75.8% | _ | 1 - | |
| Milky red areas | 4.42 | 81.8% | - | - | |
| Shiny white lines (crystalline structures) | 4.39 | 81.8% | | _ | |
| Atypical vascular pattern, polymorphous vessels (2+ types of blood vessels) | 4.24 | 81.8% | _ | - | |

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 4. Results for diagnoses related to special sites (n=30). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Feature, added, removed | Round 1: response average | Round 1: % positive responses* | Round 2: response average | Round 2: % positive responses* | Round 2: comments |
|--|---------------------------------|--------------------------------------|---------------------------------|--------------------------------------|--|
| Subungual hemorrhage (Level 1) | | | | | "Despite being for PCP- |
| Well-circumscribed red-black dots or blotches / blood spots | 4.58 | 90.9% | - | - | targeted dermoscopy, the homogenous |
| Distal streaks of red-brown coloration ('filamentous' distal end) | 4.27 | 81.8% | _ | ·- | coloration is subtle and definitely advanced. I |
| Homogenous red/purple/black coloration without melanin granules | 4.09 | 69.7% | ↓ 3.60 | ↓ 60.0% potentially | worry that having too many advanced |
| Discontiguous with the cuticle (not connected to the proximal nailfold | 4.42 | 87.9% | | include | features may render an over-confidence." – potentially include |
| or edge of nail) Lightning sign or white streaks (new) | - | - | 2.83 | 20.0% exclude | "The lightning sign is a feature of subcorneal blood. Not sure it applies to subungual blood." – excluded |
| Dermoscopic features of the face (Level | 2) | | | | (none) |
| Pseudonetwork | 4.27 | 78.8% | - | _ | , |
| Benign patterns of acral nevi (Level 2) | 7.27 | 70.070 | | | (none) |
| Parallel furrow pattern (with pattern variations including single line, double line, single dotted line, double-dotted line) | 4.73 | 93.9% | - | - | (none) |
| Lattice-like pattern | 4.55 | 87.9% | _ | _ | |
| Fibrillar pattern (soles only) | 4.48 | 84.8% | | _ | |
| Homogenous pattern | 4.21 | 75.8% | | - | |
| Peas in a pod pattern (parallel furrow + globules on ridges) (congenital nevi) | 4.03 | 69.7% | ↓ 3.40 | ↓ 56.7% potentially include | |
| Nevus of the nail (Level 2) | | | | | (none) |
| Homogenous brown background coloration | 4.15 | 84.8% | - | _ | 1.5000005 |
| Uniform band thickness, color, and spacing with parallel band configuration and unbroken lines | 4.24 | 87.9% | _ | - | |
| Lentigo of the nail (Level 2) | | | | | "There is almost always a |
| Homogenous gray band or lines +/- gray background | 4.18 | 78.8% | - | - | a coincidence between light brown and gray. I would put it this way and not use the term brown. This should be reserved for melanocytic." – changed "brown" to "light brown" |
| Regular <mark>light</mark> brown lines (new) | - | - | 3.43 | 60.0% potentially include | |
| Melanoma of the nail (Level 2) | | | | | (none) |
| Triangular shape of pigment band (band diameter wider at proximal end) | 4.45 | 87.9% | - | - | 3 - 2 |
| Pigmentation of periungual skin (micro-Hutchinson's sign) | 4.39 | 90.9% | - | : - | |
| Brown to black dots/globules associated with longitudinal lines | 3.91 | 60.6% | ↓ 3.27 | ↓ 50.0% potentially | |
| Longitudinal brown/black broken lines with irregular spacing, width, coloration, or parallelism | 4.30 | 81.8% | _ | include — | |
| Diagnosis (Level classification) Feature, added, removed | Round 1: response average | Round 1: % positive responses* | Round 2: response average | Round 2: % positive responses* | Round 2: comments |
| Band width >3 mm or 2/3 of nail plate width | 4.27 | 78.8% | _ | _ | |
| Talon noir (Level 2) | | | | | "Talon noir is so rare that |
| Homogenous or parallel-ridge red- brown coloration | 4.15 | 78.8% | _ | - | don't think this should be included." – |
| Peripheral red-brown dots/globules | 4.03 | 66.7% | ↓ 3.27 | ↓ 40.0% exclude | inclusion in Level 2 based on panel |
| Cracks (lightning bolt sign) | 3.76 | 51.5% | - | _ | consensus |

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

Table 5. Results for other diagnoses, including skin infections and infestations (Round 1, n=33; Round 2, n=30). Responses were converted to a numerical scale with a minimum of 1, representing "strongly disagree," and a maximum of 5, representing "strongly agree."

| Diagnosis (Level classification) Feature, added, removed | Round 1: response average | Round 1: % positive responses* | Round 2: response average | Round 2: % positive responses* | Round 2: comments |
|--|---------------------------------|--------------------------------------|---------------------------------|--------------------------------------|---|
| Scabies (Level 1) | | | | • | (none) |
| Delta-wing jet with contrail sign (small dark brown triangular structure located at the end of whitish structureless curved/wavy lines) | 4.52 | 90.9% | - | - | |
| Verruca (Level 1) | | | | | (none) |
| Papilliform structures | 4.67 | 93.9% | _ | - | 100000000000000000000000000000000000000 |
| Tiny red-black dots (papillary capillaries) | 4.61 | 90.9% | _ | 1- | |
| Molluscum contagiosum (Level 2) | | | | | "Crown vessels in this |
| Central pore or umbilication | 4.61 | 93.9% | _ | _ | case should also be |
| Polylobular white-yellow amorphous structures | 4.27 | 81.8% | - | - | distinguished from similar non-molluscum |
| Linear or branched vessels (red corona) / crown vessels | 3.97 | 63.6% | ↓ 3.63 | ↓ 63.3% potentially include | lesions (i.e. sebaceous hyperplasia), thus presenting this finding needs to be contrasted with a similar appearin lesion." |
| Venous lake (Level 2) | | | | | (none) |
| Homogenous purple/ blue/red coloration +/- globules/clods | 4.61 | 93.9% | _ | - | \$4.500000E |
| Psoriasis (Level 2) | | | | | (none) |
| Red or pink color with white scales / light red background | 4.03 | 75.8% | _ | - | |
| Dotted vessels in a regular distribution | 4.03 | 72.7% | _ | _ | |
| Twisted red loops in a homogenous distribution | 3.42 | 45.5% | _ | - | |
| Glomerular vessels | 3.42 | 45.5% | - | _ | |
| Radiation tattoo (Level 2) | | Apr. 11.0000000 | | | (none) |
| Homogenous blue or black coloration | 4.33 | 84.8% | _ | _ | |
| Scars (Level 2) | | | | | (none) |
| Arborizing, linear irregular, or comma vessels in keloids | 3.58 | 45.5% | _ | - | |
| White depigmentation | 4.00 | 72.7% | _ | _ | |

^{*} A positive response is defined as selection of "strongly agree" (5) or "agree" (4).

IV. Conclusion

In closing, the research team greatly appreciates all panelists' time and effort in participating in this process. Panelists who completed Round 2 of the features survey series will be invited to review the final study manuscript and included as a co-author for publication.

If you have any questions or comments related to this study or your rights as a research participant, please e-mail Tiffaney Tran at

Foundational Dermoscopy Proficiency (Level 1)

Nonmelanocytic Lesions (Level 1)

Hemangioma

- Red, blue-red, red-purple, or maroon lacunae/lagoons with white septae
- Blue-black coloring in lacunae (when thrombosed) in absence of other structures

Seborrheic keratosis

- · Milia-like cysts (cloudy or starry) and comedo-like openings
- "Fissures and ridges" / "gyri and sulci" / cerebriform pattern
- Moth-eaten (sharply demarcated) borders
- Fat fingers
- Fingerprint-like structures (parallel lines)
- · Hairpin (looped) vessels

Dermatofibroma

- · Central scar-like white patch/depigmentation
- Fine/delicate surrounding/peripheral network-like structures
- · Central shiny white lines/streaks under polarized dermoscopy
- · (optional to include) Ring-like globules

Solar lentigo

- · Moth-eaten (sharply demarcated) borders
- Fingerprint-like structures (parallel lines)
- · Homogenous light brown pigmentation
- Uniform brown perifollicular pigmentation
- (optional to include) Network-like structures

Basal cell carcinoma

- · Arborizing vessels
- Ulceration / erosion
- Leaf-like structures/areas
- Blue-gray ovoid nests
- · Spoke-wheel-like structures/areas / concentric structures
- Multiple blue-gray dots and globules (buckshot scatter)
- Shiny white blotches and strands / structures under polarized dermoscopy
- Short fine telangiectasias (superficial BCC)

Squamous cell carcinoma

- Yellow keratin mass / scale-crust
- Ulceration / blood spots / hemorrhage
- White circles ("keratin pearls")
- Glomerular (coiled) vessels
- Rosettes
- Hairpin vessels

Actinic keratosis

- Surface scale
- Rosettes
- Strawberry pattern (pink-red pseudonetwork +/- fine wavy vessels [straight or coiled] surrounding hair follicles +/- white circles with central yellow clod [targetoid hair follicles])

Benign Melanocytic Lesions (Level 1)

Overview of benign nevi patterns

- Diffuse reticular network
- Peripheral reticular network with central hypopigmentation
- Peripheral reticular network with central hyperpigmentation
- Globular pattern
- · Patchy reticular network
- Homogenous (tan, brown, blue, or pink)
- Peripheral reticular network with central globules
- Central network with evenly distributed peripheral globules
- Symmetric multicomponent pattern
- (optional to include) Symmetric two-component pattern

Intradermal nevi

- · Comma-shaped (curved) vessels
- Homogenous (structureless) brown/tan/pink pigmentation
- Peripheral network
- Globules

Melanoma (Level 1)

Overview of melanoma patterns

- Blue structures (blue-white veil, blue-gray structures)
- Shiny white lines/structures (crystalline structures)
- Atypical pigment network
- Atypical/irregular streaks (radial streaming, pseudopods)
- Atypical/irregular dots/globules
- Regression structures (white scar-like area and/or peppering)
- Negative pigment network
- Atypical vascular pattern/structures, polymorphous vessels (2+ types of blood vessels)
- · Peripheral brown/tan structureless area
- · Angulated lines (extrafacial) / polygons / zig-zag pattern
- Atypical/off-center blotch(es)

Special Sites (Level 1)

Subungual hemorrhage

- Well-circumscribed red-black dots or blotches / blood spots
- Discontiguous with the cuticle (not connected to the proximal nailfold or edge of nail)
- Distal streaks of red-brown coloration ('filamentous' distal end)
- (optional to include) Homogenous red/purple/black coloration without melanin granules

Other (Level 1)

Verruca

- Papilliform structures
- Tiny red-black dots (papillary capillaries)

Scabies

 Delta-wing jet with contrail sign (small dark brown triangular structure located at the end of whitish structureless curved/wavy lines)

Intermediate Dermoscopy Proficiency (Level 2)

Nonmelanocytic Lesions (Level 2)

Sebaceous hyperplasia

- Pale yellow lobules (popcorn-like structures) around a central follicular opening
- Crown vessels, out of focus

Pigmented actinic keratosis

- Surface scale
- Rosettes
- (optional to include) Annular-granular pattern (gray dots around follicular openings)
- (optional to include) Red pseudonetwork
- (optional to include) Patent/evident follicles

Squamous cell carcinoma in situ

- Irregularly arranged glomerular (coiled) / dotted vessels
- Surface scale

Keratoacanthoma

- Central keratin mass
- Hairpin (looped) or serpentine (linear-irregular) vessels, usually at the periphery, with white-yellow halo

Angiokeratoma

- Red/purple/black ("dark") lacunae
- Hemorrhagic crust

Lichen planus-like keratosis

- Features of a lentigo or seborrheic keratosis in an area
- (optional to include) Peppering (evenly spaced gray dots)
- (optional to include) Sharp cut-off borders (scalloped/moth-eaten)
- (optional to include) Coarse gray granularity

Ink spot lentigo

- Prominent dark homogenous (uniform) reticular network
- (optional to include) Chicken-wire fence

Benign Melanocytic Lesions (Level 2)

Blue nevi

- · Homogenous blue/blue-gray pigmentation
- Well-circumscribed lesion

Spitz nevi

- Starburst pattern with tiered globules/streaks and regularly spaced pseudopods at the periphery (radial streaming)
- Vascular pattern (pink homogenous with dotted vessels)

Congenital melanocytic nevi

- · Cobblestone pattern/globular pattern
- Reticular network
- · Homogenous background pigmentation
- Hypertrichosis
- (optional to include) Perifollicular hyper-/hypo-pigmentation

Halo nevi

- · Encircling/surrounding depigmentation/pallor
- · Central reticulation with peripheral white depigmentation
- · Benign nevi patterns, globular, homogenous

Melanoma (Level 2)

Acral melanoma

- · Parallel ridge pattern
- Ulceration
- Irregular diffuse pigmentation or blotch
- · Multicomponent pattern, asymmetry of structures/colors
- Atypical fibrillar pattern
- · Neo-vascularization, milky red

Lentigo maligna melanoma

- Annular-granular pattern (gray dots around follicular openings)
- Asymmetric pigmentation around follicular openings / asymmetric follicular openings
- Rhomboidal structures (angulated lines) / zig-zag pattern
- Dark blotches +/- obliterated hair follicles
- (optional to include) Circle within a circle (isobar)

Melanoma of the nail

- Pigmentation of periungual skin (micro-Hutchinson's sign)
- Triangular shape of pigment band (band diameter wider at proximal end)
- Longitudinal brown/black broken lines with irregular spacing, width, coloration. or parallelism
- Band width >3 mm or 2/3 of nail plate width
- (optional to include) Brown to black dots/globules associated with longitudinal

Amelanotic/hypomelanotic melanoma

- Milky red areas
- Shiny white lines (crystalline structures)
- Atypical vascular pattern, polymorphous vessels (2+ types of blood vessels)
- Scar-like depigmentation

Special Sites (Level 2)

Dermoscopic features of the face

Pseudonetwork

Benign patterns of acral nevi

- · Parallel furrow pattern (with pattern variations including single line, double line, single dotted line, double-dotted line)
- Lattice-like pattern
- · Fibrillar pattern (soles only)
- Homogenous pattern
- (optional to include) Peas-in-a-pod pattern (parallel furrow + globules on ridges) (acral congenital melanocytic nevi)

Nevus of the nail

- Uniform band thickness, color, and spacing with parallel band configuration and unbroken lines
- · Homogenous brown background coloration

Lentigo of the nail

- Homogenous gray band or lines +/- gray background
- (optional to include) Regular light brown lines

Talon noir

- Homogenous red-brown coloration
- · (optional to include) Cracks (lightning bolt sign)

Other (Level 2)

Molluscum contagiosum

- · Central pore or umbilication
- Polylobular white-yellow amorphous structures
- (optional to include) Linear or branched vessels (red corona) / crown vessels

Radiation tattoo

· Homogenous blue or black coloration

Scars

· White depigmentation

Venous lake

• Homogenous purple/blue/red coloration +/- globules/clods

Psoriasis

- · Red or pink color with white scales / light red background
- · Dotted vessels in a regular distribution